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The use of oral misoprostol for the prevention of postpartum haemorrhage 
was first suggested in 1996 in a small uncontrolled observational study. This formed 
the basis for my hypothesis that misoprostol, given in the correct dose and route, 
should produce a uterotonic effect similar to conventional oxytocics used for 
preventing postpartum haemorrhage.  
 
I reviewed the literature to examine the current strategies for the 
management of the third stage of labour as well as the history and development of 
misoprostol. Rather than the cumbersome and imprecise blood loss measurements 
used in large clinical studies, I followed the lead of Dr Selina Chua and Professor 
Sabaratnam Arulkumaran in using intrauterine pressure measurements of postpartum 
uterotonic activity to directly measure the uterotonic effect of misoprostol. The 
reliability of Gaeltec® catheter-tip transducers for measuring postpartum uterine 
activity was confirmed using double catheters studies.  
 
The first objective was to determine the dose of misoprostol that was most 
effective. I identified that the dose of misoprostol that provided the most uterotonic 
activity with the least side effects was 400 µg. Subsequently, I found that the route 
of administration that produced the fastest and greatest uterotonic effect was an oral 
aqueous solution of misoprostol. Unfortunately, this route also produced the most 
side effects, even with a dose of 400 µg. During the course of these studies, I 
discovered that even normal doses of misoprostol produced distinct side effects i.e. 
shivering and pyrexia in women after delivery. In all the literature prior to my 
report, severe side effects of misoprostol had only been reported with massive 
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overdoses. I found that shivering and pyrexia was, on the contrary, a very common 
side effect of misoprostol that was significantly associated with the dose of 
misoprostol given as well as its route of administration. 
 
I then tested a dose of 200 µg oral solution misoprostol and found that this 
produced significantly less side effects than oral solution misoprostol 400 µg while 
not affecting its onset of action. The uterine activity produced with 200 µg oral 
solution misoprostol was less than that with 400 µg oral solution misoprostol and 
intramuscular Syntometrine 1 mL but the difference was not statistically significant. 
 
Finally, I performed a systematic review of the randomised clinical trials 
using misoprostol administered by different routes for the prevention of postpartum 
haemorrhage and concluded that misoprostol, given as oral tablets or rectally, was 
less effective than conventional oxytocics with significantly more side effects. This 
may be because misoprostol administered as oral tablets or rectally has a 
significantly slower onset of action than conventional injectable oxytocics. 
Unfortunately, the randomised trials using oral solution misoprostol were 
underpowered statistically and were inconclusive.  
 
My recommendation is that low doses of oral solution misoprostol might be 
the best and safest way to use misoprostol in future studies as it produces a fast onset 
of action, good uterotonic effect, and little side effects. Whether oral solution 
misoprostol 200 µg will be really effective or safe in clinical practice needs to be 
tested in large-scale randomised controlled studies. 
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THE HYPOTHESIS 
Misoprostol, given in the correct dose and by the correct 
route, should produce a similar uterotonic effect to other 










Current strategies for the prevention of postpartum 
haemorrhage in the third stage of labour 
2 
Introduction 
Excessive bleeding at or after childbirth accounts for almost half of all the 
postpartum maternal mortalities in developing countries [Li et al 1996], and is the 
single most important cause of maternal death worldwide. Effects on maternal 
morbidity are less well documented, but are likely to include such inter-related 
outcomes as anaemia, fatigue and depression. Many factors influence the severity of 
the consequences of postpartum haemorrhage [Tsu 1993]. The high incidence of 
severe anaemia in developing countries contributes to its high mortality there. Other 
factors include the large number of deliveries conducted at home by traditional birth 
attendants or family members, and the relative inaccessibility of medical expertise 
when complications occur. 
 
Postpartum haemorrhage can occasionally lead to irreversible shock and 
death within a short time. A study in Egypt found that 88% of deaths from 
postpartum haemorrhage occur within four hours of delivery [Kane et al 1992]. 
Postpartum haemorrhage is a true obstetric emergency that demands fast vigorous 
treatment and proactive preventive management strategies. The introduction of the 
concept of active management of the third stage of labour and, in particular, the 
prophylactic use of oxytocics [Moir 1932; 1955] led to a significant decrease in the 
incidence of postpartum haemorrhage [Prendiville et al 1988] in many countries. 
However, not all maternity units practice active management of the third stage of 
labour. In this review, we will examine the evidence for the various strategies 




Strategies for the prevention of postpartum haemorrhage 
Active management of the third stage of labour 
The principle of the active management of the third stage is to hasten and 
augment uterine contraction and retraction at and after delivery of the baby and 
placenta to prevent postpartum haemorrhage due to uterine atony, thus reducing the 
blood loss. The main components include: 
1. administration of a prophylactic uterotonic agent at or soon after delivery of 
the baby, 
2. early clamping and cutting of the umbilical cord, and 
3. early delivery of the placenta by controlled cord traction after the uterus has 
contracted. 
 
Expectant management of the third stage of labour 
Expectant or physiologic management involves waiting for signs of placental 
separation and allowing the placenta to deliver spontaneously or aided by gravity or 
nipple stimulation. Expectant management is also known as conservative or 
physiological management and is popular in some northern European countries, and 
in some units in the USA and Canada. It is also the usual practice in domiciliary 
practice in the developing world. 
 
Practice preferences in different countries 
The Global Network for Perinatal and Reproductive Health (GNPRH) 
conducted an observational, cross-sectional survey of 15 university-based obstetric 
centres in ten developing and developed countries to assess the use of active 
management of the third stage of labour and to determine whether evidence-based 
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practices were being used [Festin et al 2003]. Centres surveyed included those in 
cities as varied as Dublin (100% prophylactic oxytocic usage) to Trivandrum (0% 
prophylactic oxytocic usage). Data on approximately 30 consecutive vaginal 
deliveries in each centre (452 in total) were included. Significant intra-country and 
inter-country variation in the practice of the active management of the third stage of 
labour was found. Only 24.6% deliveries were conducted with active management 
of the third stage. This confirmed the existence of a large gap between knowledge 
and practice. The number of women who received prophylactic oxytocic agents (0–
100%), additional dosages of oxytocin during the third stage of labour (4.6–100%), 
and controlled cord traction (13.3–100%) varied greatly. Most centres administered 
some form of oxytocic during the third stage of labour, but overall prophylactic 
oxytocic usage was only 44% (0–100%). As a result, the authors recommended the 
urgent implementation of evidence-based practice defined as the active management 
of the third stage of labour. 
 
In Europe, a questionnaire survey of Dutch midwives and obstetricians about 
the standard practice during the third stage of labour revealed that prophylactic 
oxytocics in the third stage were used as a routine by 55% of the obstetricians and 
only 10% of the midwives. Where given, oxytocin was the drug of first choice [de 
Groot et al 1996]. Another questionnaire survey of 55 out of 57 institutions with 
delivery units in Norway showed that routine third stage prophylaxis with 5-10 IU 




 A recent review from a midwifery unit in Dallas concluded that, on the basis 
of current evidence, an active approach to the third stage should be adopted if a 
decrease in postpartum bleeding or avoidance of manual removal is desired [Brucker 
2001]. However, an earlier questionnaire survey of 1500 obstetricians in Texas (two-
thirds in urban, and one-third in rural practices) showed that 94% of them used 
oxytocics routinely in managing the third stage of labour. However, only 14.9% 
administered the oxytocics before delivery of the placenta, in contrast to 92.1% who 
gave oxytocics after the delivery of the placenta. Oxytocin was the chosen oxytocic 
drug (95%) for routine third-stage management. Thus, Texan obstetricians use 
oxytocin routinely in the management of the third stage of labour, but few are 
converted to conventional active management [Phillips & Kinch 1994]. In the 
United States, administration of oxytocics after delivery of the placenta appears to 
be the standard practice. The rationale for this is the worry that giving oxytocics 
immediately following delivery may hamper management of undiagnosed second 
twins or placenta accreta [O’Brien et al 1996]. To support this view, a recent large 
randomized controlled trial showed that the administration of prophylactic oxytocin 
before placental delivery did not reduce the incidence of postpartum hemorrhage or 
third-stage duration when compared with oxytocin administered after placental 
delivery [Jackson et al 2001]. 
 
In the United Kingdom, mothers and midwives who had participated in the 
Bristol randomised controlled trial of active versus physiologic management of the 
Third Stage of Labour were asked for their views on their management [Prendiville 
1988a]. Both mothers and midwives commented adversely about the length of the 
third stage under physiologic management [Harding et al 1989]. The management of 
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the third stage in the United Kingdom and Australia is generally active [Garcia & 
Garforth 1989] but expectant management is more prevalent in Europe and the 
developing countries [McCormick et al 2002]. 
 
The findings of systematic reviews comparing various strategies for the prevention 
of postpartum haemorrhage 
Active versus expectant management in the third stage of labour 
A Cochrane systematic review analyzed the results of five randomised 
controlled trials comparing active versus expectant management in the third stage of 
labour [Prendiville et al 1988; Begley 1990; Thilaganathan et al 1993; Khan et al 
1997; Rogers et al 1998]. The interventions assessed included early clamping and 
cutting of the umbilical cord, controlled cord traction, and the prophylactic 
administration of one of the following uterotonics agents- intramuscular oxytocin, 
intramuscular syntometrine, or intravenous ergometrine. No comparisons were made 
among the three types of uterotonics agents used. The reviewers found that active 
management was associated with reduced risks of maternal blood loss, postpartum 
haemorrhage of more than 500 mL, and prolonged third stage of labour [Prendiville 
et al 2003]. The reviewers also found that active management was associated with 
an increased risk of maternal nausea, vomiting and raised blood pressure, probably 
due to the use of ergometrine. There were no apparent advantages or disadvantages 
for the baby. They recommended that active management should be the routine 
management of choice for women delivering a baby by the vaginal route in a 
maternity hospital but stated that the implications are less clear for other settings, 




Figure 1.1: Commonly used oxytocics- Ergometrine, Syntometrine® and 
Syntocinon® 
 
Prophylactic syntometrine versus oxytocin in the third stage of labour 
Another Cochrane review compared the prophylactic use of the two most 
widely used uterotonics agents - intramuscular syntometrine and intramuscular 
oxytocin - in the third stage of labour [McDonald et al 2003]. The review included 
six randomised controlled trials [Nieminen & Jarvinen 1963; Dumoulin 1981; 
McDonald et al 1993; Mitchell & Elbourne 1993; Khan et al 1995; Yuen et al 1995], 
and concluded that the use of intramuscular syntometrine as part of the routine 
active management of the third stage of labour appears to be associated with a 
statistically significant reduction in the risk of postpartum haemorrhage when 
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compared to intramuscular oxytocin where blood loss is less than 1000mL. No 
difference was seen between the groups for severe postpartum haemorrhage. 
However, the use of syntometrine is associated with more adverse effects. A recent 
large randomised controlled trial not included in the review showed that there were 
no important clinical differences in the effectiveness of intramuscular syntometrine 
and intravenous oxytocin for the prevention of postpartum blood loss although 
intravenous oxytocin is less likely to cause hypertension [Choy et al 2002]. 
 
Prophylactic use of oxytocin in the third stage of labour 
A third Cochrane review [Elbourne et al 2003] examined the use of various 
uterotonics agents in the third stage. In seven trials [Newton et al 1961; Howard et al 
1964; Ilancheran & Ratnam 1990; Poeschmann et al 1991; Pierre et al 1992; De 
Groot et al 1996a; Nordstrom et al 1997], prophylactic intramuscular oxytocin 
showed benefits in terms of reduced blood loss and need for additional therapeutic 
uterotonics agents compared to no uterotonics. There was a non-significant trend 
towards more manual removal of the placenta, and more blood transfusions in the 
expectant management subgroup. In six trials [McGinty 1956; Fugo & Dieckmann 
1958; Howard et al 1964; Sorbe 1978; Ilancheran & Ratnam 1990; De Groot et al 
1996], there was little evidence of any difference between oxytocin and ergot 
alkaloids, although ergot alkaloids are associated with more manual removals of the 
placenta, and more raised blood pressure than with oxytocin. In five trials [Barbaro 
& Smith 1961; Bonham 1963; Soiva & Koistinen 1964; Francis et al 1965; 
Ilancheran & Ratnam 1990], there was little evidence of a synergistic effect of 
adding oxytocin to ergometrine versus ergometrine alone. The reviewers concluded 
that oxytocin alone was beneficial in terms of preventing postpartum haemorrhage, 
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and the need for additional therapeutic oxytocics. There was insufficient information 
about other outcomes and side-effects. There was little evidence in favour of ergot 
alkaloids alone compared to either oxytocin alone, or to syntometrine. They 
suggested that more trials were needed in domiciliary deliveries in developing 
countries where third stage complications are most common. 
 
The evidence from systematic reviews 
From these comprehensive systematic reviews, the following conclusions 
may be drawn: 
1. Routine active management of the third stage of labour is superior to 
expectant management in terms of blood loss, postpartum haemorrhage and 
other serious complications, but is associated with an increased risk of 
unpleasant side effects, and hypertension, where ergometrine is used.  
2. The use of intramuscular syntometrine as part of the routine active 
management of the third stage of labour reduces the risk of postpartum 
haemorrhage when compared to intramuscular oxytocin. However, the risk 
of severe postpartum haemorrhage is not increased with oxytocin, and the 
use of syntometrine is associated with more adverse effects. 
3. There was little evidence in favour of ergot alkaloids alone compared to 






Other uterotonics agents used for prevention of primary postpartum 
haemorrhage 
 
Intraumbilical uterotonic agents 
In 1987, the first report of a randomized, double-blind, placebo-controlled 
trial was made on the influence of umbilical vein administration of oxytocin on the 
third stage of labour. Intraumbilical oxytocin produced no significant difference in 
the duration of the third stage compared to intraumbilical saline [Chestnut & Wilcox 
1987]. The subsequent randomized trials yielded conflicting results. Three other 
studies concluded that intraumbilical oxytocin was no more effective than 
intraumbilical saline in influencing the duration of and blood loss in the third stage 
[Young et al 1988; Bider et al 1991; Ozcan et al 1996]. Two placebo-controlled 
trials showed that intraumbilical oxytocin was effective in decreasing the length of 
the third stage but not the blood loss [Athavale et al 1991; Kovavisarach & 
Rojsangruang 1998]. Two studies reported that intraumbilical oxytocin was more 
effective than intravenous oxytocin in reducing the duration of and blood loss in the 
third stage [Reddy & Carey 1989; Dahiya et al 1995], while one study concluded the 
converse with increased blood loss and fetomaternal transfusion in the intraumbilical 
oxytocin group [Porter et al 1991].   
 
Several other studies and systematic reviews have been published with 
regard to the use of intraumbilical oxytocics but these studies assessed the utility of 
intraumbilical oxytocin for the treatment of retained placenta instead of postpartum 
haemorrhage prophylaxis. From the existing evidence, it would appear that the 
routine use of intraumbilical oxytocin for the prevention of postpartum haemorrhage 
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is questionable, although its use for the management of retained placenta may be 
promising [Carroli & Bergel 2003].  
 
In 1992, Bider et al [Bider et al 1992] investigated the effect of umbilical 
vein injection of prostaglandin F2 alpha on the third stage of labour in a small 
double-blind randomised controlled trial. The authors concluded that the 
intervention did not influence the duration of the third stage of labour.  
 
Oral ergometrine and methylergometrine 
The uterotonic activity of oral methylergometrine was first reported in 1972 
[Reichev et al 1972]. Oral ergometrine and methylergometrine were considered as 
possible alternatives to conventional oxytocics as they were easy to administer. Both 
these oral drugs are known for their strong uterotonic effect, and for their relatively 
slight vasoconstrictive properties. They act differently from oxytocin and 
prostaglandins, and have different adverse effects. Unfortunately, both are unstable 
even when stored under refrigerated conditions. Their pharmacokinetic and dynamic 
properties are unpredictable and no clinical effect on reduction of blood loss after 
childbirth has yet been shown [Andersen et al 1998; de Groot et al1996]. In a 
comprehensive review by de Groot et al, it was suggested that because of their 
unreliability, they had no place as routine prophylactic uterotonic agents but could 
be considered when conventional oxytocics failed to prevent postpartum 






De Groot AN et al [1995] assessed the bioavailability and pharmacokinetics 
of sublingual oxytocin in a small number of subjects. The study showed great inter-
individual variability in bioavailability. It was concluded that the sublingual route of 
administration of oxytocin, with its long lag-time and absorption half-life, did not 
seem a reliable route for the routine prevention of postpartum haemorrhage. 
 
Injectable prostaglandins 
The uterotonic activity of prostaglandins is well known. In a randomised 
controlled study, the prophylactic use of intramuscular prostaglandin 15-methyl F2 
alpha (Carboprost, Astra, India) in the active management of the third stage of 
labour gave similar results to prophylactic intramuscular syntometrine in terms of 
length of the third stage of labour, incidence of postpartum haemorrhage and total 
blood loss after delivery. However it had the disadvantage of higher cost, as well as 
statistically significant increase in the incidence of profuse and frequent diarrhoea 
[Chua et al 1995].  
 
In another randomized trial comparing Hemabate (Pharmacia-Upjohn 
Pharmaceuticals, Milton Keynes, Buckinghamshire) an analogue of 15-methyl-
prostaglandin (PGF2alpha) with syntometrine, the study was discontinued early 
because of unacceptable gastrointestinal side effects [Lamont et al 2001]. The most 
common side effect was diarrhoea which occurred in 21% of women who received 
Hemabate compared to only 0.8% of syntometrine users. PGF2alpha is as effective 
as syntometrine in the prophylaxis of primary postpartum haemorrhage in women 
delivered by caesarean section or vaginally in both high and low risk groups but 
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there was a statistically significant increased risk of diarrhoea among users of 
PGF2alpha. 
 
Cochrane reviews have found that injectable prostaglandins were associated 
with decreased blood loss and shortened duration of third stage when compared to 
other uterotonics. Adverse effects (vomiting, diarrhoea and abdominal pain) were 
more common with prostaglandins when compared to other uterotonic agents. 
Although injectable prostaglandins appear to be effective in preventing postpartum 
haemorrhage, concerns about safety and costs limit their suitability for routine 
prophylactic management of third stage of labour. However, injectable 
prostaglandins should continue to be used for the treatment of postpartum 
haemorrhage when other measures fail [Gulmezoglu 2000]. 
 
Carbetocin 
The uterotonic activity of carbetocin, a long-acting oxytocin analogue, was 
first described in 1987 [Atke & Vilhardt 1987]. In pharmacokinetic studies, 
intravenous injections of carbetocin produced tetanic uterine contractions within 2 
minutes, lasting about 6 minutes, followed by rhythmic contractions for a further 
hour. Intramuscular injection also produced tetanic contraction in less than 2 
minutes, lasting about 11 minutes, and followed by rhythmic contractions for an 
additional two hours. The prolonged duration of activity after intramuscular 
compared with the intravenous carbetocin was significant [Hunter et al 1992]. 
Carbetocin produces side effects of mild lower abdominal cramping, flushing and 
warmth. Its prolonged uterine activity may offer advantages over oxytocin in the 
management of the third stage of labour. 
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In a dose tolerance study, carbetocin was given as an intramuscular injection 
immediately after the birth of the infant in 45 healthy women with normal singleton 
pregnancies who delivered vaginally at term [van Dongen et al 1998]. The dose-
limiting adverse events recorded were hyper- or hypotension in three women, and 
retained placenta in four women. Serious adverse events occurred in seven women. 
Six had blood loss greater or equal to 1000 ml, four required manual removal of 
placenta, five required additional oxytocics, and five patients were given blood 
transfusion. Maximum blood loss was greatest at the upper and lower dose levels, 
and lowest in the 70-125 mcg dose range. The maximum tolerated dose was found to 
be 200 mcg carbetocin. Women receiving this dose experienced the most adverse 
events, including excessive blood loss. 
 
In a Canadian multicentre, double-blind, randomised clinical trial of patients 
undergoing elective cesarean section, a single 100 micrograms intravenous injection 
of carbetocin appeared to be more effective than a continuous infusion of oxytocin 
in maintaining adequate uterine tone and preventing excessive intraoperative blood 
loss during cesarean section. Carbetocin was well tolerated with a similar safety 
profile to oxytocin [Boucher et al 1998; Dansereau et al 1999].  
 
No clinical trials have yet reported the efficacy of intramuscular carbetocin 
for preventing postpartum haemorrhage in the third stage of labour for vaginal 
deliveries. The potential advantage of intramuscular carbetocin over intramuscular 
oxytocin is its longer duration of action. Its relative lack of gastrointestinal and 
cardiovascular side effects may also prove advantageous compared to syntometrine 
and other ergot alkaloids. The only limiting factor would appear to be its cost. 
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Misoprostol 
Misoprostol is a synthetic analogue of prostaglandin E1 approved by the 
United States Food and Drug Administration in 1988 to be taken orally for the 
prevention and treatment of gastric ulcers associated with the use of nonsteroidal 
anti-inflammatory drugs. Because of its uterotonic and cervical-ripening activity, 
wide-ranging off-label uses have been found for misoprostol, and it has been 
described as “one of the most important medications in obstetrical practice” 
[Goldberg et al 2001]. The first use of misoprostol for the prevention of postpartum 
haemorrhage in the third stage of labour was reported in 1996 in a prospective 
uncontrolled study [El-Refaey et al 1996]. A further review of the history, 
development and use of misoprostol will be given in the next chapter. 
 
Conclusion 
 Despite sound evidence that active management of the third stage of labour 
reduces the incidence of postpartum haemorrhage and other serious third stage 
complications, recent surveys, show that there are wide variations in practice around 
the world with expectant management still widely practised. Factors accounting for 
this situation include the desire for a more natural experience of childbirth, the 
philosophy that active management is unnecessary in low risk women, and 
avoidance of the adverse effects of conventional uterotonic agents. Intramuscular 
and intravenous oxytocin have proved to be as clinically effective as oxytocic 
preparations containing ergot alkaloids without the unfavourable side effects. Much 








Misoprostol: the accidental uterotonic agent 
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Introduction 
Misoprostol is a synthetic analogue of prostaglandin E1 approved by the 
United States Food and Drug Administration (FDA) in 1988 to be taken orally for 
the prevention and treatment of gastric ulcers associated with the use of nonsteroidal 
anti-inflammatory drugs (NSAID). In 2001, annual sales for Cytotec® (misoprostol) 
reached approximately US$95 million. However, annual sales for this product have 
been declining in recent years, which may be partially due to the introduction of 
COX-2 inhibitors that largely eliminate the need for the mucosal protective effect of 
misoprostol [Express scripts 2002]. Ironically, since the early 1990s, misoprostol 
has been viewed with increasing interest by an unintended audience- obstetricians 
and gynaecologists. Because of its uterotonic and cervical-ripening activity, wide-
ranging off-label uses have been found for misoprostol, and it has been described as 
“one of the most important medications in obstetrical practice” [Goldberg et al 
2001]. Yet until very recently, misoprostol was not approved by the FDA for use in 
pregnant women, a stand strangely and strongly supported by its manufacturer 
(Searle, Chicago, USA) [Friedman 2001]. 
 
Natural and synthetic prostaglandins are known to affect the female 
reproductive system and misoprostol is not different in this respect. However, 
misoprostol has several advantages over other forms of prostaglandins that have 
made it a central focus of research in the specialty of obstetrics and gynaecology 
over the past two and a half decades. Misoprostol is rapidly absorbed orally [Zieman 
et al 1997] and, though not formulated for parenteral use, can also be administered 
sublingually [Tang et al 2002a], rectally [Khan & El-Refaey 2003], and vaginally 
[Zieman et al 1997]. It is substantially less expensive than other preparations of 
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prostaglandins and does not require refrigerated transport or storage [Searle 1995]. 
These characteristics make it particularly suitable for use in the setting of developing 
countries. The history of misoprostol and the development of this medication for the 
various indications are described in this review. 
 
The pharmacological properties of misoprostol 
Prostaglandins are naturally occurring 20-carbon cyclopentane carboxylic 
acids present in nearly all tissues, and are metabolized like fatty acids. Unlike 
hormones, they exert their effect locally, and are metabolized where they are 
produced. 
 
Misoprostol is a synthetic 15-deoxy-16-hydroxy-16-methyl analogue of the naturally 
occurring prostaglandin E1. Misoprostol contains approximately equal amounts of 
the two diastereomers presented below (Figure 2.1). 
 
Figure 2.1: Misoprostol Chemical Structure 
Formula: C22H38O5 Molecular wt.: 382.5 
(±) methyl 11{α}//{alpha}, 16-dihydroxy-16-methyl-9-oxoprost-13E-en-1-oate 
Source: G.D. Searle & Company  
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Misoprostol is a water-soluble, viscous liquid. The commercial preparation 
commonly available are Cytotec® (Searle, Chicago, USA) tablets that contain the 
inactive ingredients hydrogenated castor oil, hydroxypropyl methylcellulose, 
microcrystalline cellulose, and sodium starch glycolate. The tablets are either 200 µg 
scored tablets or 100 µg unscored tablets. 
 
Pharmacokinetics 
The pharmacokinetic profile of misoprostol is characterized by rapid 
absorption, extensive metabolism and rapid excretion. Misoprostol is extensively 
absorbed, and undergoes rapid de-esterification to its free acid, which is responsible 
for its clinical activity and, unlike the parent compound, is detectable in plasma. The 
alpha side chain undergoes beta oxidation and the beta side chain undergoes omega 
oxidation followed by reduction of the ketone to give prostaglandin F analogues. 
 
Misoprostol is rapidly absorbed after oral administration with a Tmax of 
misoprostol acid of 12 ± 3 minutes and a terminal half-life of 20-40 minutes. There 
is high variability of plasma levels of misoprostol acid between and within studies 
but mean values after single doses show a linear relationship with dose over the 
range of 200 to 400 mcg. No accumulation of misoprostol acid was noted in 
multiple dose studies; plasma steady state was achieved within two days. Maximum 
plasma concentrations of misoprostol acid are diminished when the dose is taken 
with food and total availability of misoprostol acid is reduced by use of concomitant 
antacid [Searle 1995]. 
 
20 
Misoprostol is primarily metabolised in the liver, and less than 1% of its 
active metabolite is excreted in the urine [Foote et al 1995]. Misoprostol does not 
affect the hepatic mixed function oxidase (cytochrome P-450) enzyme systems in 
animals. The serum protein binding of misoprostol acid is less than 90% and is 
concentration-independent in the therapeutic range. Misoprostol has no known drug 
interactions. 
 
Pharmacokinetic studies in pregnant women show that the peak plasma 
levels of misoprostol are sustained for up to 4 hours after vaginal administration 
[Zieman et al 1997]. Studies have also shown that sublingual and oral tablet 
misoprostol used for first-trimester abortions produce earlier and higher peak plasma 
concentrations [Danielsson et al 1999; Tang et al 2002a; Khan & El-Refaey 2003] 
than vaginal or rectal misoprostol, resulting in earlier, more pronounced uterine 
tonus. Gemzell Danielsson and colleagues’ study also reported the times of onset of 
action for oral tablet (7.8 min, SD 3.0 min) and vaginal misoprostol (20.9 min, SD 
5.3 min). These findings have very recently been validated in women after delivery 
[Abdel-Aleem et al 2003].  
 
Misoprostol tablets are not designed for parenteral administration and may 
lead to slow or erratic absorption if given rectally or vaginally. This may be 
overcome by its proper formulation into vaginal pessaries and rectal suppositories. 
In the pharmacokinetic study by Tang et al, the peak plasma level of misoprostol 
acid was highest and earliest with sublingual misoprostol. This information has 
important significance in the clinical setting as it helps clinicians decide the most 
effective regime for their individual purpose. 
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Pharmacodynamics 
Nonsteroidal anti-inflammatory drugs block the COX-1 enzyme from 
forming beneficial prostaglandins, such as PGE1. PGE1 plays a role in protecting 
the stomach and duodenum. Administering naturally occurring PGE1 orally is 
ineffective because it is unstable in an acidic environment. Misoprostol differs 
structurally from naturally occurring PGE1, allowing it to become metabolized. 
When metabolized it acts systemically to stimulate mucous production. To a lesser 
extent, misoprostol acts locally on the stomach wall. At doses 200 micrograms and 
above misoprostol also reduces gastric acid secretion. It is not possible to determine 
if misoprostol’s ability to prevent gastric ulcers is the result of its anti-secretory 
effect, its mucosal protective effect, or both [Searle 1995]. Misoprostol has not been 
shown to aid in the healing of existing NSAID-induced ulcers, but it does prevent 
them. 
 
Since misoprostol is a synthetic prostaglandin of type E1, it can be expected 
to have an effect in other areas of the body where regulatory prostaglandins are 
created. In addition to the stomach, two areas where misoprostol has an effect are 
the kidneys and uterus. 
 
Normal prostaglandins in the kidneys are released to compensate for renal 
vasoconstriction. The prostaglandins PGE2 and PGI2 stimulate vasodilatation 
[Delmas 1995]. Use of NSAIDs reduces these prostaglandins by blocking 
constitutive cyclooxygenase. It follows that the addition of a synthetic prostaglandin 
such as misoprostol may help protect against renal impairment in chronic NSAID 
users. Misoprostol has been studied as a renal-protective agent [Shield 1995; 
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Weinblatt et al 1994; Wong et al 1995] but no statistically significant results have 
been reported.  
 
Natural prostaglandins also ripen the cervix and induce uterine contractions 
during pregnancy. It is for this reason that misoprostol has found a novel application 
in the area of obstetrics and gynaecology.  
 
Misoprostol does not produce clinically significant effects on serum levels of 
hormones, creatinine, or uric acid. Gastric emptying, immunologic competence, 
platelet aggregation, pulmonary function, and the cardiovascular system are not 
modified by recommended doses of misoprostol. 
 
The development of misoprostol 
 Early interest in the pharmacologic activity of misoprostol centered on its 
effects on the gastrointestinal tract [Dajani et al 1976; Colton et al 1978]. The 
activity of misoprostol on other organ systems, including the uterus, had been 
investigated in preclinical studies [Bauer 1985] and clinical studies [Rabe et al 1987] 
but were largely ignored initially. 
 
The antisecretory activity of misoprostol was confirmed in human subjects as 
early as 1982 [Akdamar et al 1982]. Misoprostol was first used in a multicenter 
randomized double-blind trial for patients with peptic ulcer disease in 1985 
[Agrawal et al 1985]. It inhibits the secretion of acid and pepsin in the stomach and 
has been shown to have a mucosal protective effect on the gastrointestinal mucosa 
[Hunt et al 1983]. It is therefore widely marketed for use in the prevention and 
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treatment of peptic ulcer disease. It was noted that there was no significant adverse 
effects on blood pressure, pulse, platelets, the immune system, pulmonary function, 
or the endocrine system [Steiner 1985]. 
 
Misoprostol, taken as an oral tablet, was approved by the FDA in 1988 for 
the prevention and treatment of gastric ulcers associated with the use of nonsteroidal 
anti-inflammatory drugs. 
 
Figure 2.2: Commercial misoprostol tablets 
 
Approved use and known adverse effects 
 Misoprostol is the only approved agent for prophylaxis of NSAID-induced 
ulcers and is recommended in high risk patients if NSAIDS cannot be avoided. 
Misoprostol has not been shown to reduce the risk of duodenal ulcers in patients 
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taking NSAIDs. Misoprostol should be taken for the duration of NSAID therapy. It 
has no effect, compared to placebo, on gastrointestinal pain or discomfort associated 
with NSAID use. 
 
Side effects 
Common side effects include diarrhoea and abdominal pain. Diarrhoea is 
more common with higher doses of the medication used, and usually goes away with 
continued administration. Rarely, profound and persistent diarrhoea necessitates 
stopping the medication. Less common side effects include headache, menstrual 
cramps, nausea, and flatulence, chills, shivering and fever, all of which are dose-
dependent. It is interesting to note that prior to its use in pregnant women, chills, 
shivering and fever were not commonly reported side effects. 
 
Pregnancy warning 
Women of childbearing potential using misoprostol to decrease the risk of 
NSAID induced ulcers should be told that they must not be pregnant when 
misoprostol therapy is initiated, and they must use an effective contraception method 
while taking misoprostol. Package warnings are very clear that misoprostol is not to 
be taken by pregnant women [Searle 1995]. Physicians are advised to have the 
female patient start misoprostol for ulcer protection only on the second or third day 
of her next menstrual period. It is also necessary for her to have a negative serum 
pregnancy test result within two weeks prior to misoprostol therapy, and use birth 
control while taking misoprostol They should be warned that misoprostol may cause 
abortion (often incomplete), premature labour, or birth defects if given to pregnant 
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women. Misoprostol should also be avoided in nursing mothers because of concern 
over causing diarrhoea in the baby [Abdel-Aleem et al 2003]. 
 
Teratogenic effects 
Congenital anomalies sometimes associated with fetal death have been 
reported subsequent to the unsuccessful use of misoprostol as an abortifacient 
[Pastuszak et al 1998; Gonzalez et al 1998] but the drug’s teratogenic mechanism 
has not been elicited. Several reports in the literature associate the use of 
misoprostol during the first trimester of pregnancy with skull defects, cranial nerve 
palsies, facial malformations, and limb defects [Orioli & Castilla 2000]. Misoprostol 
is not fetotoxic or teratogenic in rats and rabbits at doses 625 and 63 times the 
human dose, respectively [Searle 1995]. Misoprostol is listed as a pregnancy 
category X drug. 
 
Nonteratogenic effects 
Misoprostol may endanger pregnancy and thereby cause harm to the fetus 
when administered to a pregnant woman. Misoprostol may produce uterine 
contractions, uterine bleeding, and expulsion of the products of conception. 
Abortions caused by misoprostol may be incomplete. If a woman is or becomes 
pregnant while taking this drug to reduce the risk of NSAID induced ulcers, the drug 






Early off-label use of misoprostol 
The first report suggesting a potential off-label use of misoprostol for the 
termination of first trimester pregnancy was published in 1987 [Rabe et al 1987]. 
Two separate studies were conducted in patients in the first trimester of pregnancy 
who were about to undergo legal termination of pregnancies. In the first study, 
intrauterine pressure was monitored in eight patients by a transducer. In comparison 
with placebo, misoprostol was shown to cause a consistent increase in the frequency 
and intensity of uterine contractions and in the frequency of bleeding. In the second 
study, the effects of misoprostol 400 µg and 800 µg were compared with placebo in 
300 patients at 9 to 12 weeks of gestation the evening before a legally permitted 
termination of first-trimester pregnancy. The incidence of spontaneous partial or 
complete abortion, vaginal bleeding and softening of the cervix were all 
significantly increased by misoprostol treatment. Although the investigators 
consequently recommended that misoprostol should not be used in pregnant women, 
their results must have formed the nidus for the subsequent interest in the use of 
misoprostol for termination of pregnancy. The first formal clinical trials on the use 
of misoprostol for obstetric [Fletcher et al 1993], and gynaecological purposes 
[Norman et al 1991] followed just over three years later. 
  
Misoprostol and illegal abortion 
 Of the 46 million abortions occurring worldwide each year, 20 million take 
place in countries where abortion is prohibited by law, and every year, 
approximately 78,000 women die from complications due to illegal or unsafe 
abortions [“Facts in Brief: 2003”]. Unfortunately, in this matter, misoprostol has 
been a major factor over the last 15 years. The abuse of misoprostol for illegal 
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abortion was reported as early as 1991 by Klitsch [1991]. Misoprostol was widely 
used as an abortifacient following its introduction in 1986, especially by women in 
countries where abortion was illegal or where it was legal only in limited 
circumstances such as rape or to save a woman’s life. Most of the publications and 
reports were therefore from Brazil and other countries in South and Central 
America. The widespread popular misuse of this drug is partly due to the low cost 
and the convenience of use, and partly because it is less traumatic than the other 
abortion methods and can be taken in privacy. In the late 1980s and early 1990s, the 
media, pharmacies, physicians and manufacturers also spread the news that 
misoprostol could be used to induce abortion and the medication could be purchased 
over-the-counter in pharmacies in some countries. Many epidemiological surveys 
were performed to investigate the percentage of women using misoprostol for self-
induced abortion and the demographic characteristics of these women [Barbosa & 
Arilha 1993; Costa & Vessey 1993]. By 1990, about 70% of women hospitalised 
with abortion-related diagnoses reported use of the drug.  
 
Several studies in the early 1990s suggested that misoprostol was an 
inefficient abortifacient [Coelho et al 1993; Fonseca et al 1996; Gonzalez et al 
1998]. In retrospect, it was probably because the appropriate dosage and interval of 
administration had not been subject to detailed research at that time and the use of 
misoprostol in the setting of illegal abortion was likely to be amateurish at best. 
Coelho and colleagues reported in 1993 [Coelho et al 1993] that many women who 
used misoprostol for self-induced abortion had incomplete abortions and required 
subsequent uterine evacuation. The number of uterine evacuations in the obstetric 
28 
hospital in their study was noted to fall substantially when sales of misoprostol in 
the state was suspended in 1991. 
 
In addition to incomplete abortion, misoprostol was also associated with 
failed abortion attempts and continued pregnancy. This raised concerns about the 
effects of in utero exposure of the fetus to misoprostol. The initial evidence came 
from case reports of congenital anomalies after maternal use of misoprostol. 
Gonzalez et al [1993] reported in 1993 on seven infants whose mothers attempted to 
abort using misoprostol in the first trimester of pregnancy without success. The 
seven infants were born with limb defects and, in four of them, a diagnosis of 
Mobius syndrome was made. Bond and Van Zee [1994] reported in the subsequent 
year a case of overdosage of misoprostol in pregnancy, and showed that toxicity 
could be manifested as hypertonic uterine contractions with fetal demise, 
hyperthermia, rhabdomyolysis, hypoxaemia, respiratory alkalosis and metabolic 
acidosis. Concerns were expressed with respect to the use of misoprostol as an 
illegal abortifacient. Following these case series, more studies were performed to 
define the effects of in utero exposure of the fetus to the drug. In the report by 
Gonzalez et al [1998] in 1998, the distinctive phenotypes included equinovarus with 
cranial nerve defects, arthrogryposis confined to the legs and terminal transverse 
limb defects. The authors suggested that these deformities were attributed to 
vascular disruption, which could be due to the uterine contractions induced by 
misoprostol. It was concluded that greater awareness of the widespread use of 
misoprostol to induce abortion should lead to public health interventions to prevent 
teratogenic effects. Schuler et al [1999] conducted the first prospective controlled 
study on fetal safety after misoprostol use. Even though they suggested that a potent 
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teratogenic effect of misoprostol exposure during pregnancy was unlikely, the study 
had limited statistical power.  
 
Although sales of this abortifacient were suspended by health authorities in 
certain countries due to concerns about congenital malformations following 
unsuccessful abortion attempts in 1991, the drug remains widely available on the 
black market at an inflated price. Continued surveillance has since indicated that 
women have acquired more experience with the drug over time, resulting in lower 
and safer dosages used, and more effective use [Costa 1998]. However, the risks of 
self-induced abortion cannot be over-emphasized. Recent studies such as that by 
Pongsatha and colleagues [2002] indicate that the use of misoprostol for self-
induced abortion is an ongoing problem. There is no quick and easy solution. Public 
health education plays an essential role in encouraging the use of contraception and 
reducing the morbidity and mortality related to illegal abortion. 
 
First trimester termination of pregnancy 
 First trimester termination of pregnancy is traditionally performed by 
surgical evacuation of the uterus. This procedure is not always safe, especially in the 
setting of developing countries, and complications range from infection and uterine 
perforation to cervical stenosis and incompetence. Prostaglandins have been shown 
to be effective at inducing early abortion since the 1970s [Karim 1971]. By the 
1980s, more stable prostaglandin analogues were found to be effective for abortion. 
These include parenteral sulprostone and intravaginal gemeprost. However, the 
adverse side-effects of these medications made them unsuitable as sole agents for 
abortion.  
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Studies investigating the use of misoprostol on pregnancy were first 
published in 1987 [Rabe et al 1987] as mentioned earlier. The incidence of 
spontaneous partial or complete abortion, vaginal bleeding and softening of the 
cervix were all significantly increased by misoprostol treatment. In 1991, the 
landmark study by Norman and colleagues [1991] was published in the Lancet. The 
authors investigated the effect of misoprostol on uterine contractility and showed 
that misoprostol, with or without mifepristone, resulted in a significant increase in 
the amplitude and frequency of uterine contractions. These results showed 
misoprostol to be a promising uterotonic agent and sparked off tremendous research 
interest in this area. Misoprostol was investigated both as a cervical priming agent 
prior to surgical abortion and as an agent for medical abortion. 
 
With regard to the use of misoprostol as a cervical priming agent prior to 
vacuum aspiration of the uterus, numerous randomised controlled trials were 
published. Bugalho et al [1994] compared the use of vaginal misoprostol versus 
placebo in 1994, and Ngai et al [1995] first compared the use of oral misoprostol, 
placebo and vaginal gemeprost in 1995. The studies generally showed that 
misoprostol is as effective as or more effective than placebo and vaginal gemeprost 
in terms of the degree of cervical dilatation achieved which helped to facilitate 
surgical vacuum aspiration. The risks of the surgical procedure of cervical dilatation 
and evacuation of the uterus could therefore be minimized. These results were 




For medical abortion, the clinical testing of mifepristone, a progesterone 
antagonist, started in 1982. The initial results were that at best, only 80% of women 
treated with mifepristone alone during early pregnancy had complete abortion, a rate 
not clinically acceptable. In 1985, investigators reported that adding small doses of a 
prostaglandin analogue increased the efficacy of mifepristone as an abortifacient to 
nearly 100% [Swahn et al 1985; Bygdeman & Swahn 1985]. In 1992, Thong and 
Baird [1992] investigated the use of mifepristone followed 48 hours later by oral 
misoprostol, and reported the combination to be highly effective. Research looking 
at the use of methotrexate followed by misoprostol for early abortion also started in 
1993 [Creinin & Darney 1993]. However, the methotrexate-misoprostol regime was 
found to have lower efficacy compared to the mifepristone-misoprostol regime 
[Peyron et al 1993; Creinin et al 1995; Creinin et al 1996; Creinin et al 1997; 
Creinin et al 1997a]. In the study published by Schaff et al in 1999 [Schaff et al 
1999], the complete abortion rate of 97% did not differ between women at 49 days’ 
gestation or less and those at 50-56 days’ gestation. Generally, it is felt that when 
mifepristone is administered in conjunction with a prostaglandin analogue such as 
misoprostol, the abortion rate is comparable to that for vacuum aspiration. 
 
In 1995, El-Refaey H et al [El-Refaey et al 1995] conducted a prospective, 
randomized trial to compare oral with vaginal administration of misoprostol for first 
trimester abortion in women treated initially with mifepristone. The results were 
published in the New England Journal of Medicine and they concluded that vaginal 
administration of misoprostol was more effective and better tolerated than oral 
administration for the induction of first trimester abortion. A similar study by 
Carbonell et al [2001] also concluded that vaginal misoprostol was the best route of 
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administration, as it obtained the same or greater priming effectiveness of the cervix 
in half the time and with a much lower frequency of side effects. However, some 
studies concluded that both oral and vaginal misoprostol were of similar efficacy. 
 
As mifepristone is expensive and only available in a small number of 
countries, investigators started to evaluate the use of misoprostol without 
mifepristone or methotrexate pre-treatment. In 1996, Koopersmith and Mishell 
[1996] and Bugalho et al [1996] published the first papers about the use of 
misoprostol alone for termination of early pregnancy. The results were very 
promising and were supported by several other studies in the following years. 
However, over the years, complete abortion rates from the use of misoprostol alone 
varied from 20% to 93.9%. The studies employ different dosages and regimens of 
misoprostol administration, and the results are therefore difficult to compare. The 
success rate of abortion was also defined differently with respect to the time period 
at which it was measured, further clouding the assessment of the efficacy of 
misoprostol. 
 
In most of the studies, the misoprostol regime described takes a few days to 
complete. The dosages studied varied from 600 to 1000 micrograms every 24 hours 
for a maximum of three doses [Carbonell et al 1997; Carbonell et al 2000; Carbonell 
et al 2001a]. Only two studies used regimens that could be completed within a day 
[Koopersmith & Mishell 1996; Tang et al 1999]. Singh et al [2003] showed in their 
recent report that repeated doses of vaginal misoprostol over nine hours in a day care 
setting is an effective method of medical abortion for pregnancy up to eight weeks 
of gestation. 
33 
In 2001, one pilot study [Tang & Ho 2001] was performed to assess the use 
of sublingual misoprostol for medical abortion. Even though it was a small study 
involving a total of 43 women, 92% of the women with first trimester gestation had 
complete abortion, and all women requesting second trimester abortion had 
complete abortion. The preliminary results showed that this was a promising method 
for medical abortion and it was suggested that prospective randomised studies 
should be conducted to compare its efficacy and side effects with vaginal 
misoprostol, and to work out the dosage and dosing interval. Two prospective 
randomised placebo-controlled study comparing sublingual misoprostol and placebo 
were published in 2003 [Saxena et al 2003; Vimala et al 2003]. They concluded that 
sublingual misoprostol was effective in facilitating cervical dilatation prior to 
surgical abortion, and its usage significantly decreased the time of surgical 
evacuation, and minimized blood loss during the procedure. 
 
Early pregnancy failure 
 Several studies investigated the use of oral misoprostol for incomplete 
abortion and missed abortion. Henshaw et al [1993] published one of the first studies 
looking at the use of oral misoprostol for incomplete abortion in 1993. Since then, 
several other studies were conducted, the results of which were all very encouraging. 
Chung et al [1999] compared the complication rates between groups of women 
randomised to receive either misoprostol or surgical evacuation. The immediate, 
short-term and medium-term medical complications were significantly lower in the 
misoprostol group than in the surgical group. However, some practitioners may feel 
that incomplete abortion is associated with risks of bleeding and infection which 
may make immediate surgical evacuation of the uterus a better option. 
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Herabutya et al and Wakabayashi et al [Herabutya & O-Prasertsawat 1997; 
Wakabayashi et al 1998] evaluated the safety and efficacy of vaginal misoprostol for 
medical evacuation of first trimester missed abortions and the reports were published 
in 1997 and 1998 respectively. The authors suggested that this appeared to be a good 
alternative to dilatation and curettage. This was followed by a number of other 
studies which suggested that repeated doses of misoprostol result in high rates of 
complete expulsions with minimal side effects and complications. A small 
randomised study comparing the efficacy of oral and vaginal misoprostol for missed 
abortion found vaginal administration to be more effective (88% versus 25% 
respectively) [Creinin et al 1997b) 
 
In 2001, Xu et al [2001] studied the safety of misoprostol in the presence of a 
scarred uterus and concluded that, for termination of early pregnancy in scarred 
uteri, administration of mifepristone and misoprostol was safe and effective, but they 
suggested that further large studies were needed to confirm its acceptability as a 
routine medication in such situations. 
 
Mid-trimester termination of pregnancy / Intrauterine fetal death 
 Besides social reasons, indications for mid – trimester termination of 
pregnancy include chromosomal and structural fetal abnormalities detected in the 
second trimester of pregnancy. Surgical dilatation and evacuation of the uterus had 
been done and is still being practised in a limited number of centres. However, 
surgical evacuation of the uterus in the mid trimester is associated with greater 
maternal morbidity and mortality and complications include infection, uterine 
perforation and hysterectomy. Before the introduction of misoprostol, medical 
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methods which were used include intra-amniotic hypertonic saline instillation, intra-
amniotic prostaglandin F2α infusion, oxytocin infusion and vaginal gemeprost 
administration. 
 
In 1993, Bugalho et al studied the effectiveness of intravaginal misoprostol 
administration [Bugalho et al 1993]. During the course of the study, the 800 
micrograms dosage was successively reduced to 600, 400 and 200 micrograms. 
Many studies that were subsequently conducted aimed to achieve a balance between 
the efficacy of the dose regime and the possible adverse effects caused. A number of 
studies conducted showed that doses of 400 micrograms are effective and are 
associated with less side effects. 
 
Elsheikh et al [2001] concluded from their study that the high efficacy and 
low incidence of side effects make misoprostol a useful alternative for mid-trimester 
termination of pregnancy. Several studies were also performed which made direct 
comparison between misoprostol and the other modalities for mid-trimester 
termination of pregnancy. Three randomised controlled trials compared vaginal 
misoprostol with gemeprost among women with live and dead fetuses in the second 
trimester [Nuutila et al 1997; Dickinson et al 1998; Wong et al 1998]. In all these 
studies, misoprostol was found to be as effective as, or more effective than, 
gemeprost. Ashok and Templeton [1999] reviewed 500 consecutive cases of non-
surgical mid-trimester termination of pregnancy and concluded in 1999 that the 
combination of mifepristone followed by misoprostol provided a non-invasive and 
effective regimen for this indication. In 2001, [Munthali & Moodley [2001] 
compared the effectiveness between vaginal misoprostol and extra-amniotic 
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prostaglandins and concluded that the former was as effective as the latter. Another 
study by Ghorab and El Helw [1998] compared endocervical misoprostol and extra-
amniotic prostaglandins F2 α and showed that misoprostol was more effective. The 
paper by Perry et al [1999] compared the efficacy of vaginal misoprostol to intra-
amniotic prostaglandins F2 alpha. Although the study concluded that intra-amniotic 
prostaglandin F2 alpha was more effective than vaginal misoprostol, it was a small 
study and the dose of misoprostol used in the study was suboptimal judging by the 
doses used in other studies. Ramin et al [2002] concluded in their study in 2002 that 
high-dose oral misoprostol is more effective than concentrated oxytocin infusion for 
mid-trimester pregnancy interruption. 
 
As the dosage of misoprostol, used for mid-trimester pregnancy interruption, 
tends to be high, the side-effects are the main limiting factors when one studies the 
dosage and the interval between administration. In the study by Zieman et al [1997], 
the plasma concentration of 400 micrograms of misoprostol acid after administration 
reached maximum values between 60 and 120 minutes and declined slowly to an 
average of 60% of the peak at 240 minutes after administration. Wong and 
colleagues [2000] suggested that if the pharmacological effect of misoprostol is 
related to its concentration in the plasma, misoprostol could be administered at 
longer than 3 hours intervals which may have fewer side-effects. They therefore 
made a comparison of the efficacy and side-effects of 400 micrograms misoprostol 
administered 3 hourly and 6 hourly. The results were published in 2000 and the 
study concluded that the 3-hourly regime was more effective in terms of a 
significantly shorter drug administration to abortion interval and higher percentage 
of successful abortion within 48 hours. The incidence of side-effects was similar in 
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the two groups except that of fever but the temperatures returned to normal within 
24 hours after the last dose of misoprostol. 
 
The route of administration of misoprostol was also investigated. In 2000, 
Ngai et al [2000] suggested that oral misoprostol is as effective as vaginal 
misoprostol if the dose was doubled. However, the increased dosage was associated 
with a higher incidence of side effects. In the following year, Gilbert and Reid 
[2001] conducted a randomised trial of oral versus vaginal misoprostol and the 
results showed that the vaginal route of administration was significantly more 
effective as judged by drug administration to abortion interval and the need or 
otherwise to augment the therapy with oxytocin infusion.  
 
Induction of labour 
 Induction of labour is primarily performed with the aim of reducing maternal 
or perinatal morbidity and mortality, and is the commonest obstetric intervention 
practised. The success rate of achieving vaginal birth increases if the physiological 
mechanisms of labour can be replicated. A variety of methods have been employed 
for this intervention which include catheter balloon insertion, laminaria tent 
insertion, prostaglandin E2 analogues and oxytocin infusion. Induction of labour in 
the presence of an unfavourable cervix presents the greatest challenge and the focus 
of continuing research has been the development of an effective pharmacological 




Sanchez-Ramos et al and Fletcher et al [Sanchez-Ramos et al 1993; Fletcher 
et al 1993] were the first to look at the use of vaginal misoprostol for induction of 
labour in viable fetuses at term, and the results were published in 1993. The results 
suggested that misoprostol is a cost effective and safe alternative for induction of 
labour at term. With these promising results, the use of misoprostol became an area 
of active research in the following decade.  
 
Many studies, including two systematic reviews by Hofmeyr et al in 1999 
[Hofmeyr 1999; Hofmeyr et al 1999a] and a meta-analysis of published randomized 
trials [Sanchez-Ramos et al 1997], have shown misoprostol to be more effective than 
placebo or other prostaglandins for the induction of labour. Misoprostol can achieve 
a higher rate of vaginal delivery within 24 hours, a shorter induction to delivery 
interval, and significantly lower overall caesarean section rates than pooled figures 
for the control groups [Sanchez-Ramos et al 1997a]. It minimizes the expenses 
associated with prostaglandin E2 analogues and intravenous oxytocin infusion. The 
safety profile has been demonstrated and is felt to be comparable to that of 
dinoprostone (PGE2). Some studies showed that there was a higher frequency of 
uterine tachysystole but this generally did not translate into an increased risk of 
adverse intrapartum or perinatal outcomes. Many factors affect the likelihood of 
successful induction with vaginal misoprostol and these include parity, initial 
cervical dilatation and gestational age at entry [Wing et al 2002]. 
 
As the efficacy of misoprostol became more certain, clinical trials were 
conducted to detail the optimal route of administration. From 1997 [Toppozada et al 
1997], results of studies investigating the use of oral misoprostol for induction of 
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labour were published. The oral form of administration is appealing due to the 
convenience, lack of invasiveness and fewer digital examinations are required which 
could potentially reduce the risk of infection. From 1998, many studies were 
conducted which made direct comparison between oral and intravaginal misoprostol. 
Some studies suggested that the efficacy of oral and intravaginal misoprostol were 
similar [Adair et al 1998]. However, others reported that intravaginal administration 
of misoprostol is associated with a shorter induction to delivery interval, lower 
number of doses and lower oxytocin use [Toppozada et al 1997; Nopdonrattakoon 
2003]. 
   
Studies were also performed to compare the efficacy of vaginal misoprostol 
gel and tablets and the study by Carlan et al [1997] suggested that misoprostol gel is 
associated with fewer uterine contraction abnormalities than the tablet form of the 
drug but results in a slower time to labour or delivery. In 1999, Liu et al [1999] 
reported the use of intracervical misoprostol and suggested that it is an effective 
alternative route of administration. Recent studies published in 2003 also indicated 
that sublingual misoprostol is a promising route of administration [Shetty et al 2002; 
Shetty et al 2002a] for the induction of labour in the presence of a live fetus. 
 
With regard to the safety of misoprostol, the dosage and the interval of 
administration of the drug is as crucial as the route of administration. At the same 
time that studies comparing different routes of administration of misoprostol were 
being conducted, researchers also started comparing the differing dosing regimens of 
the misoprostol in order to ascertain the optimal and safest dose. Generally the 50 
micrograms dosage results in a shorter induction to delivery interval and a higher 
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rate of vaginal delivery after one dose [Farah et al 1997; Srisomboon et al 1996]. 
However, a vaginal dose of 25micrograms is often recommended as the more 
prudent dose for labour induction because it is associated with a lower incidence of 
uterine hyperstimulation. It is also comparable to the 50 microgram dosage in 
achieving delivery within 24 hours [Hofmeyr 1999; Farah et al 1997; Srisomboon et 
al 1996; Wing & Paul 1996; Diro et al 1999; Meydanli et al 2003]. Doses higher 
than the 50 micrograms dosage have been associated with an increased risk of 
serious complications [Majoko et al 2002].  
 
In the literature, the interval of administration of misoprostol ranged from 
every 3 to 6 hours. In 1997, [Wing & Paul [1997] studied the intervals between the 
doses of misoprostol and found that the average induction to delivery interval was 
shorter in the 3-hourly dosing group than in the 6-hourly dosing group. The former 
was associated with a slightly higher prevalence of tachysystole even though the 
difference was not statistically significant in their study. However, due to the 
possible risk of tachysystole, many centres use 6-hourly dosing intervals in their 
protocol. 
 
In 1996, Ngai et al [1996] investigated the effectiveness of oral misoprostol 
as a cervical priming agent for patients presenting with pre-labour rupture of 
membranes at term and suggested that oral misoprostol is an effective agent for this 
group of patients. Similar results were published by Sanchez-Ramos et al in 1997 
[Sanchez-Ramos et al 1997] and Shetty et al in 2002 [Shetty 2002b]. The latter 
concluded that active management with oral misoprostol resulted in more women 
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going into labour and delivering within 24 hours of prelabour rupture of membranes 
with no increase in maternal or neonatal complications. 
 
Case reports were published with regard to the risk of uterine rupture during 
induction of labour with misoprostol [Bennett 1997; Wing et al 1998]. However, the 
safety profile of misoprostol use was demostrated in the study by Bique et al [Bique 
et al 1999] who used it on a group of grand-multiparous women with no significant 
adverse maternal or neonatal outcome. However, vigilance should be exercised in 
these cases, as emphasized by the American College of Obstetricians and 
Gynaecologists Bulletin [American College of Obstetricians and Gynecologists 
1999a]. The use of misoprostol in cases of previous caesarean section is another area 
of concern. It has been shown that misoprostol is associated with a higher frequency 
of disruption of prior uterine incisions compared to the use of dinoprostone or 
oxytocin. Many authors recommend that misoprostol should be avoided for women 
with prior caesarean deliveries. In their meta-analysis, Plaut et al [1999] reported a 
5.6% rate of rupture of uterine scars associated with the use of misoprostol 
compared with 0.2% in patients attempting vaginal birth after caesarean delivery 
with no stimulation. 
 
In studying the safety profile of misoprostol, Urban et al [2003] performed 
Doppler velocimetry of umbilical, uterine and arcuate arteries immediately before 
and two to three hours after the administration of vaginal misoprostol or cervical 
dinoprostone. The results, published in 2003, indicated that both increase the 
uteroplacental resistance but do not affect the umbilical blood flow, therefore 
suggesting that misoprostol should be as safe as dinoprostone.  
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Third stage of labour 
The first use of misoprostol for the prevention of postpartum haemorrhage in 
the third stage of labour was reported in 1996 in a small, prospective, uncontrolled 
study [El-Refaey 1996]. This formed the basis for my hypothesis that misoprostol, 
given in the correct dose and route, should produce a uterotonic effect similar to 
conventional oxytocics used for preventing postpartum haemorrhage. I have 
performed a systematic review of the randomised controlled clinical trials conducted 
since I began this thesis on the use of misoprostol for the prevention of postpartum 
haemorrhage in Chapter 10. 
 
Legitimacy at last 
 Research interest in the off-label use of misoprostol for obstetric and 
gynaecological purposes over the last 15 years has matched, if not exceeded, the 
interest in misoprostol for its intended and approved use for the prevention of 
NSAID-induced gastric ulcers in the preceding ten years. The FDA guidelines on the 
use of marketed drugs [United States Food and Drug Administration 1998] states 
that “if physicians use a product for an indication not in the approved labeling, they 
have the responsibility to be well informed about the product, to base its use on firm 
scientific rationale and on sound medical evidence, and to maintain records of the 
product's use and effects”. The large body of medical evidence for the efficacy and 
relative safety of misoprostol used judiciously in obstetric and gynaecology practice 
clearly provides the scientific basis for its “creative misuse” in pregnant women. In 
November 1999, the American College of Obstetricians and Gynecologists (ACOG) 
published an Obstetric Practice Committee opinion [American College of 
Obstetricians and Gynecologists 1999], and a practice bulletin [American College of 
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Obstetricians and Gynecologists 1999a], to provide guidelines for its members on 
the appropriate use of misoprostol. 
 
Matters came to a head when Searle, the manufacturer of misoprostol 
(Cytotec®), sent a letter to obstetricians and other physicians in the United States on 
August 23, 2000, warning that misoprostol “administration by any route is 
contraindicated in women who are pregnant because it can cause abortion”, and that 
misoprostol “is not approved for the induction of labour or abortion”. The letter 
further stated that “Searle has not conducted research concerning the use of Cytotec 
for cervical ripening prior to termination of pregnancy or for induction of labour, nor 
does Searle intend to study or support these uses”. This drug warning was unusual 
because many other medications have been and are used for off-label indications 
without precipitating similar responses from their manufacturers. This letter resulted 
in the wide-spread refusal by many hospitals and pharmacies to allow misoprostol to 
be dispensed for off-label use. The issue was further confused when the FDA 
announced the approval of mifepristone (RU 486) for the termination of pregnancies 
less than 49 days’ gestation one month later on September 23, 2000. The FDA 
protocol for mifepristone termination of pregnancy includes the use of misoprostol 
400 µg as part of the management. In December 2000, the ACOG published another 
committee opinion [American College of Obstetricians and Gynaecologists 2000] to 
specifically address the Searle drug warning, reaffirming that misoprostol is safe and 




An irate editorial by representatives of the ACOG [Hale & Zinberg 2001] 
accompanying a major review article on misoprostol and pregnancy [Goldberg et al 
2001] in the first issue of 2001of the New England Journal of Medicine, lamented 
the fact that Searle had made no attempt “to contact the ACOG or any scientific 
group to review the evidence regarding the benefits and risks of misoprostol in 
pregnant women” before issuing their warning letter. A reply by a Searle 
representative in the same issue [Friedman 2001] stated that they “fully support the 
role of physicians, using their own professional judgment, to prescribe an approved 
pharmaceutical product for a use outside of its FDA-approved indication in the best 
interest of their patients, on the basis of published research, expert clinical opinion, 
or their own clinical experience”, and that they “fully recognize the importance of a 
better dialogue with the American College of Obstetricians and Gynecologists, and 
with caregivers, on the issues and concerns reflected in the editorial”. 
 
The result of the ensuing dialogue was that just over a year later, on April 17, 
2002, the FDA finally approved a new label for the use of misoprostol during 
pregnancy [American College of Obstetricians and Gynecologists 2003]. The new 
labelling revises the contraindication and the precaution that misoprostol should not 
be used in pregnant women by stating that the contraindication is only for pregnant 
women who are using the medication to reduce the risk of nonsteroidal anti-
inflammatory drug-induced stomach ulcers. Misoprostol is now a legitimate part of 
the FDA-approved regime for use with mifepristone to induce abortion in early 




 For obstetrics and gynaecology, misoprostol has been a central focus of 
research for the past quarter century. It plays an important role in the field of 
termination of pregnancy at various gestations and induction of labour, and possibly 
for the management of postpartum haemorrhage. The increased access to and 
information on the use of misoprostol could help improve women’s health and 












The gold standard for the assessment of any intervention in the third stage of 
labour for preventing postpartum haemorrhage is quantitative measurement of blood 
loss. Unfortunately, like most reference standards, the objective measurement of 
blood loss in the third stage is impractical and difficult to achieve with any 
precision. Various methods have been described including direct collection using 
specially-designed birthing beds and bedpans [Calkins 1929; Murdoch 1958] with 
subsequent measurement of the blood collected. This is often combined with the 
collection of pre-weighed linen and pads that have been soaked with blood at 
delivery, which are then re-weighed to calculate the amount of blood collected 
[Hofmeyr et al 1998]. One major criticism of this method, besides the obvious 
inconvenience and unpleasantness of the collection, is the contamination of the 
collected fluids by liquor, leading to overestimation of the actual blood loss. 
 
Another method involves collection of all fluids, blood loss and clots in large 
pads laid out under the woman when delivery is imminent [Razvi et al 1996]. The 
pads are then processed and the blood loss determined using colorimetric methods 
[Newton et al 1977]. This method is more accurate but still inconvenient, time-
consuming, and difficult to perform for large studies. As a result, many investigators 
have resorted to clinical estimation of blood loss. This could be a simple visual 
estimation [Ng et al 2001], or estimation with the aid of various blood collection 
strategies [Cook et al 1999]. Unfortunately, it has been well documented that clinical 
estimation of blood loss is inaccurate by a large enough margin [Brant 1967; Duthie 
et al 1991; Razvi et al 1996] to render it next to useless for objective assessment of 
interventions in the third stage of labour. 
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Other indirect measures of blood loss such as changes in pulse rate, fall in 
blood pressure, the need for additional uterotonic drugs to stop excessive bleeding, 
the need for blood transfusion, and a fall in haemoglobin levels are thus commonly 
used to assess blood loss in the third stage. Although they are easier and more 
convenient to document in a clinical trial setting than direct measurement of blood 
loss, they all lack sufficient precision and objectivity for accurately assessing 
methods of intervention in the third stage of labour [Lavery et al 1995]. 
 
Even if a convenient method is found for accurately measuring the blood loss 
in the third stage of labour, it should be borne in mind that if the intervention being 
assessed is a uterotonic agent, then the blood loss may not always reflect the efficacy 
of the therapy. Blood loss in the third stage does not only come from the placental 
bed. Blood is also lost from episiotomy wounds, lacerations, and other trauma to the 
birth canal. The type of vaginal delivery performed, the size of the baby, and the 
skill of the accoucheur, all influence the amount of blood lost from sites outside the 
uterus. However, any uterotonic agent being used can only influence the blood loss 
by inducing contraction and retraction of the uterine muscles and, hence, occluding 
the open vessels in the placental bed. Interventions that influence more than one 
aspect of the third stage, such as comparing active versus expectant management, or 
non-uterotonic drugs such as tranexamic acid are still best assessed by measuring 
blood loss. But for uterotonic drugs, the key factor that should be assessed is the 
uterotonic effect they induce, as they do not affect blood loss from other factors. In a 
previous study [Choo et al 1998], we found that uterotonic activity had no linear 
correlation with measured blood loss after vaginal delivery. Rather than placing 
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doubt on the utility of intrauterine pressure measurements, this proves that blood 
loss after vaginal delivery is dependent on factors other than uterine activity, factors 
that are not influenced by uterotonic agents.  
 
Finally, it is generally accepted that uterine atony is the commonest cause of 
postpartum haemorrhage [Prendiville et al 1990], and most drugs used for the 
prophylaxis of postpartum haemorrhage act by increasing myometrial contractility. 
Hence, it has been proposed that uterotonic drugs are best assessed using methods to 
directly measure the uterine activity they induce [Chua 1998]. 
 
Direct measurement of uterine activity 
Intrauterine pressure measurements are known to reflect the pressure within 
the myometrium [Hendricks et al 1962]. A variety of methods have been used to 
measure postpartum intrauterine pressure changes [Smith 1984]. These range from 
microballoons, to open-ended fluid-filled catheters [Hendricks et al 1962], and more 
recently, intrauterine pressure transducers [Ulmsten & Andersson 1979; Forman et 
al 1982; Forman et al 1982a; Ingemarsson et al 1989]. The earlier systems were 
cumbersome and more difficult to use, and common problems included hydrostatic 
instability and damping in fluid-filled catheters, as well as changing elasticity, wall 
contact, and induced uterine activity associated with balloons. The electronic 
microtransducer catheters are simple to insert and give more reliable and 
reproducible readings. Intrauterine pressure transducers have been used to measure 
intrapartum uterine activity by many researchers [Steer et al 1978; Chua et al 1992], 
and have been proven to be accurate and reliable. The use of intrauterine pressure 
transducers is employed by many maternity units to allow safe monitoring of uterine 
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workloads for augmentation of labour in high risk situations e.g. when high doses of 
oxytocin are being used, in multiparous women, or when a trial of scar is being 
conducted [Arulkumaran et al 1992]. 
 
Intrauterine pressure transducers 
Prior to the introduction of intrauterine pressure transducers, intrauterine 
pressure measurements were taken using fluid column techniques that transmit 
pressure changes through a fluid column contained within a catheter to a connected 
transducer for conversion to a recordable form. These methods are extremely 
sensitive to motion and to the relative position of the tip of the catheter to the 
externally placed transducer. Compliance of tubing, fluid leaks, the problems of 
damping and resonance all combine to induce errors and artefacts. 
 
The intrauterine pressure transducer obviates the problems of hydrostatic 
instability, resonance, and damping of fluid columns, along with those of elasticity, 
wall contact, and induced uterine activity associated with fluid-filled systems. By 
moving the pressure sensor into the uterus, the inaccuracies of pressure wave 
transmission to an external manaometer or strain gauge are avoided. The first 
pressure transducer was a small carbon granule, and the resistance of the carbon 
granules were altered by pressure from the uterine walls in a proportionate way 
[Karlsson 1944]. This initial design was improved when Kelly & Schleifer 
introduced a small fine wire strain gauge in 1962 that could be passed through the 
cervical os [Kelly & Schleifer 1962]. The concept of the strain gauge for 
measurement of uterine contractions is based on the property of a wire to change its 
electrical resistance when subjected to stresses. It is, in essence, a rheostat where 
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resistance changes in proportion to the mechanical force to which it is subjected. 
Calibration of this strain gauge tocometer was performed in a simple pressure 
chamber connected to a mercury manometer [Kelly & Schleifer 1962]. The initial 
strain gauge was well tolerated by the patient and did not require severe restrictions 
of movement or position. 
 
In 1973, Millar introduced an ultraminature catheter-tip pressure transducer 
based on a silicon strain gauge [Millar & Baker 1973]. These were shown to be 
useful in evaluating uterine activity during labour [Steer et al 1978]. This transducer 
was stronger, durable, and more stable than earlier semiconductor types. These 
improvements made it possible to provide stable in vivo calibration. It has gained 
wide acceptance for use in women in labour. Forman et al [1982; 1982a] first 




Figure 3.1: The Gaeltec® transducer-tipped pressure catheter 
 
We used a commercially available transducer-tipped intrauterine catheter to 
measure uterine activity in the postpartum uterus. The pressure transducer (Gaeltec 
Ltd Dunvegan, Isle of Skye) is a bridge strain gauge deposited on the thin metal 
pressure-sensing surface (Fig. 3.1). The transducer is mounted on the end of a 900-
mm woven Dacron catheter and is situated so that it measures lateral pressure and 
not head-on pressure. The sensing area is recessed to minimise the risk of damage 
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(Fig. 3.2). The catheter and transducer are sealed with a silicone rubber sleeve 
giving a diameter of 2.7 mm. The transducer is connected by a plug at the distal end 
of the catheter to a 2 m flexible extension cable, which is in turn connected to the 
contraction socket of the fetal monitor. 
 
Figure 3.2: The recessed sensing area of the Gaeltec® transducer tip 
 
The Gaeltec ® transducers have a specified full scale pressure range of 0-20 
kPas (0-150 mmHg) within a temperature range of 0° to 4°C and a sensitivity of 
37.5 µV/V/kPa (5 µV/VmmHg). They can be calibrated in a small sealed tube 
connected to a sphygmomanometer. The pressure reading drift is less than ±0.27 kPa 
(2 mmHg) in 24 hours. The catheters are connected to a Sonicaid Meridian fetal 
heart rate monitor (Oxford Sonicaid Ltd, Chichester, UK) and calibrated before use 
according to instructions set out in the Sonicaid handbook (Oxford Sonicaid Ltd, 
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Chichester, UK). The Sonicaid Meridian fetal monitor measures frequency, duration, 
and amplitude of uterine contractions automatically, and calculates the uterine 
activity or workload as area under the curve (active contraction area or uterine 
activity integral) every 15 minutes [Steer et al 1978]. 
 
The Gaeltec® transducer-tipped catheter is a reliable means of measuring 
intrauterine pressure in the first and second stage of labour [Chua et al 1992]. In the 
postpartum uterus, there is no amniotic sac. The microtransducer lies instead in a 
potential space, with the uterine walls separated by a film of blood and clots. The 
catheter, once placed in utero in this manner, is capable of giving an accurate 
reflection of the changes in the uterine contractility [Hendricks et al 1962], 
regardless of whether or not the amniotic cavity is present as is the situation after 
delivery. Theoretically, there are several problems associated with intrauterine 
pressure measurements after delivery: 
1. the cervical os is open, allowing pressure generated by contractions to 
escape, 
2. there is no amniotic fluid to transmit the intrauterine pressure accurately to 
the transducer, 
3. placement of the intrauterine pressure transducer is difficult, 
4. difficulty securing the intrauterine pressure transducer in a fixed place 
relative to the uterine fundus. 
However, it has been shown that when a catheter is lying free within the 
upper portion of the puerperal uterus, it will record the same contractile pattern as 
does a catheter placed within the myometrium itself [Hendricks et al 1962]. 
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To demonstrate the reliability of the Gaeltec catheter-tip pressure transducers 
for measuring postpartum uterine activity, we performed a study to check the 
correlation between the intrauterine pressure readings recorded by two catheter-tip 
pressure transducers inserted simultaneously into the postpartum uterus [Chua et al 
1998]. 
 
Summary of study 
Methods 
We recruited 20 women who delivered vaginally without complications. 
Informed consent was obtained in the first stage of labour and the women were 
assigned randomly to two groups using a random number table. The study was 
approved by the department ethics committee.  
 
The Gaeltec® (Gaeltec® Ltd., Dunvegan, Scotland) catheters were 
calibrated before use according to instructions in the Sonicaid handbook (Oxford 
Sonicaid Ltd, Chichester, UK). The delivery of the fetus was left entirely to the 
accoucheur, and routine administration of oxytocics in the third stage was carried 
out. Within 5 minutes of delivery of the placenta, a pair of calibrated Gaeltec® 
catheters was inserted transcervically into the uterine cavity. The women in Group 1 
had two sterile Gaeltec® catheters inserted into the uterus with one inserted until the 
tip of the catheter could be felt to impinge on the fundus of the uterus, and the other 
catheter inserted similarly but then withdrawn 3-4 cm outwards and away from the 
tip of the first catheter. For Group 2, the two catheters were tied together with sterile 
catgut before insertion so that the tips of both catheters were next to each other at all 
times. The two catheters were inserted together into the uterine cavity until the tips 
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were felt to impinge on the uterine fundus. The catheters in both groups were then 
secured in place with adhesive tape to the maternal thigh and connected to a 
Sonicaid® FM6 fetal heart rate monitor individually (Sonicaid Ltd., Oxford Medical 
Instruments, Chichester, U.K.). The active pressures were recorded from the two 
catheters every 30 seconds in the 10 women in the two groups. The catheters that 
were tied together were checked on removal and showed no displacement from each 
other. 
 
The agreement of the active pressure recorded by the two catheters for each 
woman was assessed in a 3-step procedure. Firstly, the Pearson’s correlation was 
determined. Secondly, a Bland Altman plot was performed (± 2SD). Thirdly, the 
magnitude of the absolute difference in active pressures recorded by the two 
catheters was determined. All analyses were carried out using SPSS 13.0. 
 
Results 
Intrauterine catheters tied together 
436 contractions were analysed with two catheters tied together. The 
Pearson’s correlation between the readings was 0.993 (p < 0.001) (Figure 3.3), with 
18/436 (4.1%) outside the mean difference ± 2SD range in the Bland Altman 
analysis (Figure 3.4). Table 3.1 shows that 2.5% of the absolute differences between 
the active pressures recorded by the two catheters were beyond 15 mmHg. If we set 
the acceptable clinical difference to be 10 mmHg, then only 8.2% (< 10%) were 
beyond. In 67.0% of these pairs, the active pressure values did not differ by more 
than 5 mmHg; and in 24.8% of the pairs, there was only a 6-10 mmHg difference in 
active pressure readings. 
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Figure 3.3: Scatter plot of active pressure readings between two transducers 














































The upper and lower lines indicate mean difference ± 2SD (-13.17 to 13.23) 
 
Figure 3.4: Bland Altman plot- Difference against mean active pressure from 
two transducers tied together and inserted into the uterine cavity 
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Table 3.1: Contraction to contraction difference in active pressure readings 
between two transducers tied together and inserted into the uterine cavity 
Difference in active pressure readings 
between 2 catheters (mmHg) 
Number Percentage of total (%) 
0 - 5 292 67.0 
6 - 10 108 24.8 
11 - 15 25 5.7 
>15 11 2.5 
Total 436 100 
 
 
Intrauterine catheters inserted separately 
975 contractions were analysed with transducers separately inserted. The 
Pearson’s correlation between the readings was 0.970 (p < 0.001) (Figure 3.5), with 
49/975 (5.0%) outside the mean difference ± 2SD range in the Bland Altman 
analysis (Figure 3.6). Table 3.2 shows that 7.2% and 14.0% of the absolute 
differences in active pressures recorded by the two catheters were beyond 15 and 10 
mmHg respectively. In 56.7% of these pairs, the active pressure values did not differ 
by more than 5 mmHg and 29.3% of the pairs, there was only a 6-10 mmHg 
difference in active pressure readings. 
60 
300.00250.00200.00150.00100.0050.000.00

































Figure 3.5: Scatter plot of active pressure readings between two transducers 
inserted separately into the uterine cavity 
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The upper and lower lines indicate mean difference ± 2SD (-19.96 to 19.64) 
 
Figure 3.6: Bland Altman plot- Difference against mean active pressure from 









Table 3.2: Contraction to contraction difference in active pressure readings 
between two transducers inserted separately into the uterine cavity 
Difference in active pressure readings 
between 2 catheters (mmHg) 
Number Percentage (%) 
0 - 5 553 56.7 
6 - 10 286 29.3 
11 - 15 66 6.8 
>15 70 7.2 





The postpartum uterus provides a good model for in vivo evaluation of the 
uterine effect of drugs used in labour and the puerperium. We found that whether the 
transducers were inserted tied together in the uterine cavity near the fundus of the 
uterus, or separate within the uterine cavity, the correlation coefficient derived when 
the active pressures recorded by two transducers were compared showed good 
correlation (r >0.9) with more than 85% of the absolute differences in the active 
pressures recorded being less than 15 mmHg. 
  
The smaller variance in contraction to contraction differences when both 
catheters were tied together and inserted near the uterine fundus  could be explained 
by the fact that when the catheters are inserted seperately, the second catheter was 
specifically pulled down towards the cervix away from the first catheter whose tip 
impinged on the uterine fundus. This could have resulted in some cases in the 
catheter tip being pulled near the cervix, and giving less accurate readings because 
of the pressure leak from an open cervix. 
 
The results show that Gaeltec® transducer-tip catheters, which have been 
proven to be able to measure intrauterine pressure reliably during labour (Chua et al 
1992), can also be used to measure uterine activity reliably in the immediate 
postpartum period. Although there is no liquor as in the intrapartum uterus, the 
blood between the apposed walls of the postpartum uterine cavity still provides a 
fluid medium to transmit pressure to the transducer. To reduce inaccuracies due to 
pressure leak from an open cervix, the transducer-tip catheters should be inserted as 
far into the uterine cavity as possible until the catheter is felt to impinge on the 
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uterine fundus. While there may be minor contraction by contraction differences in 
recordings of individual active pressure from two catheter-tip transducers, there was 




The use of intrauterine pressure transducers to measure uterine activity after 
delivery has been validated by other researchers [Hendricks et al 1962; Forman et al 
1982; Forman et al 1982a] and has been found to be reliable by us. In this setting, its 
use is purely for research as the measurement of uterine activity after delivery is not 
routinely practised. Recording uterine activity in the postpartum uterus will improve 
our ability to evaluate drugs of potential use in the puerperium. Based on this 
premise, we have chosen to assess the uterotonic effect of misoprostol using the 











Determining the optimum dose of oral tablet misoprostol using 
intramuscular syntometrine for comparison:  
Postpartum intrauterine pressure studies of the uterotonic effect 
of oral misoprostol and intramuscular Syntometrine 
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Introduction 
The practice of prophylactic administration of parenteral oxytocics in the 
active management of the third stage of labour has led to a 30% to 40% reduction in 
the incidence of postpartum haemorrhage [Prendiville et al 1988; Yuen et al 1995]. 
Despite this, postpartum haemorrhage remains a major cause of maternal deaths in 
the developing world [World Health Organisation 1991; Kwast 1991]. Maternal 
mortality and morbidity due to postpartum haemorrhage are 50 times commoner in 
developing countries than in the United Kingdom [Report of Technical Working 
Group 1990]. Several factors contribute to this including the paucity of supervised 
deliveries, blood transfusion resources and anaesthetic services. Another major 
factor could be the unavailability or ineffectiveness of routine oxytocic use in the  
third stage [Report of Technical Working Group 1990]. Oxytocin, ergometrine and 
Syntometrine® (Sandoz, Basel, Switzerland), the most commonly used oxytocic 
agents for this purpose, are parenteral drugs requiring sterile needles and syringes 
for administration as well as cool storage conditions (between 2°C to 8°C and away 
from light) [Data sheet compendium 1993]. Studies [Longland & Roebottom 1987; 
Walker et al 1988; Hogerzeil et al 1993; Chua et al 1993]  have questioned the 
potency of injectable oxytocics in tropical climates. Financial constraints may also 
prevent both their routine use and proper storage. Early suckling has been suggested 
[Bullough et al 1989; Chua et al 1994; Irons et al 1994] as an alternative modality 
for reducing the incidence of postpartum haemorrhage in women in developing 
countries, but its efficacy is uncertain. There is thus a place for an effective but 
inexpensive uterotonic drug that can be administered orally and which does not 
require special storage conditions. 
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Misoprostol is an orally-administered prostaglandin E1 methyl analogue 
which has been used widely for the prevention of nonsteroidal anti-inflammatory 
drug-induced gastric ulcers and, more recently, for the induction of labour and 
abortion [Sanchez-Ramos et al 1993; Creinin & Vittinghoff 1994; El-Refaey et al 
1995]. Misoprostol is very quickly absorbed orally [Karim 1987], has a shelf-life of 
three years [GD Searle & Co 1991] at room temperature (30°C) in the tropics, is 
relatively inexpensive and has recently been proposed for the active management of 
the third stage of labour [El-Refaey et al 1996; El-Refaey et al 1997]. We conducted 
a phase II study to determine the effect of oral misoprostol at various doses on 
uterine activity following normal vaginal delivery and compared these with the 
effect of intramuscular Syntometrine® 1 mL. We also documented the side effects 
associated with the use of these drugs. 
 
Methods 
We recruited 57 women who delivered vaginally after spontaneous labours 
not requiring induction or augmentation with oxytocin or prostaglandins. Informed 
consent was obtained in the first stage of labour and the women were assigned 
sequentially into six groups (Table 4.1) and prescribed either oral misoprostol 
(Cytotec®, Searle, Chicago) 200 μg, 400 μg, 500 μg, 600 μg, 800 μg or 
intramuscular Syntometrine 1 mL (oxytocin 5 units, ergometrine maleate 500 
μg/mL). Exclusion criteria included anaemia (haemoglobin < 11.0 g/dL), multiple 
pregnancy, a history of postpartum haemorrhage in previous pregnancies or 
antepartum haemorrhage in the current pregnancy. The study was approved by the 
department ethical committee.  
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Table 4.1.   Profile of women recruited for the study  
Medication given Intramuscular 





Oral misoprostol  
500 μg 




Number of women recruited 10 10 10 10 10 7* 
Multiparous women 9 8 7 8 10 7 
















































Figures in [ ] denote range. 
*Recruitment of women into the 800 μg misoprostol group was stopped after one woman developed severe hyperthermia. 
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The delivery of the fetus was left entirely to the accoucheur. However, the 
routine administration of oxytocics in the third stage was omitted. Within 5 minutes 
of delivery of the placenta, a calibrated Gaeltec® (Gaeltec® Ltd., Dunvegan, 
Scotland) catheter with an intrauterine pressure transducer at its tip was inserted 
transcervically into the uterine cavity until the tip of the catheter could be felt to 
impinge on the fundus of the uterus. The catheter was then secured in place and 
connected to a Sonicaid® Meridian fetal monitor (Sonicaid Ltd., Oxford Medical 
Instruments, Chichester, U.K.), and uterine active contraction areas were recorded 
automatically. A researcher was with the woman throughout the two-hour period of 
the recording to document the temperature, pulse and blood pressure of the mother 
every 15 minutes, as well as any side effects experienced. The blood loss was 
closely monitored and if any women were thought to have excessive blood loss (> 
500 mL), they would have been given conventional therapy for postpartum 
haemorrhage and taken out of the trial. No woman recruited for the study was 
excluded for excessive blood loss. 
 
The baseline uterine activity of each woman was recorded for 30 minutes 
before the administration of the assigned medication. Uterine activity was then 
recorded for a further 90 minutes (Figure 4.1). Mean cumulative uterine activity in 
the 90-minute period after administration of the uterotonic drug was compared to the 
woman’s baseline cumulative uterine activity in the 30 minutes before drug 
administration to determine the effect of the medication on the postpartum uterus as 
a percentage increase in uterine activity (i.e. each woman acted as her own control).  
The difference in uterine activity in the 90 minutes following the various doses of 
misoprostol relative to Syntometrine was compared using analysis of covariance, 
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with adjustment for the baseline uterine activity in the 30 minutes before treatment.  
The onset of action of the drug was calculated from each recording.  The duration of 
action of the medication was defined as the period of time the mean uterine activity 
remained above the individual woman’s baseline uterine activity. Statistical analysis 




Ten women received intramuscular Syntometrine® 1 mL and 47 women 
were prescribed oral misoprostol (Table 4.1). Although the intention was to recruit 
10 women in each group with different doses of misoprostol, the numbers were 
limited to seven in the group who were given 800 μg misoprostol. Because the 
seventh case developed severe hyperthermia [Chong et al 1997] that needed intense 
treatment, we felt it was unethical to continue with the 800 μg dosage.  
 
Figure 4.1: Intrauterine pressure recordings before and after intramuscular 




 The largest increase in uterine activity (Table 4.2) was achieved with 
intramuscular Syntometrine 1 mL (152%, SD 67.0%), followed by oral misoprostol 
600 μg (144%, SD 72.7%). However, there were no statistical differences in the 
mean increase in uterine activity following all the doses of oral misoprostol 
compared to intramuscular Syntometrine 1 mL (p=0.737). The mean onset of action 
(Table 4.2) of oral misoprostol (6.1, SD 2.1 min) was significantly (p=0.002) slower 
than that of intramuscular Syntometrine (3.2, SD 1.5 min) while the mean duration 
of action (Table 4.2) was similar in all the treatment groups (p=0.637).  
 
There was substantial variation in the mean baseline cumulative uterine 
activity in the 30 minutes before medication across treatment groups, fluctuating 
from a low of 5358 to 7216 kPas sec. Thus the mean difference in cumulative 
uterine activity between the various doses of misoprostol and Syntometrine in the 90 
minutes after treatment were compared after adjusting for the baseline cumulative 
uterine activity. There was no statistical difference (p=0.887) between the treatment 
groups, even with the largest difference of –2282 kPas sec (95% CI -7954 to 3390 
kPas sec) comparing oral misoprostol 200 μg versus Syntometrine (Table 4.3, 
Figure 4.2). 
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Mean increase in uterine activity 








































*The mean increase in uterine activity alone is not sufficient indication of the uterotonic effect of the drug as it is dependent on the baseline 
uterine activity before medication. The baseline uterine activity (see Table 4.3) allows each woman to act as her own control.  




Table 4.3.   Mean cumulative uterine activity in the different treatment groups 
Medication given Baseline 
cumulative uterine 
activity over 30 min
Post treatment 
cumulative uterine 
activity over 90 min 
Unadjusted mean difference 
in cumulative uterine activity 
(relative to Syntometrine) 
Adjusted mean difference in 
cumulative uterine activity 
(relative to Syntometrine) 
Intramuscular Syntometrine 1 mL 5806 (3610) 22530 (9521) - - 
Oral misoprostol 200 μg 5838 (1559) 20309 (6168) -2221 [-9758 to 5316] -2282 [-7954 to 3390] 
Oral misoprostol 400 μg 5358 (1877) 20000 (8860) -2531 [-11171 to 6110] -1683 [-7362 to 3996] 
Oral misoprostol 500 μg 6212 (3650) 22203 (9937) -328 [-9471 to 8815] -1095 [-6773 to 4583] 
Oral misoprostol 600 μg 6428 (2838) 24395 (7375) 1865 [-6136 to 9866] 689 [-4997 to 6375] 
Oral misoprostol 800 μg 7216 (2776) 23049 (5383) 518 [-8656 to 9693] -2147 [-8757 to 4463] 
Figures in ( ) denote standard deviation, [ ] 95% confidence intervals. 
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All the women in the study were observed closely for side effects in the two-
hour period of uterine activity recording. These side effects are listed in Table 4.4. In 
the Syntometrine group, the most commonly observed side effect was moderate 
uterine pain of which nine women complained. A rise in diastolic blood pressure of 
20 mmHg was noted in 2 women, as was nausea and retching. 
 
In the misoprostol group, the commonest side effects were shivering (17, 
36%) and a rise in body temperature above 38°C (19, 40%) (Figure 4.3). The 
shivering experienced by 16 of the 17 women was mild and transient starting 
between 12 minutes to 88 minutes (mean 26 mins) after misoprostol was taken, and 
lasting between 12 minutes to 55 minutes (mean 32 mins). The rise in body 
temperature in 18 of the 19 women varied between 38.2°C to 39.1°C (mean 38.7°C) 
and lasted from 10 minutes to 8 hours. The increase in body temperature was not 
accompanied by any ill effects except the shivering which usually preceded it. Most 
of the women were not aware of a sensation of fever. However, one woman 
receiving 800 μg of oral misoprostol experienced shivering for about an hour 
followed by severe hyperthermia requiring vigorous treatment [Chong et al 1997]. 
Shivering and mild pyrexia occurred in 60% of women given oral misoprostol 500 
μg and 600 μg, and 43% of those given 800 μg. Shivering only occurred in 10%, 
and mild pyrexia in 20%, of the women given 200 μg and 400 μg of oral 
misoprostol. Only five women (11%) receiving oral misoprostol complained of 
uterine pain. 
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Table 4.4.   Side effects of oral misoprostol and intramuscular Syntometrine  
























Shivering 0 1  1  6  6  3  
Temperature rise > 38°C 0 2  2  6  6  3  
Uterine pain 9  1  0 1  2  1  
Rise in diastolic blood pressure > 
20 mmHg 
2  0 0 0 0 0 




Maximum temperatures of women
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Figure 4.3. Maximum temperatures of women in each treatment group 
 
Discussion 
This pilot study was conducted to determine whether the effect of oral 
misoprostol on uterine activity after delivery would be similar to that of the 
commonly used oxytocic, intramuscular Syntometrine. The study was also designed 
to determine the optimum oral dose of misoprostol in terms of uterotonic effect and 
safety. Uterine activity was taken as a surrogate measure of the potential efficacy of 
oral misoprostol in the management of the third stage as all drugs given to prevent 
postpartum haemorrhage act by stimulating uterine contractions and retraction.  
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Catheter-tip pressure transducers have been used to measure uterine activity 
in the third stage of labour reliably and safely in various studies [Ingemarsson et al 
1989; Chua et al 1993; Chua et al 1994; Chua et al 1998]. In our study, the women 
acted as their own controls to provide their own baseline uterine activity before 
administering an uterotonic drug. The change in uterine activity after drug 
administration should then be an accurate measure of the uterotonic effect of the 
drugs studied. Although the time of drug administration in this study was much later 
than in a normal situation, we felt that it was essential to account for biological 
variation in uterine activity by establishing each individual’s baseline uterine 
activity before administering the drug. The delayed administration may not reflect 
the actual response if the drugs had been given immediately post delivery, but this 
was necessary to control for the biological variation in baseline uterine activity.  
 
In our phase II study, we found that the uterotonic effect of oral misoprostol, 
at all the five doses tested, was not statistically different to that of intramuscular 
Syntometrine 1 mL (p=0.737) although intramuscular Syntometrine did produce the 
largest mean increase in uterine activity. While the uterotonic effect of oral 
misoprostol 500 μg and 600 μg were closest to that of intramuscular Syntometrine 1 
mL (adjusted mean difference in cumulative uterine activity of –1095 kPas sec, 95% 
CI –6773 to 4583 kPas sec; and 689 kPas sec, 95% CI –4997 to 6375 kPas sec 
respectively), the incidence of shivering and pyrexia with these doses were high 
(60%).  
 
Oral misoprostol 200 μg and 400 μg had definite but marginally lower 
uterotonic activity as compared with intramuscular Syntometrine 1 mL (adjusted 
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mean difference in cumulative uterine activity of –2282 kPas sec, 95% CI –7954 to 
3390 kPas sec; and –1683 kPas sec, 95% CI –7362 to 3996 kPas sec respectively). 
The incidences of side effects with these doses (10% shivering and 20% mild 
pyrexia) were much lower than with doses above 400 μg. The safe oral dosage of 
misoprostol would thus seem to be 200 μg to 400 μg. These doses of misoprostol are 
already widely prescribed for the prevention of nonsteroidal anti-inflammatory drug-
induced gastric ulcers and have been found to be safe for use in non-pregnant 
patients. Whether the uterotonic effect of oral misoprostol 200 μg to 400 μg will be 
sufficient to prevent postpartum haemorrhage is a question that will have to be 
answered by large randomised controlled clinical trials.  The results so far are 
mixed. Two randomised controlled trials have compared rectal misoprostol 400 μg 
against Syntometrine 1mL [Bamigboye et al 1998a] as well as oral misoprostol 400 
μg against placebo [Hofmeyr et al 1998]. These trials suggest that misoprostol at 
400 μg may be as effective as Syntometrine and better than placebo.  Conversely, 
two other trials found oral [Cook et al 1999] and rectal [Bamigboye et al 1998] 
misoprostol 400 μg to be significantly less effective than intramuscular oxytocin or 
Syntometrine, and no better than placebo.  The data regarding side effects is clearer. 
Shivering was reported to be the main side effect in 19% of women in two of the 
studies [Hofmeyr et al 1998; Lumbiganon et al 1999] while pyrexia only occurred in 
2% in one study [Lumbiganon et al 1999] using misoprostol 400 μg, and was not 
reported by the other authors. However, in three other recent studies [Amant et al 
1999; Lumbiganon et al 1999; Surbek et al 1999] using a higher dose of oral 




The onset of action of oral misoprostol was significantly slower than that of 
intramuscular Syntometrine, but the durations of action of both drugs were similar. 
As the majority of postpartum haemorrhage occurs at separation of the placenta and 
in the moments immediately following due to uterine atony [Cunningham  et al 
1989; Still 1994] the critical period of action of uterotonic drugs used for the active 
management of the third stage of labour should be within the first 10 minutes of 
delivery of the neonate. However, regardless of when postpartum haemorrhage 
begins, it may not manifest as a sudden, massive bleed but rather as a steady, 
moderate ooze that persists unnoticed until serious hypovolaemia develops 
[Cunningham et al 1989]. The slower onset of action of oral misoprostol may 
require its earlier routine administration, perhaps at delivery of the fetal head rather 
than after the delivery of the neonate, but its long duration of action should prevent 
haemorrhage from delayed uterine hypotonia as effectively as Syntometrine. 
 
 The side effects observed with oral misoprostol were transient shivering and 
an asymptomatic rise in body temperature in all but one of the women affected. 
Shivering has been described as occurring in about 10% of women after routine 
vaginal deliveries while its incidence with epidural anaesthesia is as high as 33% to 
60%, and it is regarded as being more of a nuisance rather than serious morbidity 
[El-Refaey et al 1997]. Mild pyrexia is a known but unexplained side effect of most 
prostaglandins used clinically. None of the other commonly reported side effects of 
prostaglandins such as nausea, vomiting, diarrhoea or significant changes in blood 
pressure was experienced by any of the women given oral misoprostol. Few women 
complained of uterine pain, probably because the increase in uterine contractility 
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following prostaglandin E1 tends to be a gradual one [Crowshaw 1983]. Women 
receiving intramuscular Syntometrine, however, uniformly complained of moderate 
uterine pain. Hypertension, nausea and retching also occurred in 20% of the women 
receiving Syntometrine.  
  
In conclusion the results of this phase II study show that oral misoprostol has 
a definite uterotonic effect on the postpartum uterus. At doses of 200 μg to 400 μg, 
oral misoprostol has a uterotonic effect that is not statistically different to 
intramuscular Syntometrine® 1 mL, and side effects were less common than with 
the higher doses tested. It remains to be seen whether the slower onset of action of 
oral misoprostol will be an important factor in its use in the active management of 
the third stage of labour, perhaps necessitating its use in a more easily absorbable 







Chapter 5  
 
Determining the optimum route of administration for 
misoprostol: 
The uterotonic effect and side effects of misoprostol given by 




Despite the findings of the World Health Organization multicentre 
randomized trial [Gulmezoglu et al 2001a] and the recent Cochrane systematic 
review [Gulmezoglu et al 2001] that injectable uterotonics are preferable to 
misoprostol for the routine active management of the third stage of labour in hospital 
settings, interest in misoprostol remains [Darney 2001; El-Refaey 2002; Khan & 
Sharma 2002; O’Brien et al 2002; Shannon & Winikoff 2002], especially in 
developing countries. The ease of use and storage of misoprostol relative to 
parenteral oxytocics, as well as its low cost are the main attractions of misoprostol. 
These properties make misoprostol practical for use in home deliveries, or by 
traditional birth attendants in less developed areas, and may help reduce the 
relatively high rate of maternal mortality from postpartum haemorrhage in these 
areas. 
 
Since oral misoprostol was first suggested for use in the third stage of labour 
in 1996 [El-Refaey et al 1996], there have been at least 21 randomized controlled 
trials conducted on this subject, reflecting the importance placed on the use of 
misoprostol for preventing postpartum haemorrhage.  
 
However, there has been little agreement on the optimum dose and route of 
administration of misoprostol for prophylactic use in the third stage of labour. The 
dose of misoprostol used in randomized controlled trials has varied between 400 μg 
in ten studies [Bamigboye et al 1998; Bamigboye et al 1998a; Hofmeyr et al 1998; 
Cook et al 1999; Walley et al 2000; Acharya et al 2001; Bugalho et al 2001; 
Gerstenfeld & Wing 2001; Kundodyiwa et al 2001; Karkanis et al 2002], 500 μg in 
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one study [El-Refaey 2000], 600 μg in nine studies [Zhao et al 1998; Amant et al 
1999; Surbek et al 1999; Gulmezoglu et al 2001a; Hofmeyr et al 2001; Ng et al 
2001; Caliskan et al 2002; Caliskan et al 2003; Oboro & Tabowei 2003], and 800 μg 
in one study [Lokugamage et al 2001]. The route of administration has been oral in 
14 trials [Hofmeyr et al 1998; Zhao et al 1998; Amant et al 1999; Cook et al 1999; 
Surbek et al 1999; El-Refaey et al 2000; Walley et al 2000; Acharya et al 2001; 
Gulmezoglu et al 2001a; Hofmeyr et al 2001; Kundodyiwa et al 2001; Ng et al 2001; 
Caliskan et al 2003; Oboro & Tabowei 2003] and rectal in seven [Bamigboye et al 
1998; Bamigboye et al 1998a; Bugalho et al 2001; Gerstenfeld & Wing 2001; 
Lokugamage et al 2001; Caliskan et al 2002; Karkanis et al 2002]. The common 
factor among all the trials using oral misoprostol was an increased incidence of 
shivering, going as high as 72% [El-Refaey et al 2000] and a rise in temperature as 
frequently as 34% [Amant et al 1999]. Interestingly, only three studies using rectal 
misoprostol [Bugalho et al 2001; Caliskan et al 2002; Karkanis et al 2002] reported 
a statistically significant increase in the incidence of shivering (38.1%, 23.6% and 
11.8% respectively), and only one [Caliskan et al 2002] found a statistically 
significant increase in the incidence of pyrexia (4%). 
 
In an earlier study using postpartum intrauterine pressure measurements as a 
surrogate endpoint for the uterotonic action of oral misoprostol [Chong et al 2001], 
we found that doses of oral misoprostol above 400 μg were associated with high 
incidences of shivering and pyrexia (60%). Oral misoprostol 400 μg produced a 
similar uterotonic effect to intramuscular syntometrine 1 ml while being associated 
with less shivering (10%) and pyrexia (20%). However, the onset of action of 
 85
misoprostol given as an oral tablet was significantly slower than that of 
intramuscular syntometrine. Earlier pharmacokinetic studies [Zieman et al 1997; 
Danielsson et al 1999] reported that oral misoprostol produced an earlier onset of 
action and greater initial increase in uterine tonus compared to vaginal misoprostol, 
mirroring the higher initial plasma levels of misoprostol acid achieved by the oral 
route, but did not compare oral misoprostol against parenteral oxytocics. With these 
findings in mind, we decided to study misoprostol 400 μg administered by different 
routes in order to identify the ideal route in terms of onset of action, uterotonic effect 
and side effects. Postpartum uterine activity was used as a surrogate measure 
[Danielsson et al 1999; Chong et al 2001] of the efficacy of misoprostol and 
syntometrine for the prevention of postpartum haemorrhage as all oxytocics work 
primarily by causing uterine contractions. 
 
Materials and methods 
Fifty women who delivered vaginally after spontaneous labours not requiring 
induction or augmentation with oxytocin or prostaglandins were recruited. None of 
the women used epidural analgesia. The women were all kept fasted except for sips 
of water in active labour to prevent oral intake from interfering with absorption of 
any oral medication. They were assigned sequentially into five groups (Table 5.1) 
and prescribed misoprostol (Cytotec®; Searle AG, Chicago, IL) 400 μg given as 
tablets orally, rectally, vaginally, or as an aqueous solution orally (two Cytotec® 
200 μg tablets dissolved in 20 ml lukewarm water). The fifth group was given 
intramuscular syntometrine 1 ml (oxytocin 5 units, ergometrine maleate 500 
μg/mL). Exclusion criteria included anemia (hemoglobin < 11.0 g/dl), maternal 
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infection, multiple pregnancy, a history of postpartum haemorrhage in previous 
pregnancies or antepartum haemorrhage in the current pregnancy. All women who 
met the criteria for inclusion and who consented to participate in the study were 
recruited if they did not require augmentation of labour, assisted or operative 
delivery and did not have retained placentas. The departmental ethics review 
committee approved the study, and informed consent was obtained from each 





 The delivery of the fetus was left entirely to the obstetrician. 
However, the routine administration of oxytocics in the third stage was omitted. 
Within 5 minutes of delivery of the placenta, a calibrated Gaeltec® (Gaeltec® Ltd., 
Dunvegan, Scotland, UK) catheter with an intrauterine pressure transducer at its tip 
was inserted transcervically into the uterine cavity until the tip of the catheter could 
be felt to impinge on the fundus of the uterus. The catheter was then secured in place 
and connected to a Sonicaid® Meridian fetal monitor (Sonicaid Ltd., Oxford 
Medical Instruments, Chichester, England, UK), and uterine activity contraction 
areas were recorded automatically every 15 minutes by the machine [Chong et al 
2001]. Uterine activity is recorded as active pressures in real time continuously and 
the contraction areas for each 15-minute periods was automatically calculated every 
15 minutes and printed on the recording paper. The summation of the 15-minute 
readings provides the cumulative uterine activity over specified periods of time e.g. 
30, 60, and 90 minutes. A researcher was with the woman throughout the two-hour 
period of the recording to document the temperature, pulse and blood pressure of the 
mother every 15 minutes, as well as any side effects experienced. The blood loss 
was closely monitored and if any women were thought to have excessive blood loss 
(> 500 ml), they would have been given conventional therapy for postpartum 
haemorrhage and taken out of the trial. It was difficult logistically to blind the 
investigator monitoring the patient during the two hours of the study, and this was 
not attempted. The primary outcome was uterine activity recorded automatically and 
objectively by the Sonicaid® Meridian fetal monitor every 15 minutes. The onset of 
action was separately assessed later by investigators blinded to the type of treatment 
given. None of the mothers initiated breastfeeding until after the study period of two 
hours when they were transferred to the postnatal ward.    
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 The postpartum uterine activity was measured for 30 minutes as a baseline 
before the assigned medication was administered, allowing each woman to be her 
own control The uterine activity was then monitored for a further 90 minutes. The 
uterine activity of each group after treatment was compared using the repeated 
measurement technique adjusted for the baseline pre-treatment uterine activity and 
parity. Repeated measurement technique or longitudinal data analysis was used to 
analyze the effect of time as well as other variables on the uterine activity outcome. 
The incidence of shivering and pyrexia (temperature >38°C) within the four 
misoprostol treatment groups were compared using Fisher’s Exact test, and logistic 
regression was used to test the effect of the post-treatment cumulative uterine 
activity. The relationship between the maximum body temperature recorded and the 
cumulative uterine activity in the 90 minutes after misoprostol was administered, 
and the route of administration was assessed using linear regression. The onset of 
action of the treatment given was determined from the intrauterine pressure 
recordings as the time interval after treatment was administered till the 
commencement of an increase in uterine contractions. The investigator assessing the 
onset of action was blinded to the type of treatment given. The Kruskal-Wallis test 
was used to assess the difference among the times of onset of action of the five 
treatment groups.  Multiple comparison was done using the Mann-Whitney U test. 






The details of the women recruited are given in Table 5.1. There was a 
significant difference in parity between the treatment groups. There were more 
nulliparous women in the group given rectal misoprostol than in the other groups. 
The sequential recruitment of women for this study led to an uneven distribution of 
parity across the groups that was purely incidental. The pre-treatment cumulative 
uterine activity in both the rectal and vaginal misoprostol groups were less than that 
in the other three treatment groups.  Both the effects of parity and pre-treatment 
cumulative uterine activity were taken into account in the analysis on uterine 
activity. The other parameters were similar in all the treatment groups. None of the 
women recruited were later excluded after the study treatment was given. No woman 
recruited for the study was excluded for excessive blood loss. 
 
The uterotonic activity produced by misoprostol administered via different 
routes is shown in Table 5.2. Figure 5.1 is the error bar chart showing the mean 
uterine activity produced by each form of treatment in each 15-minute period after 
drug administration. Repeated measurement technique was used to evaluate the 
effects of route of administration, time elapsed, parity and pre-treatment baseline 
uterine activity, and the interaction between time and route. This statistical analysis 
method looks at differences between subjects (treatment groups) and within subjects 
(time trend), and whether there is any interaction between groups and time.  We 
found that not only were the effects of the time elapsed and pre-treatment baseline 
uterine activity significant (p<0.001, p<0.001 respectively), but also the interaction 
between time and route (p=0.009).  However, the effect of parity was not significant 
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(p=0.625). The mean uterine activity produced by each treatment in each 15-minute 








































Table 5.2. Mean uterine activity in each 15-minute period after treatment 




syntometrine 1 mL 
Misoprostol 400 μg 
Oral tablet 
Misoprostol 400 μg 
Oral solution 
Misoprostol 400 μg 
Rectal 





4508 (3293 – 5723) 
 
2815 (1885 – 3746) 
 
5468 (4046 – 6890) 
 
2958 (1644 – 4273) 
 
1991 (928 – 3054) 
30 min 4873 (3184 – 6561) 4101 (2782 – 5419) 4905 (3573 – 6236) 3353 (2048 – 4658) 2858 (1480 – 4235) 
45 min 3910 (2532 – 5287) 3967 (2331 – 5604) 4494 (3167 – 5820) 2920 (1845 – 3996) 2848 (1690 – 4006) 
60 min 
 
3526 (2252 – 4799) 3792 (2333 – 5252) 4242 (3107 – 5377) 2237 (1195 – 3280) 2853 (1378 – 4327) 
75 min 3035 (1853 – 4216) 2954 (1798 – 4111) 3816 (2454 – 5177) 1914 (1182 – 2646) 2586 (1380 – 3792) 
90 min 2680 (1778 – 3581) 2370 (1658 – 3081) 3432 (2182 – 4681) 2150 (1263 – 3037) 2393 (1428 – 3357) 
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The mean uterine activity produced by the oral solution misoprostol group 
was highest within the first 15 minutes and gradually declined, while that of the 
other treatment groups reached their peak during the second 15-minute period before 
declining (Table 5.2). Looking into each treatment group (Figure 5.1), we found that 
the mean uterine activity produced by oral solution misoprostol was significantly 
higher than that produced by rectal misoprostol (p= 0.028), and vaginal misoprostol 
(p= 0.018).  The mean uterine activity produced by oral solution misoprostol was 
higher than that produced by oral tablet misoprostol but the difference was not 
statistically significant (p=0.060). There was no significant difference between the 
mean uterine activity produced by oral solution and intramuscular syntometrine 
groups (p= 0.132). 
 
Figure 5.2 is the error bar chart showing the mean cumulative uterine activity 
produced in the 30-, 60- and 90-minute periods after treatment.  Again, the repeat 
measurement technique was used to evaluate the effects of route, time elapsed, 
parity and pre-treatment baseline uterine activity, and the interaction between time 
and route.  We found that the effects of route, time elapsed and pre-treatment 
baseline uterine activity were significant (p=0.010, p< 0.001 and p<0.001 
respectively).  However, the interaction between time and route was not significant 
(p=0.131), and neither was the effect of parity (p=0.906).  The mean cumulative 
uterine activity produced by oral solution misoprostol was significantly higher than 
that produced by oral tablet misoprostol (p=0.045, mean difference 4753.3 kPas s, 
95% CI 110.0-9396.6), rectal misoprostol (p=0.004, mean difference 7152.7 kPas s, 
95% CI 2397.1-11908.0) and vaginal misoprostol (p=0.002, mean difference 7731.0 














































Figure 5.2. Error bar plot of cumulative uterine activity in the 90 minutes after 
treatment 
 
Onset of action 
The difference in time of onset of action among the different groups was 
highly statistically significant (p<0.001). Misoprostol given as an aqueous oral 
solution had a significantly shorter median onset of action (4.0 min, range 2.0 to 5.0 
min) compared to misoprostol given as tablets orally (6.0 min, range 4.0 to 10.0 
min, p=0.01), rectally (11.0 min, range 7.0 to 13.0 min, p<0.001) or vaginally (20.0 
min, range 11.0 to 25.0 min, p<0.001) (Table 5.2). The time of onset of action for 
oral solution misoprostol 400 μg was not significantly different from that of 
intramuscularly administered syntometrine (2.5 min, range 2.0 to 6.0 min, p=0.393). 
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The side effects of misoprostol 
The two main side effects noted in the women were shivering and pyrexia 
(body temperature >38°C). Women receiving intramuscular syntometrine and 
vaginal misoprostol experienced neither of these side effects. One of the women 
assigned to vaginal misoprostol had a temperature of 38°C before misoprostol was 
given to her but her temperature did not rise subsequently. In the group of 40 women 
receiving misoprostol via different routes, six women (15%), among whom five 
were from the oral solution group and one from the oral tablet group, experienced 
shivering lasting a median of 36.5 (range 11.0 to 50.0) minutes. The incidence of 
shivering was significantly different (p=0.008) among the women receiving 
misoprostol by different routes.  Logistic regression was used to adjust for the 90-
minute post-treatment cumulative uterine activity.  We found that neither the route 
of administration of misoprostol nor the post-treatment cumulative uterine activity 
significantly affected the incidence of shivering (p=0.54 and p=0.16 respectively) 
after using logistic regression to adjust for the post-treatment cumulative uterine 
activity. 
 
Twelve women (30%) (two from the oral tablet group, nine from the oral 
solution group and one from the rectal group), including the six with shivering,  
developed an increase in body temperature over 38°C (median maximum 
temperature 38.3°C, range 38.1°C to 39.9°C). The incidence of fever was 
significantly different (p<0.001) among women receiving misoprostol by different 
routes.  Logistic regression was used to adjust for the 90-minute post-treatment 
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cumulative uterine activity.  We found that the route of administration was 
significantly associated with pyrexia (p=0.04) but not the post-treatment cumulative 
uterine activity (p=0.27).  Women who received oral solution misoprostol were 
significantly more likely to have fever than those who received oral tablet 
misoprostol (p=0.012, OR = 30.7, 95% CI 2.1 to 434.8) or rectal misoprostol 
(p=0.012, OR = 47.6, 95% CI 2.4 to 909.1).  
 
The maximum body temperature experienced was also significantly different 
(p=0.001) among women receiving misoprostol via different routes (Figure 5.3). 
Linear regression was used to adjust for the 90-minute post-treatment cumulative 
uterine activity.  We found that the route of administration was significantly 
associated with the maximum temperature (p=0.006) but not the post-treatment 
cumulative uterine activity (p=0.120). Women who received oral solution 
misoprostol had significantly higher maximum body temperatures than those who 
received oral tablet misoprostol (p=0.005, mean difference of maximum body 
temperature was 0.85°C [95% CI 0.28°C to 1.42°C]), rectal misoprostol (p=0.009, 
mean difference was 0.82°C [95% CI 0.21°C to 1.42°C]), or vaginal misoprostol 
(p=0.001, mean difference was 1.07°C [95% CI 0.47°C to 1.67°C]).  
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Figure 5.3. Maximum temperature reached plotted against cumulative uterine 
activity over 90 minutes   
 
Comment 
Despite the small size of this study, it is apparent that misoprostol, 
administered by different routes, results in significantly different uterotonic action, 
with an aqueous solution of misoprostol 400 μg taken orally producing uterotonic 
activity faster and greater than oral tablet, rectal or vaginal misoprostol. Oral 
solution misoprostol 400 μg also acted on the postpartum uterus as quickly and as 
strongly as intramuscular syntometrine 1 ml, which is the standard drug routinely 
given for the prevention of postpartum haemorrhage in many maternity units.  
 
 The work for this study was performed in 1997 to 1998 when the use of 
misoprostol for preventing postpartum haemorrhage was just beginning. As we were 
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uncertain of the efficacy of misoprostol at that time, we planned our pilot study one 
step at a time, beginning with oral tablets, oral solution, rectal, and finally the 
vaginal route. We acknowledge that random allocation of treatment would have 
been a superior method of allocation, possibly avoiding the problem of the 
imbalance in parity of subjects. However, our results have been adjusted for the 
difference in parity. The two main routes of administration being considered for 
misoprostol in the third stage in 1997 was oral tablet and rectal. However, prior to 
this, misoprostol had been administered successfully by the vaginal route for 
induction of labour and medical abortions and we decided to try this route of 
administration as well. Unfortunately, we did not think to include the buccal route. 
Sample size calculations were not performed a priori as the effect size was unknown 
and, as this was a pilot study using very labour-intensive methodology, we restricted 
the sample sizes.  
 
The quick onset of action of misoprostol given as an aqueous solution orally 
is not surprising as time is not required for the dissolution of the tablets after 
swallowing, and, hence, absorption of the drug will be enhanced. The rapid 
absorption of misoprostol given as an oral solution may lead to higher peak plasma 
concentrations and stronger initial uterine contractions as opposed to gentler 
contractions with more gradual increases in plasma concentrations resulting from 
misoprostol administered rectally or vaginally. Pharmacokinetic studies have shown 
that sublingual and oral tablet misoprostol used for first-trimester abortions produce 
earlier and higher peak plasma concentrations [Zieman et al 1997; Danielsson et al 
1999; Tang et al 2002a; Khan & El-Refaey 2003] than vaginal or rectal misoprostol, 
resulting in earlier, more pronounced uterine tonus [Danielsson et al 1999]. Gemzell 
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Danielsson and colleagues’ study [Danielsson et al 1999] also reported times of 
onset of action for the oral tablet (7.8 min, SD 3.0 min) and vaginal misoprostol 
(20.9 min, SD 5.3 min) similar to those in our study. Misoprostol tablets are not 
designed for parenteral administration and may lead to slow or erratic absorption if 
given rectally or vaginally [Zieman et al 1997; Tang et al 2002a; Khan & El-Refaey 
2003]. This may be overcome by its proper formulation into vaginal pessaries and 
rectal suppositories, or by the use of makeshift mini-enemas, as described by 
Bugalho and colleagues [Bugalho et al 2001]. Another reason for poor absorption 
via the vaginal route in the postpartum period is the presence of bleeding and 
passage of lochia that may dilute or wash out the misoprostol. 
 
The finding of a 50% rate of shivering and 90% rate of pyrexia in the women 
given aqueous solutions of misoprostol was unexpected. The incidence of side 
effects in this group of women was significantly higher than in the other treatment 
groups. There was also a strong association between the route by which misoprostol 
was administered and the maximum body temperature reached. In our earlier study 
[Chong et al 2001], we found that doses of oral tablet misoprostol above 400 μg 
resulted in higher incidences of side effects. This study shows that, besides the 
dosage used, the route of administration of misoprostol also influences the rate of 
side effects.  
 
We hypothesized that this was due to the higher peak plasma concentrations 
of misoprostol acid achieved by giving an oral solution of misoprostol. In the 
pharmacokinetic study by Tang et al [2002a], the peak plasma level of misoprostol 
acid was highest and earliest with sublingual misoprostol. They also reported the 
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highest rate of shivering and pyrexia with their pilot study using sublingual 
misoprostol for first trimester termination of pregnancy [Tang et al 2002]. It is 
probable that high plasma concentrations of misoprostol acid, besides acting on 
uterine receptors to produce contractions, also act on thermoreceptors, primed by the 
pregnancy state, resulting in disturbed thermoregulation. There is probably a 
threshold plasma concentration of misoprostol acid at which these side effects are 
triggered. This threshold level may be lowered in pregnancy, as shivering and 
pyrexia is uncommon when misoprostol is taken by women who are not pregnant. It 
is also possible that beyond a certain threshold plasma concentration, no further 
increase in uterine activity is produced as the uterine receptor sites may be saturated. 
We found that in women given misoprostol, the uterotonic activity produced was 
higher in those with side effects than in those without. But, when adjusted for the 
route of administration, this effect was not statistically significant. Another possible 
explanation could be that parenteral routes of administering misoprostol bypass 
certain metabolic pathways that increase the occurrence of these side effects. The 
rate of rise of the plasma levels of misoprostol acid may also be a factor in causing 
these side effects. 
 
Shivering and pyrexia in women receiving misoprostol in the immediate 
postpartum period have both been widely documented. Although these side effects 
are usually mild and self-limiting, they can occasionally be severe [Chong et al 
1997]. Authors have suggested the concomitant use of epidural anesthesia as a factor 
[Villar et al 2002], but none of the women in this study or our previous trial [Chong 
et al 2001] were on epidural anesthesia. Pregnant women given misoprostol, by any 
route, for induction of labor [le Roux et al 2002] do not experience significant 
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shivering or pyrexia as the dosages used in the presence of a live, term fetus are 
generally low. Initial reports about the use of misoprostol for abortion, when large 
doses were used, did not highlight these side effects. However, recent studies 
[Schaff et al 2001; Tang et al 2002] have documented high rates of fever (32% to 
72%). The highest rates of fever (72%) and chills (82%) when misoprostol was used 
for first-trimester abortions were reported with sublingual misoprostol [Tang et al 
2002]. The sublingual route has been shown to produce significantly higher serum 
peak concentrations of misoprostol acid than either oral tablet or vaginal misoprostol 
[Tang et al 2002]. These findings support our hypothesis [Chong et al 2002] that 
shivering and pyrexia are triggered off by high plasma concentrations of misoprostol 
acid. 
 
The oral solution and sublingual routes promise to be the most effective 
ways of administering misoprostol, resulting in the fastest onset of action and 
strongest initial uterotonic effect. However, these routes also result in the highest 
rates of shivering and pyrexia. These side effects appear to be related to the peak 
plasma concentrations of misoprostol acid achieved. One strategy to consider for the 
safe routine use of misoprostol in the third stage would be to give lower doses of 
misoprostol by either the oral solution or sublingual route. Another strategy may be 
to aim for a more gradual and sustained increase in plasma levels of misoprostol 
using the rectal [Khan & El-Refaey 2003] or vaginal route, bearing in mind the 
slower onset of action and lower initial intensity of uterotonic effect. Perhaps, rectal 
misoprostol may be combined with injectable uterotonics to overcome its 
disadvantage of a slow onset of action. The authors of the World Health 
Organization multicentre randomized trial and the Cochrane systematic review on 
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the use of misoprostol for the prevention of postpartum haemorrhage have observed 
that the lesser efficacy of misoprostol compared to injectable uterotonics could be 
related to its later peak in plasma levels after oral or rectal administration [Abdel-
Aleem et al 2003].  
 
This study highlights the need to carefully reexamine the route and dose of 
misoprostol used for the purpose of preventing or treating postpartum haemorrhage. 
We suggest that misoprostol administered as an aqueous solution be further studied. 
A lower dose of misoprostol given as an oral solution may reduce the side effects 






Chapter 6  
 
The side effects of shivering and pyrexia when oral 
misoprostol is administered in the immediate postpartum 
period 
 




Oral misoprostol has been prescribed in daily doses of 800 μg for preventing 
nonsteroidal anti-inflammatory drug-induced gastric ulcers since it was approved for 
this indication by the FDA in 1988. Its off-label use, both orally and vaginally, for 
inducing abortions and labour has been reported since the early 1990s [Sanchez-
Ramos et al 1993; Creinin & Vittinghoff 1994]. Up to the time of this report, only 
two cases of misoprostol overdose had been reported in the literature [Graber & 
Meier 1991; Bond & Van Zee 1994]. Both involved doses (3 mg and 6 mg 
respectively) greatly exceeding the recommended daily dosage (400 μg to 800μg), 
and both patients exhibited hyperthermia as one of the toxic effects of misoprostol. 
Prior to this report, no cases of severe hyperthermia had ever been documented with 
normal doses. We observed a woman who developed severe hyperthermia after a 
single 800 μg oral dose of misoprostol given soon after a normal vaginal delivery. 
 
Case report 
A previously healthy 20-year-old woman, gravida 2, para 1 presented at 41 
weeks’ gestation in spontaneous labour after an uneventful antenatal period. She had 
not experienced any previous adverse drug reactions. After a short, uncomplicated 
labour, she had a normal vaginal delivery of a healthy female neonate weighing 
3605 g. She was given 800 μg of misoprostol orally for prophylaxis against 
postpartum haemorrhage as part of a clinical trial. She received no other medication. 
Postpartum blood loss was 450 mls. Thirteen minutes after receiving misoprostol, 
the patient complained of chills and rigors. Her axilla temperature was 36.8°C and 
her pulse and blood pressure were 80 beats/min and 120/80 mmHg respectively. She 
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was given more blankets to keep herself warm but she continued to complain of 
chills. One hour later, she appeared to enter a trance-like state, refusing to open her 
eyes and not responding to questions despite being conscious. Her pulse was 80 
beats/min, blood pressure 110/75 mmHg and axilla temperature was 37.0°C. Thirty 
minutes after that, she became restless and disoriented and she was then noted to 
have an axilla temperature of 41.4°C and pulse of 180 beats/min. Her blood pressure 
was normal, 130/70 mmHg. Her rectal temperature was measured at 41.9°C. 
Cooling was immediately started by splashing ice water on the patient and 
evaporating the water with fans. Ice packs and water-soaked sheets were also placed 
on the patient. Intravenous fluids (normal saline 0.9% and Hartman’s solution) were 
started and she was catheterised to monitor her renal output and to watch for 
myoglobinuria. Core temperature was monitored continuously with a rectal probe. 
Oxygen was administered via a hudson mask at 15 L/min. 
 
Initial investigations revealed essentially normal full blood counts and serum 
urea and electrolytes. Arterial blood-gas determination showed an oxygen partial 
pressure (PaO2) of 90.7 mmHg, carbon dioxide partial pressure (PaCO2) of 21.3 
mmHg, pH of 7.43, bicarbonate level of 18.5 mmol/L and base deficit of -7.4 
mmol/L indicating respiratory alkalosis with metabolic compensation. Serum 
ionised calcium was low, 1.05 mmol/L (1.15-1.35), while phosphate was normal, 
1.18 mmol/L (0.85-1.45). Other abnormalities included serum alkaline phosphatase 
levels of 227 IU/L (38-126), lactic dehydrogenase (LDH) of 1416 IU/L (300-550), 
and creatinine phosphokinase of 504 IU/L (60-375). Coagulation studies were 
normal. Her electrocardiogram showed uncomplicated sinus tachycardia. Pulse 
oximeter readings showed oxygen saturation levels between 98%-100%. 
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 Despite the measures taken to cool the patient, her core temperature 
remained above 40°C and she still had a tachycardia of 168 beats/min one hour after 
the start of treatment. A nasogastric tube was inserted and ice saline lavage was 
instituted. After 30 minutes of lavage, the core temperature was brought down to 
38.9°C and the lavage was stopped to avoid inadvertent hypothermia. Cold sponging 
was continued until the core temperature reached 38°C forty-five minutes later. At 
this point, her pulse was 135 beats/min, blood pressure was 120/60 mmHg and she 
was no longer delirious. Her renal output after catheterisation was only 20 mls 
despite receiving 2.5 L of intravenous fluids. An intravenous bolus of furosemide 20 
mg was given. After this, her urinary output remained constantly above 60 mls an 
hour and the urine was clear. 
 
 The patient’s rectal temperature returned to 37.3°C three hours forty minutes 
after the commencement of treatment for her hyperthermia, and only then was she 
fully alert and coherent. She had no recall of the entire episode starting from the 
point she began experiencing chills and rigors. 
 
 Repeat investigations revealed that her serum ionised calcium and phosphate 
levels were normal 6 hours after the episode. Serum LDH reached a peak of 3075 
IU/L (300-550) on the first postnatal day, while serum glutamic-oxaloacetic 
transaminase was 161 IU/L (5-40), and creatinine phosphokinase was 4715 IU/L 
(60-375). Subsequently, serum creatinine phosphokinase levels dropped to 1714 
IU/L on the second postnatal day. Urine myoglobin index measured on the day of 
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delivery and the first postnatal day were both normal, 0.849 and 0.886 
(myoglobinuria > 0,95) respectively. Other investigations were essentially normal. 
 
The patient’s subsequent postnatal course was uneventful. She remained 
afebrile and asymptomatic and unable to remember the events during the period of 
hyperthermia. She was discharged on the third postnatal day. 
 
Discussion 
This is the first published report [Chong et al 1997] in the medical literature 
of severe side effects with a non-excessive dose of oral misoprostol when used in the 
postpartum period. Single and repeated oral doses of 600-800 μg of misoprostol for 
inducing abortions have been used in various studies [El-Refaey & Templeton 1994; 
El-Refaey et al 1994a; El-Refaey et al 1995] with no adverse effects. The severity 
and rapid course of this patient’s hyperthermia was thus unexpected. 
 
 In a previous case of misoprostol overdosage [Bond & Van Zee 1994] in 
pregnancy, a 19-year-old woman developed hyperthermia, tachycardia, dyspnoea, 
uterine tetany with resultant fetal death, metabolic acidosis, hypoxemia, and 
biochemical rhabdomyolysis after an intentional overdose of 30 tablets of 200 μg 
misoprostol and four tablets of 2 mg trifluoperazine. In the only other report of 
misoprostol overdose [Graber & Meier 1991], a 71-year-old woman experienced 
hyperthermia, tremor, tachycardia, hypertension, nausea and abdominal cramps after 
ingesting fifteen 200 μg tablets of misoprostol. Both patients recovered within 12 
hours of misoprostol. Reports of fever following normal doses of misoprostol have 
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been rare, mild and of dubious causal relationship [Product Information, Cytotec®, 
G D Searle & Co., 1991]. 
 
 Our patient developed chills and rigors 13 minutes after ingesting 800 μg of 
misoprostol. This coinciding with an increase in uterine activity measured by an 
intrauterine pressure transducer inserted after delivery of the placenta. Despite 
persistence of these symptoms and a change in sensorium later, her axilla 
temperature remained normal. However, within 30 minutes of the last measured 
axilla temperature of 37°C, she became restless and incoherent and her axilla 
temperature had risen to 41.4°C. Rectal temperature was 41.9°C and remained above 
38°C for three hours despite intensive measures taken to lower her body 
temperature. She also developed hypocalcaemia and biochemical markers of 
rhabdomyolysis as well as transient hypoxaemia and respiratory alkalosis. All her 
symptoms resolved within eight hours of drug ingestion, and biochemical 
investigations were returning to normal levels by the second postnatal day. She had 
no persistent ill effects of the hyperthermia on discharge and subsequent follow-up. 
 
The differential diagnosis of hyperthermia includes infection, hypothalamic 
injury, thyroid storm, phaeochromocytoma, heat stroke, malignant hyperthermia, the 
neuroleptic malignant syndrome and drug overdose. Our patient had no signs of 
infection before or following her delivery, and none of the medical problems listed 
above. She only received one drug, misoprostol, before the onset of the 
hyperthermia. Drugs may cause hyperthermia by several mechanisms including 
local inflammation, endotoxin release, tissue necrosis, haemolysis, hypersensitivity 
 109
immunologic reaction, idiosyncratic reaction or by altering thermo-regulation. 
Prostaglandin E1 and E2 are drugs known to be responsible for drug-induced fevers 
[Mackowiak & LeMaistre 1987]. Their fever-inducing property, as suggested by 
experiments on pigs [Parott et al 1995] and rats [Monda et al 1994], is thought to be 
mediated by its action on the anterior and posterior hypothalamus.  
 
Figure 6.1: Even normal doses of misoprostol can cause severe side effects in 
the immediate postpartum period 
 
Conclusion 
 Misoprostol overdose has been reported to cause serious toxic effects 
including hyperthermia [Graber & Meier 1991; Bond & Van Zee 1994]. This case 
shows that even routinely-prescribed maximal doses of misoprostol may cause an 
idiosyncratic hyperthermia that requires rapid and vigorous treatment. Clinicians are 








The side effects of shivering and pyrexia when oral 
misoprostol is administered in the immediate postpartum 
period 
 
Part 2: Relationship with dose of misoprostol,  
uterine workload produced, and route of administration 
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Introduction 
Along with the case report of severe hyperpyrexia and shivering in a woman 
given 800 μg of oral misoprostol postpartum in 1997 [Chong et al 1997], I reported 
that doses of oral misoprostol above 400 µg were associated with high incidences of 
shivering and pyrexia [Chong et al 1997a; 2001]. My study suggested that the safe 
dose of misoprostol for use in the third stage would be 400 µg. 
 
At that point in time (1997-1998), the Steering Committee of the World 
Health Organisation multicentre randomised controlled trial of oral misoprostol for 
the third stage were concerned about the side effects of shivering and pyrexia at the 
two doses they were considering (400 µg and 600 µg) for their study. They decided 
to evaluate the effects of these two doses in a randomised, double-blinded, placebo-
controlled pilot trial [Lumbiganon et al 1999] conducted in South Africa and 
Thailand. They concluded that the side effects of oral misoprostol used in the third 
stage were dose-related with 600 µg having significantly more pyrexia (RR 3.7, 95% 
CI 1.3-10.9) and shivering (RR 1.5, 95% CI 1.0-2.1) than 400 µg. The reported rates 
of shivering and pyrexia were 19% and 2% for 400 µg, and 28% and 7.5% for 600 
µg, respectively. The Steering Committee decided to use 600 µg misoprostol in the 
main trial “in order to achieve higher effectiveness” [Lumbiganon et al 1999]. Since 
then, other authors have reported incidences of pyrexia and shivering with 
misoprostol given in the third stage as high as 34% [Amant et al 1999] and 72% [El-
Refaey et al 2000] respectively.  
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The relationship of the shivering and pyrexia produced by misoprostol with 
the dose administered, uterine activity produced, and the route of administration will 
now be examined. 
 
Dose studies using oral tablet misoprostol 
In the study to determine the optimum dose of oral misoprostol for use to 
prevent postpartum haemorrhage (Chapter 4), we documented the side effects of 
shivering and pyrexia (temperature above 38°C) in the 47 women given oral 
misoprostol after normal vaginal delivery. All the women in the study were observed 
closely for side effects in the two-hour period of uterine activity recording.  
 
Methods 
Informed consent was obtained in the first stage of labour from 47 women 
who delivered vaginally after spontaneous labours not requiring induction or 
augmentation. The women were assigned sequentially into five groups and received 
oral misoprostol 200 μg, 400 μg, 500 μg, 600 μg, or 800 μg. The study was 
approved by the department ethical committee.  
 
The delivery of the fetus was left entirely to the accoucheur. However, the 
routine administration of oxytocics in the third stage was omitted. Within 5 minutes 
of delivery of the placenta, a calibrated Gaeltec® catheter with an intrauterine 
pressure transducer at its tip was inserted transcervically into the uterine cavity until 
the tip of the catheter could be felt to impinge on the fundus of the uterus. The 
catheter was then secured in place and connected to a Sonicaid® Meridian fetal 
monitor (Sonicaid Ltd., Oxford Medical Instruments, Chichester, U.K.), and uterine 
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active contraction areas were recorded automatically. A researcher was with the 
woman throughout the two-hour period of the recording to document any side 
effects experienced. 
 
Statistical analysis was performed using the SPSS 11.0 for Windows 
statistical package with statistical significance set at p < 0.05. The association 
between misoprostol dosages with side effects (shivering & pyrexia) was assessed 
using Chi-square/Fisher’s Exact test with odds ratios (OR) presented where 
applicable. 
 
The relationship between cumulative uterine workload 90 min after 
misoprostol with the side effects of shivering and pyrexia was assessed using linear 




Relationship of side effects with dose of oral tablet misoprostol given 
These side effects are listed in Table 7.1. Shivering occurred in 17 women 
(36%), and pyrexia (defined as a rise in body temperature above 38°C) occurred in 
19 women (40%). Shivering and pyrexia occurred in 60% of women given oral 
misoprostol 500 μg and 600 μg, and 43% of those given 800 μg. Shivering only 
occurred in 10%, and mild pyrexia in 20%, of the women given 200 μg and 400 μg 
of oral misoprostol. 
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Women given doses of oral tablet misoprostol more than 400 µg experienced 
significantly more shivering than women given doses 200 µg and 400 µg (OR 11.3, 
95% CI 2.2-58.4, p=0.001). 
 
Women given doses of oral tablet misoprostol more than 400 µg also 
experienced significantly more pyrexia than women given doses 200 µg and 400 µg 
(OR 5.0, 95% CI 1.3-19.0, p=0.014). 
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Relationship of side effects with uterine activity recorded 
The cumulative uterine workload at 90 min produced by oral tablet 
misoprostol was not associated with the side effects of shivering (p=0.128) (Figure 
7.1) and pyrexia (p=0.199) (Figure 7.2) controlling for the cumulative uterine 












































































Figure 7.2. Relationship of pyrexia and uterine activity 
 
Comment 
The side effects of oral tablet misoprostol given after vaginal delivery are 
increased with doses above 400 µg, independent of the uterotonic activity produced. 
 
Route of administration studies 
Methods 
In this study (Chapter 5), 40 women who delivered vaginally after 
spontaneous labours not requiring induction or augmentation with oxytocin or 
prostaglandins were assigned sequentially to receive misoprostol 400 μg given as 
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tablets orally, rectally, vaginally, or as an aqueous solution orally (two Cytotec® 
200 μg tablets dissolved in 20 ml lukewarm water). The departmental ethics review 
committee approved the study, and informed consent was obtained from each 
participant. 
 
 The postpartum uterine activity was measured for 30 minutes as a baseline 
before the assigned medication was administered, allowing each woman to be her 
own control The uterine activity was then monitored for a further 90 minutes. The 
uterine activity of each group after treatment was compared using the repeated 
measurement technique adjusted for the baseline pre-treatment uterine activity and 
parity. The incidence of shivering and pyrexia (temperature >38°C) within the four 
misoprostol treatment groups were compared using Fisher’s Exact test, and logistic 
regression was used to test the effect of the post-treatment cumulative uterine 
activity. The relationship between the maximum body temperature recorded and the 
cumulative uterine activity in the 90 minutes after misoprostol was administered, 
and the route of administration was assessed using linear regression. Statistical 
analysis was performed using the SPSS 11.0 for Windows statistical package. 
 
Shivering 
In the group of 40 women receiving misoprostol via different routes, the 
incidence of shivering was significantly different (p=0.008) among the women 
receiving misoprostol by different routes (Table 7.2). Logistic regression showed 
that neither the route of administration of misoprostol nor the post-treatment 
cumulative uterine activity significantly affected the incidence of shivering (p=0.54 
and P=0.16 respectively). 
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Table 7.2. Shivering and pyrexia in women given misoprostol 400 μg by 
different routes 



























No. of women with 
temperature >38°C 
2 9 1 0 
 
Pyrexia 
The incidence of fever was significantly different (p<0.001) among women 
receiving misoprostol by different routes. We found that the route of administration 
was significantly associated with pyrexia (p=0.04) but not the post-treatment 
cumulative uterine activity (p=0.27).  Compared to the women who received oral 
solution misoprostol, those who received oral tablet misoprostol ( OR = 30.7, 95% 
CI 2.1 to 434.8, p=0.012) or rectal misoprostol (OR = 47.6, 95% CI 2.4 to 909.1, 




The maximum body temperature experienced was also significantly different 
(p=0.001) among women receiving misoprostol via different routes. Linear 
regression showed that the route of administration was significantly associated with 
the maximum temperature (p=0.006) but not the post-treatment cumulative uterine 
activity (p=0.120). Women who received oral solution misoprostol had significantly 
higher maximum body temperatures compared to those who received oral tablet 
misoprostol (P=0.005, mean difference of maximum body temperature was 0.85°C 
[95% CI 0.28°C to 1.42°C]), rectal misoprostol (P=0.009, mean difference was 
0.82°C [95% CI 0.21°C to 1.42°C]), or vaginal misoprostol (p=0.001, mean 
difference was 1.07°C [95% CI 0.47°C to 1.67°C]). 
 
Comment 
Based on the findings of our dose and route studies, we conclude that the 
dose of misoprostol and the route by which it is administered after vaginal delivery 
are both significantly associated with its side effects of shivering and pyrexia. 
 
Doses of 400 µg or less and both the rectal and vaginal routes give the least 
side effects. Oral solution misoprostol produces the most side effects. However, the 
side effects experienced are generally mild and self-limiting. Another option for 
avoiding the troublesome side effects of misoprostol, while retaining the better 
uterotonic effect of oral solution misoprostol, would be to give low doses (< 400 μg) 







Chapter 8  
 
Comparing the uterotonic effect and side effects of oral 
solution misoprostol 200 µg and 400 µg: 
Can low-dose oral solution misoprostol be used as a uterotonic 
agent after delivery? 
 121
Introduction 
Two recent systematic reviews [Gulmezoglu et al 2001; Villar et al 2002a] 
on the use of misoprostol to prevent postpartum haemorrhage concluded that 
injectable oxytocin or oxytocin-ergot preparations were more effective than either 
oral or rectal misoprostol. The authors also concluded that the observed rate of side 
effects with misoprostol was already high and that it was unlikely that higher doses 
of misoprostol could be used to increase its efficacy for the routine prevention of 
postpartum haemorrhage [Villar et al 2002a] without unacceptable rates of side 
effects. However, an alternative approach to increasing the efficacy of misoprostol 
would be to administer it by either the sublingual [Tang et al 2002] or oral solution 
[Chong et al 2002] route, both of which have shown evidence of increasing the 
uterotonic effect of misoprostol. At the same time, lower doses of misoprostol 
administered by these routes could moderate the rates of side effects. 
 
In an earlier study using postpartum intrauterine pressure measurements as a 
surrogate endpoint for the uterotonic action of oral misoprostol [Chong et al 2001], 
we found that doses of oral misoprostol above 400 μg were associated with high 
incidences of shivering and pyrexia (60%). Oral misoprostol 200 µg and 400 μg 
produced uterotonic effects similar to intramuscular syntometrine 1 ml while being 
associated with less shivering (10%) and pyrexia (20%). However, the onset of 
action of misoprostol given as an oral tablet was significantly slower than that of 
intramuscular syntometrine.  
 
With these findings in mind, we studied misoprostol 400 μg administered by 
different routes [Chong et al 2004] and found that the uterotonic effect produced by 
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oral solution misoprostol 400μg was significantly higher than that of oral tablet, 
rectal and vaginal misoprostol. The onset of action after administering oral solution 
misoprostol was also significantly faster than by the oral tablet, rectal and vaginal 
routes. Unfortunately, shivering and pyrexia were also more common with oral 
solution misoprostol. 
 
We thus hypothesized that a lower dose of oral solution misoprostol might 
produce a uterotonic effect similar to intramuscular syntometrine, with less side 
effects than solution misoprostol 400 µg. The aim of this study was to compare the 
uterotonic effect and side effects of a lower dose of misoprostol, 200 μg, 
administered by the oral solution route, to oral solution misoprostol 400 μg and 
intramuscular syntometrine 1 ml. 
 
Materials and methods 
Thirty women who delivered vaginally after spontaneous labors not requiring 
induction or augmentation with oxytocin or prostaglandins were recruited. None of 
the women used epidural analgesia, and they all had nil orally other than sips of 
water in active labor. The women were assigned sequentially into three groups 
(Table 8.1) and prescribed misoprostol (Cytotec®; Searle AG, Chicago, IL, USA) 
200 μg or 400 μg given as an aqueous solution orally (Cytotec® tablets dissolved in 
20 mls lukewarm water). The third group was given intramuscular syntometrine 1 
mL (oxytocin 5 units, ergometrine maleate 500 μg/ml). Exclusion criteria included 
anemia (haemoglobin < 11.0 g/dl), maternal infection, multiple pregnancy, a history 
of postpartum hemorrhage in previous pregnancies or antepartum hemorrhage in the 
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current pregnancy. The departmental ethics review committee approved the study, 
and informed consent was obtained from each participant. 
 
Table 8.1. Characteristics of women recruited for the study 









No. of women 
recruited 
 10 10 10 
No. of multiparous 
women 
 10 9 10 










































The delivery of the fetus was left entirely to the obstetrician. However, the 
routine administration of oxytocics in the third stage was omitted. Within 5 minutes 
of delivery of the placenta, a calibrated Gaeltec® (Gaeltec® Ltd., Dunvegan, 
Scotland, UK) catheter with an intrauterine pressure transducer at its tip was inserted 
transcervically into the uterine cavity until the tip of the catheter could be felt to 
impinge on the fundus of the uterus. The catheter was then secured in place and 
connected to a Sonicaid® Meridian fetal monitor (Sonicaid Ltd., Oxford Medical 
Instruments, Chichester, UK), and uterine activity contraction areas were recorded 
automatically at 15-minute intervals by the machine [Chong et al 2001]. A 
researcher was with the woman throughout the two-hour period of the recording to 
document the temperature, pulse and blood pressure of the mother every 15 minutes, 
as well as any side effects experienced. The blood loss was closely monitored and if 
any women were thought to have excessive blood loss (> 500 ml), they would have 
been given conventional therapy for postpartum hemorrhage and taken out of the 
trial. No woman recruited for the study was excluded for excessive blood loss. 
 
The postpartum uterine activity was measured for 30 minutes as a baseline 
before the assigned medication was administered. The uterine activity was then 
monitored for a further 90 minutes. The uterine activity of each group after 
treatment was compared using the repeated measurement technique adjusted for the 
baseline pre-treatment uterine activity. Repeated measurement technique or 
longitudinal data analysis was used to analyze the effect of time as well as other 
variables on the uterine activity outcome. The occurrence of shivering and pyrexia 
(temperature >38°C) within the two misoprostol treatment groups were compared 
using Fisher’s Exact test, and logistic regression was used to test the effect of the 
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post-treatment cumulative uterine activity. The relationship between the maximum 
body temperature recorded and the cumulative uterine activity in the 90 minutes 
after misoprostol was administered and the treatment given was assessed using 
linear regression. The Kruskal-Wallis test was used to assess the difference among 
the times of onset of action of the three treatment groups.  Multiple comparison was 
done using the Mann-Whitney U test. Statistical analysis was performed using the 




The details of the women recruited are given in Table 8.1. Baseline 
characteristics of the women recruited were similar in all the treatment groups. 
 
Figure 8.1 is the error bar chart showing the mean uterine activity produced 
by each form of treatment in each 15-minute period after drug administration. 
Repeat measurement technique was used to evaluate the effects of the treatment 
given, time elapsed and pre-treatment baseline uterine activity.  We found that the 
time elapsed and pre-treatment baseline uterine activity significantly affected the 
mean uterine activity recorded (p<0.0001, p<0.0001 respectively), but the type of 
treatment given did not result in any significant difference in the mean uterine 
activity produced among the three groups (p=0.702).  The mean uterine activity 
produced by oral solution misoprostol 200 µg and 400 µg was highest within the 
first 15 minutes and gradually declined, while that of the intramuscular syntometrine 
reached its peak during the second 15-minute period before declining. Looking into 
each treatment group (Figure 8.1), we found that the differences in mean uterine 
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activity between oral solution 200 µg and oral solution 400 µg (mean difference 
145.0 kPas s, 95% CI -812.4 to 1102.4, p=0.758), and intramuscular syntometrine 1 
mL (mean difference -231.7 kPas s, 95% CI -1188.4 to 724.9, p=0.623) were small 








































Figure 8.1. Error bar plot of uterine activity measured at 15-minute 
intervals after treatment 
 
Figure 8.2 is the error bar chart showing the mean cumulative uterine activity 
produced in the 30-, 60- and 90-minute periods after treatment.  Again, the repeat 
measurement technique was used to evaluate the effects of the treatment given, time 
elapsed and pre-treatment baseline uterine activity.  We found that the time elapsed 
and pre-treatment baseline uterine activity significantly affected the mean 
cumulative uterine activity (p<0.0001 and p=0.003 respectively).  However, the type 
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of treatment given did not result in any significant difference in the mean cumulative 
uterine activity produced among the three treatment groups (p=0.862).  We also 
found that the mean cumulative uterine activity produced by oral solution 
misoprostol 200 µg was not significantly different from that of oral solution 400 µg 
(p=0.601, mean difference -360.9 kPas s, 95% CI -1761.0 to 1039.3), and 
intramuscular syntometrine 1 ml (p=0.693, mean difference -271.9 kPas s, 95% CI -








































Figure 8.2. Error bar plot of cumulative uterine activity in the 90 
minutes after treatment 
 
Onset of action 
The difference in time of onset of action among the different groups was not 
statistically significant (p=0.132). The median time of onset of action of oral 
solution misoprostol 200 μg (4.0, range 3.0 to 6.0 min) was not significantly 
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different from that of oral solution 400 µg (4.0, range 2.0 to 5.0 min, p=0.278) or 
intramuscularly administered syntometrine 1 ml (2.5, range 2.0 to 6.0 min, p=0.393). 
 
The side effects of misoprostol 
The two main side effects noted in the women were shivering and pyrexia 
(body temperature >38°C). Women receiving intramuscular syntometrine 
experienced neither of these side effects. In the group of 20 women receiving oral 
solution misoprostol, seven women experienced shivering lasting a median of 33.0 
(range 11.0 to 50.0) minutes. The incidence of shivering was higher in the oral 
solution misoprostol 400 µg group (50%) than in women given oral solution 
misoprostol 200 µg (20%) but the difference was not statistically significant 
(p=0.350).  Logistic regression was used to adjust for the 90-minute post-treatment 
cumulative uterine activity.  We found that neither the effects of dose nor that of 
post-treatment cumulative uterine activity was significant (p=0.495 and p=0.112 
respectively).  
 
Ten women developed an increase in body temperature over 38°C (median 
maximum temperature 38.4°C, range 38.2°C to 39.5°C). The incidence of fever was 
significantly different (p=0.005) between women receiving oral solution misoprostol 
200 µg (10%) and 400 µg (90%).  Women taking oral solution misoprostol 200 µg 
had a significantly lower risk of developing pyrexia (OR=0.028, 95% CI 0.002 – 
0.367). Logistic regression was used to adjust for the 90-minute post-treatment 
cumulative uterine activity.  We found that the dose of misoprostol given was 
significantly associated with pyrexia (p=0.019) but not the post-treatment 
cumulative uterine activity (p=0.299).   
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The maximum body temperature experienced was also significantly different 
(p=0.001) between women given different doses of misoprostol (Figure 8.3). Linear 
regression was used to adjust for the 90-minute post-treatment cumulative uterine 
activity.  We found that both the dose of misoprostol given (p= 0.001) as well as the 
post-treatment cumulative uterine activity (p=0.025) were significantly associated 
with the maximum temperature recorded. Women who received oral solution 
misoprostol 400 µg had significantly higher maximum body temperatures than those 
who received oral solution misoprostol 200 µg (p=0.001, mean difference of 









































Figure 8.3. Maximum temperature reached plotted against cumulative 




From the results of this study, it appears that low-dose (200 µg) misoprostol, 
administered by oral solution, results in similar times of onset of action and 
uterotonic activity as oral solution misoprostol 400 μg and intramuscular 
syntometrine 1 ml. Because of the small sample size in this study, there was 
insufficient power to prove equivalence or non-inferiority. However, the estimated 
differences in the uterotonic effect produced by oral solution misoprostol 200 µg 
compared to oral solution 400 µg and intramuscular syntometrine 1 ml were small 
and not likely to be of clinical significance. With regards to side effects, the lower 
dose of oral solution misoprostol (200 µg) produced less shivering (20% versus 
50%, p=0.350) and pyrexia (10% versus 90%, p=0.005) than oral solution 
misoprostol 400 µg. The maximum temperature experienced was significantly 
associated with both the dose of misoprostol given and the cumulative uterotonic 
activity produced. 
 
The quick onset of action of misoprostol given as an aqueous solution orally 
is not surprising as time is not required for the dissolution of the tablets after 
swallowing, and, hence, absorption of the drug will be enhanced. The rapid 
absorption of misoprostol given as an oral solution may lead to higher peak plasma 
concentrations and stronger initial uterine contractions as opposed to gentler 
contractions with more gradual increases in plasma concentrations resulting from 
misoprostol administered as oral tablets. Pharmacokinetic studies have shown that 
sublingual and oral tablet misoprostol used for first trimester abortion produce 
earlier and higher peak plasma concentrations [Zieman et al 1997; Danielsson et al 
1999; Tang et al 2002a; Khan & El-Refaey 2003] than vaginal and rectal 
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misoprostol, resulting in earlier, more pronounced uterine tonus [Danielsson et al 
1999]. Another recent study performed in women after delivery with oral tablet 
misoprostol confirmed that the pharmacokinetics did not differ in the postpartum 
period [Abdel-Aleem et al 2003]. Unfortunately, similar studies have not been 
conducted using oral solution misoprostol in pregnant women. 
 
In our earlier study [Chong et al 2001], we found that doses of oral tablet 
misoprostol above 400 μg resulted in higher incidences of side effects. When we 
compared misoprostol 400 µg administered by different routes [Chong et al 2002], 
we found that, besides the dosage used, the route of administration of misoprostol 
also influenced the rate of side effects. We hypothesize that this was due to either 
the higher peak plasma concentrations of misoprostol acid achieved by giving an 
oral solution of misoprostol or the fact that parenteral routes of administering 
misoprostol bypass metabolic pathways that increase the occurrence of these side 
effects. 
 
This study shows that the differences in uterotonic effect produced by 
misoprostol 200 µg and 400 µg administered as oral solutions and intramuscular 
syntometrine 1 ml were small, while the difference in side effects produced was 
significantly different. The limitations of the existing evidence against the routine 
use of oral misoprostol in the third stage of labor may lie in the fact that misoprostol 
administered as oral tablets have a slower onset of action [Chong et al 2001] than the 
parenteral oxytocics with which it was compared. This view is shared by the authors 
of the WHO misoprostol trial and the Cochrane systematic review on the use of 
misoprostol for the prevention of postpartum haemorrhage [Abdel-Aleem et al 
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2003]. We suggest that a strategy to consider for the safe routine use of misoprostol 
in the third stage would be to give low doses of misoprostol by either the oral 
solution or sublingual route. This study highlights the need to carefully re-examine 








Chapter 9  
 
The use of misoprostol administered by different routes in the 
third stage of labour to prevent postpartum haemorrhage:  
A Systematic Review 
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Introduction 
Although there has been marked improvement in the prevention of 
postpartum haemorrhage (PPH) in the third stage of labour in recent years, it is still 
a significant contributor to maternal morbidity and mortality in developing countries 
[Li et al 1996]. There is good evidence that clinicians should practice active 
management of the third stage of labour and administer appropriate prophylactic 
uterotonic agents to prevent PPH [Prendiville et al 2003]. Currently, the uterotonic 
agents used by most maternity units are injectable oxytocics and ergot alkaloids such 
as oxytocin, syntometrine, and ergometrine. The first use of oral misoprostol for the 
prevention of postpartum haemorrhage in the third stage of labour was reported in 
1996 in a prospective uncontrolled study [El-Refaey et al 1996]. Within two years, 
the first randomised controlled trial (RCT) was published [Bamigboye et al 1998a], 
and over the next five years, another 26 RCTs were reported. Most were small to 
medium sized trials ranging from 40 to 2058 subjects. The largest single study was 
that by the WHO Collaborative Group, with 18530 subjects [Gulmezoglu et al 
2001a].  
 
The WHO Misoprostol multicentre trial concluded that oral tablet 
misoprostol 600 µg given in the third stage of labour was associated with a higher 
risk of severe postpartum haemorrhage, need for additional uterotonics, shivering, 
and pyrexia compared to intramuscular or intravenous oxytocin 10 IU. Until this 
study, none of the RCTs had proven conclusively that misoprostol was either more 
or less effective than injectable uterotonics in preventing postpartum haemorrhage or 
the need for additional uterotonics. Earlier studies [Cook et al 1999; Ng et al 2001] 
had shown that the blood loss was significantly greater with oral tablet misoprostol 
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than with injectable uterotonics, but the clinical significance of the increase in blood 
loss (less than 100 ml) was doubtful. As expected, the results of the large WHO 
study overwhelmed the existing evidence, and the resulting Cochrane review 
[Gulmezoglu et al 2003] that followed concluded that conventional injectable 
oxytocics were preferable to misoprostol for the routine prevention of postpartum 
haemorrhage. The Cochrane review combined the studies using oral tablet and oral 
solution misoprostol together and this could have influenced the overall treatment 
effect. Also, the injectable uterotonics used to compare with misoprostol were all 
analysed together in the review. When studies of misoprostol oral tablet were 
compared with injectable uterotonics, there was a significant increase in blood loss 
in the misoprostol oral tablet group. But when studies with oral solution misoprostol 
were combined the relative effect seemed to have decreased. 
 
Based on our own observations [Chong et al 2002; Chong et al 2004], we 
feel that misoprostol given orally as a tablet may not be the optimal method of 
administering this drug for the purpose of preventing postpartum haemorrhage. 
Pharmacokinetic studies [Abdel-Aleem et al 2003; Khan & El-Refaey 2003] have 
shown that the peak plasma concentration of misoprostol acid with oral tablet 
administration after delivery is around 18 to 20 minutes. From our intrauterine 
pressure measurement studies, we have found that the onset of uterotonic action 
after swallowing misoprostol tablets is 6 minutes [Chong et al 2004]. This compares 
with a peak plasma concentrations of oxytocin within 3 minutes of intramuscular 
injection [Gibbens et al 1972], and onset of uterotonic action by 2.5 minutes [Chong 
et al 2004]. These few minutes difference in onset of action is of great clinical 
significance as delay in uterine contraction in the third stage can lead to a large 
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volume of blood loss within a very short period of time. The delay in onset of action 
for rectal misoprostol is even greater, with peak plasma levels at 40.5 minutes [Khan 
& El-Refaey 2003], and onset of uterotonic activity at 11 minutes [Chong et al 
2004]. Hence, we feel that the current RCTs, which have either used misoprostol as 
oral tablets, or as rectal suppositories (for which most misoprostol tablets were not 
formulated), will not show misoprostol to be an effective uterotonic agent for the 
purpose of preventing postpartum haemorrhage in the third stage. 
 
We separated out the two trials using oral solution misoprostol [Walley et al 
2000; Oboro & Tabowei 2003] from those using oral tablet misoprostol as we feel 
that this method of administration may result in quicker absorption and greater 
uterotonic efficacy. In addition, we examined the use of misoprostol for the 
prevention of postpartum haemorrhage during caesarean sections. The hypotheses 
tested were:  
1. oral tablet and rectal misoprostol are inferior to parenteral oxytocics in 
preventing postpartum blood loss, 
2. oral solution misoprostol is equivalent to parenteral oxytocics in preventing 
postpartum blood loss, 
3. misoprostol is more effective than placebo or no treatment, and  




Search strategy for identification of studies 
We used the same search strategy used by the earlier reviewers but did an 
extended search up to 2003. Randomised clinical trials of misoprostol used for the 
routine prevention of postpartum haemorrhage were identified from the Cochrane 
central register of controlled trials (CENTRAL) maintained by the Cochrane 
Library, and the MEDLINE and PubMed (National Library of Medicine, 
Bethesda,MD) computerised databases (1995 to 2003). We did not search for earlier 
studies as the first report of the use of misoprostol in the third stage was published in 
1996 [El-Refaey et al 1996]. The date of the latest search was July 1, 2003. The 
medical search terms used included misoprostol, third stage, prevention of 
postpartum haemorrhage, randomised controlled trial.  
 
Criteria for considering studies for this review 
Eligibility criteria for inclusion included randomised clinical trials 
comparing misoprostol administered by any route for the active management of the 
third stage of labour with no treatment, placebo or other uterotonic drugs; random 
allocation to treatment and comparison groups; reasonable measures to ensure 
allocation concealment [Clarke & Oxman 1999]. Trials with inadequate allocation 
concealment or with primary outcomes other than clinical effectiveness were 
excluded.  
Types of outcome measures:  
1. Blood loss equal or more than 1000 mL 
2. Blood loss equal or more than 500 mL 
3. Need for additional oxytocic therapy 
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4. Side effect of shivering 
5. Side effect of fever 
These outcomes were selected as they were the ones most consistently 
documented in the RCTs as well as having the most clinical significance. Volume of 
blood loss, change in haemoglobin or haematocrit values, and other side effects were 
not consistently measured in the studies, and of doubtful clinical relevance. 
 
Trials under consideration were evaluated for methodological quality and 
appropriateness for inclusion, without consideration of their results, independently 
by two reviewers. No language preferences were applied either during the search or 
selection of trials. Data were extracted independently by two reviewers. 
 
In addition to the main outcomes, the following data were systematically 
extracted for each study: 
1. trial entry criteria (high versus low risk, other specific exclusion criteria); 
2. exclusions and missing data after randomization; 
3. management of the third stage of labour; 
4. the duration and technique of assessment of blood loss. 
 
Comparisons:  
Prespecified primary comparisons for oral tablet misoprostol 400 to 600 μg 
were as follows: 
1. Misoprostol vs placebo 
2. Misoprostol vs any injectable uterotonic 
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Prespecified primary comparisons for oral solution misoprostol 400 and 600 
μg were as follows: 
1. Misoprostol vs oxytocin 
 
Prespecified primary comparisons for rectal misoprostol 400 μg were as 
follows: 
1. Misoprostol vs placebo 
2. Misoprostol vs any injectable uterotonic 
 
Data Synthesis: 
 Data were extracted from the sources and entered into the RevMan computer 
software  (Cochrane Collaboration, Copenhagen, Denmark) and double-checked for 
accuracy. For dichotomous data, relative risks (RR) and 95% confidence intervals 
were calculated; and for continuous outcomes weighted mean difference (WMD). If 
there was heterogeneity among the study results a random effects model was used 
and if there was not a fixed effects model was used. 
 
Description of included studies 
Twenty-seven randomized controlled clinical trials were identified and 
considered for inclusion in this review. These trials were conducted in both 
developing and developed countries, and their results were published from 1998 to 
2003. Four studies were excluded (reasons given in Table 9.6). This review includes 
six trials [Daly et al 1999; Benchimol et al 2001; Caliskan et al 2002; Karkanis et al 
2002; Caliskan et al 2003; Oboro & Tabowei 2003] not considered in the most 
recent Cochrane Review [Gulmezoglu et al 2003]. 
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In 16 trials, the risk status of the women for postpartum haemorrhage was 
not mentioned. Low-risk women were studied in five trials, and one trial included 
women at both high and low risk of postpartum haemorrhage.  
 
‘Active’ management of the third stage was described in 17 of the trials with 
cord traction being universally performed, but the actual practice varied in the 
different centres. In four studies, the management of the third stage was not 
described, while two studies involved caesarean deliveries. 
 
Oral tablets were used in 13 trials [Hofmeyr et al 1998; Hofmeyr et al 1998a; 
Amant et al 1999; Cook et al 1999; Lumbiganon et al 1999; Surbek et al 1999; El-
Refaey et al 2000; Benchimol et al 2001; Gulmezoglu et al 2001a; Hofmeyr et al 
2001; Kundodyiwa et al 2001; Ng et al 2001; Caliskan et al 2003] for the prevention 
of postpartum haemorrhage after vaginal deliveries. Five of these studies compared 
oral tablet misoprostol against placebos [Hofmeyr et al 1998; Hofmeyr et al 1998a; 
Surbek et al 1999; Benchimol et al 2001; Hofmeyr et al 2001], while nine compared 
misoprostol to injectable uterotonics [Amant et al 1999; Cook et al 1999; 
Lumbiganon et al 1999; El-Refaey et al 2000; Benchimol et al 2001; Gulmezoglu et 
al 2001a; Kundodyiwa et al 2001; Ng et al 2001; Caliskan et al 2003]. Two other 
studies assessed the use of oral tablet misoprostol during caesarean deliveries 
[Acharya et al 2001; Lokugamage et al 2001a]. 
 
Oral solution misoprostol was given in two trials [Walley et al 2000; Oboro 
& Tabowei 2003]. In both these trials, powdered misoprostol was used to enable 
blinding of the drug identity, with powdered lactose as the identical placebo. The 
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powdered misoprostol and the lactose were dissolved in 50 mL of water before 
administration. Both these trials compared misoprostol with intramuscular oxytocin 
10 IU. We did not find any studies that compared oral solution against placebo or no 
treatment. 
 
The route of administration was rectal in six studies [Bamigboye et al 1998; 
Bamigboye et al 1998a; Bugalho et al 2001; Gerstenfeld & Wing 2001; Caliskan et 
al 2002; Karkanis et al 2002]. All except one used normal misoprostol tablets (meant 
for oral administration) inserted rectally. One group of investigators used 
microenemas composed of misoprostol 400 μg (2 tablets) made into a paste in 5 mL 
of saline [Bugalho et al 2001]. Only one study compared rectal misoprostol with 
placebo [Bamigboye et al 1998]. 
 
The injectable uterotonic used was intramuscular oxytocin in eight trials, 
intravenous oxytocin in nine trials, intramuscular syntometrine in four trials, 
intravenous ergometrine or methylergometrine in two trials, and intramuscular 
methyleronovine in two trials. Five studies used more than one type of injectable 
uterotonics. 
 
The estimation of blood loss varied in precision. Eleven studies measured 
blood loss using various methods of collection and volume measurement, eight of 
these studies weighed linen and swabs as well. Nine studies used visual estimation 
only while three combined visual estimation with volume measurement and 
weighing of linen. Two studies used pre- and post-delivery haemaglobin 
measurements, one combined with linen weighing. 
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Most trials had postpartum blood loss, defined as severe postpartum 
haemorrhage ≥1000 ml or postpartum haemorrhage ≥500 ml, and the use of 
additional uterotonics as the primary outcome. The rate of side effects was the 
primary outcome in two trials [Hofmeyr et al 1998a; Lumbiganon et al 1999]. 
 
Overall, the methodological quality of the included trials was acceptable, 
with moderate risk of bias. All trials were properly randomised and allocation 
concealment efforts were made. Outcome assessment was not blinded in six trials 
[Cook et al 1999; Amant et al 1999; Bugalho et al 2001;Gerstenfeld & Wing 2001; 
Acharya et al 2001; Karkanis et al 2002]. No major protocol deviations were 
reported in most of the trials. Intention to treat analysis was not followed in six trials 
[Amant et al 1999; Cook et al 1999; Bugalho et al 2001; Gerstenfeld & Wing 2001; 
Karkanis et al 2002; Caliskan et al 2003]. Because of the diversity of the 
interventions, and our aim of categorizing misoprostol given by three routes 
separately, there were few studies in the meta-analysis for each comparison. Thus, it 
was not possible to conduct sensitivity analyses based on trial quality, risk status or 
method of blood loss ascertainment.  
 
Results 
Oral tablet misoprostol 
Oral tablet misoprostol versus placebo/no treatment (five studies, 2367 women) 
 Five studies compared oral tablet misoprostol with placebo (Table 9.1). Four 
trials used oral tablet misoprostol 600 µg [Hofmeyr et al 1998a; Surbek et al 1999; 
Benchimol et al 2001; Hofmeyr et al 2001] and two used 400 µg [Hofmeyr et al 
1998; Hofmeyr et al 1998a]. Two trials had three arms- 600 µg, 400 µg misoprostol, 
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and placebo [Hofmeyr et al 1998a]; 600 µg misoprostol, nothing, and intravenous 
oxytocin 2.5 mg bolus [Benchimol et al 2001]. 
 
One study [Hofmeyr et al 1998a] reported a significantly increased risk of 
severe haemorrhage (≥1000ml) when patients were treated with 600 µg of 
misoprostol but in two other studies [Hofmeyr et al 1998; Benchimol et al 2001] 
there were no significant differences between the two groups. The overall effect 
shows that there is an increased risk of severe postpartum haemorrhage when treated 
with 600 µg misoprostol oral tablet but the result was not statistically significant 
(RR 1.43, 95% CI 0.78 to 2.62) (Figure 9.1a). Two studies compared 400 µg 
misoprostol with placebo. One study showed that there was a significant increase in 
postpartum haemorrhage with misoprostol [Hofmeyr et al 1998a] but the other study 
[Hofmeyr et al 1998] reported a decrease in the number of severe postpartum 
haemorrhage (≥1000mls) cases compared to the control group. Overall treatment 
effect shows that the risk of having postpartum haemorrhage was high with 400 µg 
misoprostol but it was not statistically significant (RR 1.27, 95% CI 0.32 to 5.04). 
There was also significant result heterogeneity between these two studies 
(Chi2=6.20, p=0.01). In one study [Surbek et al 1999], the risk of having postpartum 
haemorrhage (≥500 mls) was reported to be less in the misoprostol (600 µg) treated 
group compared to the placebo group, but the result was not statistically significant 
((RR 0.44, 95% CI 0.09-2.10) (Figure 9.1b). There was less use of additional 
uterotonics in the oral tablet misoprostol groups (400 and 600 µg) compared to the 
placebo groups (RR 0.88, 95% CI 0.47 to 1.66; RR 0.84, 95% CI 0.48 to 1.47 
respectively) (Figure 9.1d). 
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The risks of having shivering were significantly higher when patients were 
treated with 400 and 600 μg of oral misoprostol than if they were not treated or 
given placebo (overall treatment effect: RR 2.70, 95% CI 1.61 to 4.53; RR 3.40, 
95% CI 2.39 to 4.85 respectively) (Figure 9.1e).  Of the three studies that were 
considered for inclusion, only two of them had very precise estimates. The third 
study [Surbek et al 1999] had imprecise results, which were probably due to a small 
sample size. This study did not examine the side effect of pyrexia. The three other 
studies showed that oral tablet misoprostol at 400 μg and 600 μg significantly 
increased the risks of pyrexia compared to placebo (RR 5.60, 95% CI 2.21 to 14.21; 
RR 7.55, 95% CI 4.70 to 12.15 respectively) (Figure 9.1f). For the side effects of 
shivering and pyrexia, there was no significant result heterogeneity. All the studies 
showed that oral tablet misoprostol at both doses significantly increased the risk of 
these side effects, with a dose response relationship. 
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Table 9.1 Oral tablet misoprostol versus placebo/no treatment (5 studies) 
























Oral tablet misoprostol 





Management of third stage: 
placenta delivered by cord 
traction once uterus 
contracted. 
 
No withdrawals after 
randomization. 
 
Measurement of blood loss: 
collected in bedpans and 

























Oral tablet misoprostol 




oral tablet misoprostol 





Management of third stage: 
placenta delivered by cord 
traction once uterus 
contracted. 
 
No withdrawals after 
randomization. 
 
Measurement of blood loss: 
collected in bedpans for 1 
























Management of third stage: 
early cord clamping and  
cord traction. 
 
No withdrawals after 
randomization. 
 
Measurement of blood loss: 

























Oral tablet misoprostol 






Management of third stage: 
placenta delivered by cord 
traction once uterus 
contracted. 
 
No withdrawals after 
randomization. 
 
Measurement of blood loss: 
collected in bedpans and 
volume assessed; linen and 
sanitary towels weighed. 
Benchimol 















Oral tablet misoprostol 








i/voxytocin 2.5IU bolus 
Management of third stage: 
early cord clamping. 
 
Withdrawals after 
randomization: no details. 
 
Measurement of blood loss:  
estimated by midwife; blood 
loss collected in special 




Review: The use of misoprostol administered by different routes to prevent postpartum haemorrhage: A Systematic Review (Version 03)
Comparison: 01 Oral misoprostol Vs Placebo/nothing                                                                        
Outcome: 01 Severe postpartum haemorrhage (>1000 mls)                                                                  
Study  Misoprostol  Placebo  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 600 mcg
 Hofmeyr 1998 b            17/200              6/200        26.66      2.83 [1.14, 7.04]        
 Benchimol 2001            16/186             13/220        33.04      1.46 [0.72, 2.95]        
 Hofmeyr 2001              27/300             29/299        40.29      0.93 [0.56, 1.53]        
Subtotal (95% CI) 686                719 100.00      1.43 [0.78, 2.62]
Total events: 60 (Misoprostol), 48 (Placebo)
Test for heterogeneity: Chi² = 4.67, df = 2 (P = 0.10), I² = 57.2%
Test for overall effect: Z = 1.15 (P = 0.25)
02 400 mcg
 Hofmeyr 1998 a            15/250             23/250        57.49      0.65 [0.35, 1.22]        
 Hofmeyr 1998 b            16/200              6/200        42.51      2.67 [1.07, 6.68]        
Subtotal (95% CI) 450                450 100.00      1.27 [0.32, 5.04]
Total events: 31 (Misoprostol), 29 (Placebo)
Test for heterogeneity: Chi² = 6.20, df = 1 (P = 0.01), I² = 83.9%
Test for overall effect: Z = 0.33 (P = 0.74)
 0.1  0.2  0.5  1  2  5  10
 Favours misoprostol  Favours placebo  




Review: The use of misoprostol administered by different routes to prevent postpartum haemorrhage: A Systematic Review (Version 03)
Comparison: 01 Oral misoprostol Vs Placebo/nothing                                                                        
Outcome: 02 Postpartum haemorrhage (> 500 mls)                                                                         
Study  Misoprostol  Placebo  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 600 mcg
 Surbek 1999                2/31               5/34          7.78      0.44 [0.09, 2.10]        
 Benchimol 2001            52/186             60/220        92.22      1.03 [0.75, 1.41]        
Subtotal (95% CI) 217                254 100.00      0.96 [0.61, 1.50]
Total events: 54 (Misoprostol), 65 (Placebo)
Test for heterogeneity: Chi² = 1.09, df = 1 (P = 0.30), I² = 8.4%
Test for overall effect: Z = 0.18 (P = 0.86)
 0.1  0.2  0.5  1  2  5  10
 Favours misoprostol  Favours placebo  








Review: The use of misoprostol administered by different routes to prevent postpartum haemorrhage: A Systematic Review (Version 03)
Comparison: 01 Oral misoprostol Vs Placebo/nothing                                                                        
Outcome: 03 Blood Loss                                                                                                 
Study  Misoprostol  Placebo  WMD (fixed)  Weight  WMD (fixed)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
01 600 mcg
Surbek 1999             31    345.00(19.50)         34    417.00(25.90)    100.00    -72.00 [-83.09, -60.91]    
Subtotal (95% CI)     31                          34 100.00    -72.00 [-83.09, -60.91]
Test for heterogeneity: not applicable
Test for overall effect: Z = 12.73 (P < 0.00001)
 -100  -50  0  50  100
 Favours misoprostol  Favours placebo  









Review: The use of misoprostol administered by different routes to prevent postpartum haemorrhage: A Systematic Review (Version 03)
Comparison: 01 Oral misoprostol Vs Placebo/nothing                                                                        
Outcome: 04 Use of additional uterotonics                                                                              
Study  Misoprostol  Placebo  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 600 mcg
 Hofmeyr 1998 b            32/200             23/200        36.52      1.39 [0.85, 2.29]        
 Surbek 1999                5/31              13/34         18.51      0.42 [0.17, 1.05]        
 Hofmeyr 2001              42/300             54/300        44.97      0.78 [0.54, 1.13]        
Subtotal (95% CI) 531                534 100.00      0.84 [0.48, 1.47]
Total events: 79 (Misoprostol), 90 (Placebo)
Test for heterogeneity: Chi² = 6.18, df = 2 (P = 0.05), I² = 67.6%
Test for overall effect: Z = 0.61 (P = 0.54)
02 400 mcg
 Hofmeyr 1998 a            21/250             33/250        49.89      0.64 [0.38, 1.07]        
 Hofmeyr 1998 b            28/200             23/200        50.11      1.22 [0.73, 2.04]        
Subtotal (95% CI) 450                450 100.00      0.88 [0.47, 1.66]
Total events: 49 (Misoprostol), 56 (Placebo)
Test for heterogeneity: Chi² = 3.03, df = 1 (P = 0.08), I² = 67.0%
Test for overall effect: Z = 0.39 (P = 0.70)
 0.1  0.2  0.5  1  2  5  10
 Favours misoprostol  Favours placebo  




Review: The use of misoprostol administered by different routes to prevent postpartum haemorrhage: A Systematic Review (Version 03)
Comparison: 01 Oral misoprostol Vs Placebo/nothing                                                                        
Outcome: 05 Shivering                                                                                                  
Study  Misoprostol  Placebo  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 600 mcg
 Hofmeyr 1998 b            81/199             30/199        45.68      2.70 [1.87, 3.91]        
 Surbek 1999                7/31               1/34          2.92      7.68 [1.00, 58.92]       
 Benchimol 2001             5/186              1/220         2.66      5.91 [0.70, 50.17]       
 Hofmeyr 2001             133/300             33/300        48.74      4.03 [2.85, 5.70]        
Subtotal (95% CI) 716                753 100.00      3.42 [2.58, 4.54]
Total events: 226 (Misoprostol), 65 (Placebo)
Test for heterogeneity: Chi² = 3.33, df = 3 (P = 0.34), I² = 9.8%
Test for overall effect: Z = 8.51 (P < 0.00001)
02 400 mcg
 Hofmeyr 1998 a            48/250             13/250        37.21      3.69 [2.05, 6.64]        
 Hofmeyr 1998 b            65/199             30/199        62.79      2.17 [1.47, 3.19]        
Subtotal (95% CI) 449                449 100.00      2.70 [1.61, 4.53]
Total events: 113 (Misoprostol), 43 (Placebo)
Test for heterogeneity: Chi² = 2.25, df = 1 (P = 0.13), I² = 55.6%
Test for overall effect: Z = 3.75 (P = 0.0002)
 0.1  0.2  0.5  1  2  5  10
 Favours misoprostol  Favours placebo  




Review: The use of misoprostol administered by different routes to prevent postpartum haemorrhage: A Systematic Review (Version 03)
Comparison: 01 Oral misoprostol Vs Placebo/nothing                                                                        
Outcome: 06 Pyrexia                                                                                                    
Study  Misoprostol  Placebo  RR (fixed)  Weight  RR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 600 mcg
 Hofmeyr 1998 b            53/200              5/200        27.09     10.60 [4.33, 25.96]       
 Benchimol 2001             6/186              0/220         2.48     15.36 [0.87, 270.93]      
 Hofmeyr 2001              86/299             13/299        70.43      6.62 [3.78, 11.59]       
Subtotal (95% CI) 685                719 100.00      7.91 [4.95, 12.64]
Total events: 145 (Misoprostol), 18 (Placebo)
Test for heterogeneity: Chi² = 1.01, df = 2 (P = 0.60), I² = 0%
Test for overall effect: Z = 8.66 (P < 0.00001)
02 400 mcg
 Hofmeyr 1998 b            28/200              5/200       100.00      5.60 [2.21, 14.21]       
Subtotal (95% CI) 200                200 100.00      5.60 [2.21, 14.21]
Total events: 28 (Misoprostol), 5 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.63 (P = 0.0003)
 0.1  0.2  0.5  1  2  5  10
 Favours misoprostol  Favours placebo  




Oral tablet misoprostol versus injectable uterotonics (eight studies, 25402 women) 
 There were eight studies comparing oral tablet misoprostol with injectable 
uterotonics (Table 9.2). Their sample sizes ranged from 40 to 18403. Five studies 
used a dose of 600 µg [Amant et al 1999; Lumbiganon et al 1999; Gulmezoglu et al 
2001a; Ng et al 2001; Caliskan et al 2003], one used 500 µg [El-Refaey et al 2000], 
and three used 400 µg [Cook et al 1999; Lumbiganon et al 1999; Kundodyiwa et al 
2001]. One trial [Lumbiganon et al 1999] compared 600 µg and 400 µg oral tablet 
misoprostol with intramuscular oxytocin 10 IU. The injectable uterotonics used 
include intramuscular or intravenous oxytocin, syntometrine, ergometrine, and 
methylergometrine. The WHO study [Gulmezoglu et al 2001a], with 18530 subjects 
randomized to either oral tablet misoprostol 600 µg or injectable oxytocin 10 IU, 
dominated the results. 
 
For the primary outcome of severe postpartum haemorrhage (≥1000 mL), 
there was no statistically significant result heterogeneity among the studies (Figure 
9.2a). At all three doses, oral tablet misoprostol was either as effective, or less 
effective than injectable uterotonics. Only the WHO study showed a significantly 
increased risk of severe postpartum haemorrhage with oral tablet misoprostol 600 
µg. However, the overall treatment effects were not statistically significant.  
 
For postpartum haemorrhage (≥500 mL), and the use of additional 
uterotonics, there was statistically significant result heterogeneity among the studies 
at 600 µg and 400 µg. Oral tablet misoprostol 600 μg was significantly less effective 
than injectable uterotonics at preventing postpartum haemorrhage (RR 1.27, 95% CI 
1.01 to 1.58) (Figure 9.2b). At 500 μg and 400 μg, the overall treatment effect 
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showed a slight increased risk of postpartum haemorrhage but the results were not 
statistically significant. With all three concentrations of oral misoprostol the risk of 
having to use additional uterotonics to prevent bleeding was higher when compared 
to the injectable uterotonics group but the overall effect was only statistically 
significant for oral tablet misoprostol 600 µg (RR 1.30, 95% CI 1.03-1.65) (Figure 
9.2d). 
 
The dose response effect was evident for both side effects. Oral tablet 
misoprostol at all three doses significantly increased the risk of shivering (overall 
treatment effect: RR 2.62, 95% CI 2.03 to 3.40 for 600 μg; RR 1.94, 95% CI 1.69 to 
2.22 for 500 μg; and RR 1.77, 95% CI 1.20 to 2.62 for 400 μg) (Figure 9.2e). There 
was significant result heterogeneity at the doses of 600 µg and 400 µg. However, all 
except two studies showed that oral tablet misoprostol at all three doses significantly 
increased the risk of shivering. The remaining two studies showed a non-statistically 
significant increased risk of shivering. Oral tablet misoprostol 600 μg significantly 
increased the risk of pyrexia (RR 5.84, 95% CI 3.91 to 8.73) (Figure 9.2f). The 
overall treatment effects also showed an increased risk of pyrexia at lower doses of 
misoprostol compared to injectable oxytocics but these were not statistically 
significant. There was significant result heterogeneity at the dose of 400 µg.  
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Table 9.2 Oral tablet misoprostol versus injectable uterotonics (8 studies) 
 
Study Methods Participants Interventions Comments 
Lumbiganon 
et al 1999 
Random 
allocation; pilot 
































i/m oxytocin 10 
IU 
 
Management of third 
stage:  uterotonics, early 
clamping and cutting of 
cord, fundal or suprapubic 
pressure with cord traction 




randomization: 1 (0.5%),1 
(0.5%) and 8 (4%) women 
in the misoprostol 600 μg, 
400 μg and oxytocin 
groups respectively. 
 
Measurement of blood 
loss:  blood and small 
gauze swabs collected in 
standard measuring jar; 
linen not weighed. 
 














No mention of 
risk status. 
 













i/m oxytocin 10 
IU 
or 
i/m syntometrine 1 
mL 
Management of third 
stage: not mentioned. 
 
31/455 women (7%) 
excluded after 
randomization in the 
misoprostol group; 36/475 




Measurement of blood 
loss:  estimated by 
clinician; measured with 
calibrated measuring jug; 
linen weighed; all 
combined. 
 




























Management of third 
stage: uterine massage, 
cord traction, manual 
removal of placenta after 
30-60 min. 
 
5/100 women (5%) 
excluded after 
randomization in the 
misoprostol group; 8/108 
(7.4%) excluded in the 
methylergometrine group. 
 
Measurement of blood 


















Both high and 










High risk women- 
i/v ergometrine 
(2%) or oxytocin 
(18%). 
Low risk- i/m 
syntometrine 1 mL 
(80%). 
 
Management of third 
stage: cord traction, 
oxytocics at delivery of 
anterior shoulder. 
 
No withdrawals after 
randomization. 
 
Measurement of blood 
loss:  estimated by 
midwives. 















No mention of 
risk status. 
 










Management of third 
stage: cord traction after 
signs of placental 
separation. 
 
No withdrawals after 
randomization. 
 
Measurement of blood 









































i/v  or i/m 
oxytocin 10 IU 
Management of third 
stage:  uterotonics, early 
clamping and cutting of 
cord, fundal or suprapubic 
pressure with cord traction 




randomization: 37 and 34 
women with caesarean 
delivery, and 13 and 4 
women lost to follow-up 
in misoprostol and 
oxytocin groups, 
respectively, for blood 
loss, and 2 and 4 women 
without information on the 
need for additional 
uterotonics. 
 
Measurement of blood 
loss:  blood and small 
gauze swabs collected in 
standard measuring jar; 














similar in size 
and colur but 



















i/m oxytocin 10 
IU 
Management of third 
stage: not mentioned. 
 
Exclusions after 
randomization: 1 woman 
because of undiagnosed 
twins (0.2%). 
 
Measurement of blood 
loss:  linen soiled with 
amniotic fluid removed; 
fresh disposable 
incontinence pads with 
plastic backing placed 
under women; blood loss 
measured with calibrated 
jug; linen saver and 












similar in size 
and colur but 


















µg in total plus i/v 
oxytocin 10 IU 










i/v oxytocin 10 IU 






0.2 mg plus i/v 
oxytocin 10 IU 
over 30 min 
 
Management of third 
stage: early cord clamping, 
cord traction with uterine 
massage; manual removal 
of placenta if not delivered 




women (12.6%) because 
of caesarean delivery or 
lack of haemoglobin 
testing; no details of 
distribution by group. 
 
Measurement of blood 
loss:  estimated by 
physician in charge of 
labour; blood collected in 
bedpan for 1 hour after 
delivery; gauzes and pads 
weighed; haemoglobin on 






Review: New review (MISOPROSTOL)
Comparison: 07 Oral misoprostol (tablet) Vs Injectable uterotonics [With WHO trial]                                       
Outcome: 01 Severe postpartum haemorrhage (> 1000mls)                                                                  
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 600 mcg
 Amant 1999                 1/100              0/100         0.20      3.00 [0.12, 72.77]       
 Gulmezoglu 2001          366/9214           263/9228       84.25      1.39 [1.19, 1.63]        
 Lumbiganon 1999            8/199             13/200         2.77      0.62 [0.26, 1.46]        
 Ng 2001                    5/1026             4/1032        1.19      1.26 [0.34, 4.67]        
Subtotal (95% CI) 10539              10560  88.41      1.24 [0.86, 1.78]
Total events: 380 (Treatment), 280 (Control)
Test for heterogeneity: Chi² = 3.58, df = 3 (P = 0.31), I² = 16.2%
Test for overall effect: Z = 1.15 (P = 0.25)
02 500 mcg
 El-Rafaey 2000             9/501             10/499         2.57      0.90 [0.37, 2.19]        
 Lokugamage 2001            3/20               3/20          0.94      1.00 [0.23, 4.37]        
Subtotal (95% CI) 521                519   3.51      0.92 [0.43, 1.98]
Total events: 12 (Treatment), 13 (Control)
Test for heterogeneity: Chi² = 0.02, df = 1 (P = 0.90), I² = 0%
Test for overall effect: Z = 0.21 (P = 0.84)
03 400 mcg
 Cook 1999                 13/424              7/439         2.47      1.92 [0.77, 4.77]        
 Kundodyiwa 2001            9/243              5/256         1.76      1.90 [0.64, 5.58]        
 Lumbiganon 1999           14/198             13/200         3.85      1.09 [0.52, 2.25]        
Subtotal (95% CI) 865                895   8.08      1.46 [0.88, 2.42]
Total events: 36 (Treatment), 25 (Control)
Test for heterogeneity: Chi² = 1.21, df = 2 (P = 0.55), I² = 0%
Test for overall effect: Z = 1.48 (P = 0.14)
Total (95% CI) 11925              11974 100.00      1.35 [1.17, 1.56]
Total events: 428 (Treatment), 318 (Control)
Test for heterogeneity: Chi² = 5.86, df = 8 (P = 0.66), I² = 0%
Test for overall effect: Z = 4.10 (P < 0.0001)
 0.1  0.2  0.5  1  2  5  10
 Favours misoprostol  Favours inje uteroto  
Figure 9.2a Oral misoprostol (tablet) vs injectable uterotonics; Outcome: Severe postpartum haemorrhage (>1000 mL) 
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Review: New review (MISOPROSTOL)
Comparison: 07 Oral misoprostol (tablet) Vs Injectable uterotonics [With WHO trial]                                       
Outcome: 02 Severe postpartum haemorrhage (> 500mls)                                                                   
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 600 mcg
 Amant 1999                 8/96               4/93          2.14      1.94 [0.60, 6.22]        
 Caliskan 2003             35/388             28/384         7.96      1.24 [0.77, 1.99]        
 Gulmezoglu 2001         1793/9213          1248/9227       17.12      1.44 [1.35, 1.54]        
 Lumbiganon 1999           45/199             52/200        10.70      0.87 [0.61, 1.23]        
 Ng 2001                   60/1026            44/1032        9.95      1.37 [0.94, 2.00]        
Subtotal (95% CI) 10922              10936  47.87      1.27 [1.01, 1.58]
Total events: 1941 (Treatment), 1376 (Control)
Test for heterogeneity: Chi² = 8.39, df = 4 (P = 0.08), I² = 52.3%
Test for overall effect: Z = 2.08 (P = 0.04)
02 500 mcg
 El-Rafaey 2000            62/501             56/499        10.89      1.10 [0.79, 1.55]        
 Lokugamage 2001           17/20              17/20         12.90      1.00 [0.77, 1.30]        
Subtotal (95% CI) 521                519  23.79      1.04 [0.84, 1.27]
Total events: 79 (Treatment), 73 (Control)
Test for heterogeneity: Chi² = 0.34, df = 1 (P = 0.56), I² = 0%
Test for overall effect: Z = 0.34 (P = 0.73)
03 400 mcg
 Cook 1999                 63/424             24/439         8.45      2.72 [1.73, 4.27]        
 Kundodyiwa 2001           37/243             34/256         8.84      1.15 [0.74, 1.76]        
 Lumbiganon 1999           51/198             52/200        11.06      0.99 [0.71, 1.38]        
Subtotal (95% CI) 865                895  28.34      1.44 [0.79, 2.62]
Total events: 151 (Treatment), 110 (Control)
Test for heterogeneity: Chi² = 13.38, df = 2 (P = 0.001), I² = 85.0%
Test for overall effect: Z = 1.18 (P = 0.24)
Total (95% CI) 12308              12350 100.00      1.24 [1.03, 1.49]
Total events: 2171 (Treatment), 1559 (Control)
Test for heterogeneity: Chi² = 29.95, df = 9 (P = 0.0004), I² = 70.0%
Test for overall effect: Z = 2.33 (P = 0.02)
 0.1  0.2  0.5  1  2  5  10
 Favours misoprostol  Favours inje uteroto  
Figure 9.2b Oral misoprostol (tablet) vs injectable uterotonics; Outcome: Postpartum haemorrhage (>500 mL) 
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Review: New review (MISOPROSTOL)
Comparison: 07 Oral misoprostol (tablet) Vs Injectable uterotonics [With WHO trial]                                       
Outcome: 03 Blood Loss (mls)                                                                                           
Study  Treatment  Control  WMD (random)  Weight  WMD (random)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
01 600 mcg
Caliskan 2003          388    328.00(152.00)       384    312.00(176.00)    21.23     16.00 [-7.21, 39.21]      
Gulmezoglu 2001       9213    332.80(274.60)      9227    289.70(262.10)    40.73     43.10 [35.35, 50.85]      
Lumbiganon 1999        199    340.90(295.08)       200    352.60(309.59)     5.33    -11.70 [-71.04, 47.64]     
Ng 2001               1026    296.00(160.00)      1032    254.00(157.00)    32.72     42.00 [28.30, 55.70]      
Subtotal (95% CI)  10826                       10843 100.00     34.37 [20.29, 48.44]
Test for heterogeneity: Chi² = 7.72, df = 3 (P = 0.05), I² = 61.1%
Test for overall effect: Z = 4.79 (P < 0.00001)
02 500 mcg
Subtotal (95% CI)      0                           0         Not estimable
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 400 mcg
Cook 1999              424    279.00(300.60)       439    209.00(188.55)    83.88     70.00 [36.39, 103.61]     
Lumbiganon 1999        100    370.90(326.55)        99    352.60(309.59)    16.12     18.30 [-70.10, 106.70]    
Subtotal (95% CI)    524                         538 100.00     60.98 [22.53, 99.43]
Test for heterogeneity: Chi² = 1.15, df = 1 (P = 0.28), I² = 12.9%
Test for overall effect: Z = 3.11 (P = 0.002)
 -100  -50  0  50  100
 Favours treatment  Favours control  
Figure 9.2c Oral misoprostol (tablet) vs injectable uterotonics; Outcome: Blood loss (mL) 
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Review: New review (MISOPROSTOL)
Comparison: 07 Oral misoprostol (tablet) Vs Injectable uterotonics [With WHO trial]                                       
Outcome: 04 Use of additional uterotonics                                                                              
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 600 mcg
 Amant 1999                12/94               4/91          3.40      2.90 [0.97, 8.67]        
 Caliskan 2003             42/388             40/384        11.60      1.04 [0.69, 1.56]        
 Gulmezoglu 2001         1398/9225          1002/9228       18.70      1.40 [1.29, 1.51]        
 Lumbiganon 1999           18/199             28/200         8.66      0.65 [0.37, 1.13]        
 Ng 2001                  232/1026           144/1032       16.79      1.62 [1.34, 1.96]        
Subtotal (95% CI) 10932              10935  59.15      1.30 [1.03, 1.65]
Total events: 1702 (Treatment), 1218 (Control)
Test for heterogeneity: Chi² = 13.41, df = 4 (P = 0.009), I² = 70.2%
Test for overall effect: Z = 2.22 (P = 0.03)
02 500 mcg
 El-Rafaey 2000            68/501             50/499        13.13      1.35 [0.96, 1.91]        
 Lokugamage 2001            6/20               1/20          1.14      6.00 [0.79, 45.42]       
Subtotal (95% CI) 521                519  14.26      2.02 [0.55, 7.40]
Total events: 74 (Treatment), 51 (Control)
Test for heterogeneity: Chi² = 2.04, df = 1 (P = 0.15), I² = 50.9%
Test for overall effect: Z = 1.06 (P = 0.29)
03 400 mcg
 Cook 1999                 95/424             34/439        12.54      2.89 [2.00, 4.18]        
 Kundodyiwa 2001           13/243              7/256         4.61      1.96 [0.79, 4.82]        
 Lumbiganon 1999           23/198             28/200         9.43      0.83 [0.50, 1.39]        
Subtotal (95% CI) 865                895  26.59      1.68 [0.70, 4.03]
Total events: 131 (Treatment), 69 (Control)
Test for heterogeneity: Chi² = 14.97, df = 2 (P = 0.0006), I² = 86.6%
Test for overall effect: Z = 1.16 (P = 0.25)
Total (95% CI) 12318              12349 100.00      1.42 [1.14, 1.78]
Total events: 1907 (Treatment), 1338 (Control)
Test for heterogeneity: Chi² = 34.62, df = 9 (P < 0.0001), I² = 74.0%
Test for overall effect: Z = 3.11 (P = 0.002)
 0.1  0.2  0.5  1  2  5  10
 Favours treatment  Favours control  
Figure 9.2d Oral misoprostol (tablet) vs injectable uterotonics; Outcome: Use of additional uterotonics 
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Review: New review (MISOPROSTOL)
Comparison: 07 Oral misoprostol (tablet) Vs Injectable uterotonics [With WHO trial]                                       
Outcome: 05 Shivering                                                                                                  
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 600 mcg
 Amant 1999                66/86              38/94         10.83      1.90 [1.45, 2.49]        
 Caliskan 2003             44/388             19/384         8.10      2.29 [1.36, 3.85]        
 Gulmezoglu 2001         1620/9227           466/9232       12.17      3.48 [3.15, 3.84]        
 Lumbiganon 1999           56/199             25/200         9.11      2.25 [1.47, 3.46]        
 Ng 2001                  310/1026           102/1032       11.45      3.06 [2.49, 3.76]        
Subtotal (95% CI) 10926              10942  51.66      2.62 [2.03, 3.40]
Total events: 2096 (Treatment), 650 (Control)
Test for heterogeneity: Chi² = 21.66, df = 4 (P = 0.0002), I² = 81.5%
Test for overall effect: Z = 7.31 (P < 0.00001)
02 500 mcg
 El-Rafaey 2000           319/445            147/401        11.94      1.96 [1.70, 2.25]        
 Lokugamage 2001           13/20               8/20          7.00      1.63 [0.87, 3.04]        
Subtotal (95% CI) 465                421  18.94      1.94 [1.69, 2.22]
Total events: 332 (Treatment), 155 (Control)
Test for heterogeneity: Chi² = 0.32, df = 1 (P = 0.57), I² = 0%
Test for overall effect: Z = 9.41 (P < 0.00001)
03 400 mcg
 Cook 1999                 79/424             31/439         9.51      2.64 [1.78, 3.91]        
 Kundodyiwa 2001          106/243             78/256        11.20      1.43 [1.13, 1.81]        
 Lumbiganon 1999           38/198             25/200         8.70      1.54 [0.96, 2.44]        
Subtotal (95% CI) 865                895  29.40      1.77 [1.20, 2.62]
Total events: 223 (Treatment), 134 (Control)
Test for heterogeneity: Chi² = 7.20, df = 2 (P = 0.03), I² = 72.2%
Test for overall effect: Z = 2.87 (P = 0.004)
Total (95% CI) 12256              12258 100.00      2.17 [1.69, 2.79]
Total events: 2651 (Treatment), 939 (Control)
Test for heterogeneity: Chi² = 94.72, df = 9 (P < 0.00001), I² = 90.5%
Test for overall effect: Z = 6.05 (P < 0.00001)
 0.1  0.2  0.5  1  2  5  10
 Favours treatment  Favours control  
Figure 9.2e Oral misoprostol (tablet) vs injectable uterotonics; Outcome: Shivering 
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Review: New review (MISOPROSTOL)
Comparison: 07 Oral misoprostol (tablet) Vs Injectable uterotonics [With WHO trial]                                       
Outcome: 06 Pyrexia                                                                                                    
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 600 mcg
 Amant 1999                34/100              3/100         8.51     11.33 [3.60, 35.70]       
 Caliskan 2003             17/388              5/384         9.25      3.36 [1.25, 9.03]        
 Gulmezoglu 2001          559/9198            78/9205       12.05      7.17 [5.67, 9.07]        
 Lumbiganon 1999           15/199              6/199         9.53      2.50 [0.99, 6.31]        
 Ng 2001                   87/1026            13/1032       11.04      6.73 [3.78, 11.98]       
Subtotal (95% CI) 10911              10920  50.38      5.84 [3.91, 8.73]
Total events: 712 (Treatment), 105 (Control)
Test for heterogeneity: Chi² = 7.39, df = 4 (P = 0.12), I² = 45.9%
Test for overall effect: Z = 8.62 (P < 0.00001)
02 500 mcg
 El-Rafaey 2000            68/501             50/499        11.80      1.35 [0.96, 1.91]        
 Lokugamage 2001            6/20               1/20          5.17      6.00 [0.79, 45.42]       
Subtotal (95% CI) 521                519  16.97      2.02 [0.55, 7.40]
Total events: 74 (Treatment), 51 (Control)
Test for heterogeneity: Chi² = 2.04, df = 1 (P = 0.15), I² = 50.9%
Test for overall effect: Z = 1.06 (P = 0.29)
03 400 mcg
 Cook 1999                 95/424             34/439        11.74      2.89 [2.00, 4.18]        
 Kundodyiwa 2001           13/243              7/256         9.64      1.96 [0.79, 4.82]        
 Lumbiganon 1999           23/198             28/200        11.27      0.83 [0.50, 1.39]        
Subtotal (95% CI) 865                895  32.65      1.68 [0.70, 4.03]
Total events: 131 (Treatment), 69 (Control)
Test for heterogeneity: Chi² = 14.97, df = 2 (P = 0.0006), I² = 86.6%
Test for overall effect: Z = 1.16 (P = 0.25)
Total (95% CI) 12297              12334 100.00      3.16 [1.73, 5.79]
Total events: 917 (Treatment), 225 (Control)
Test for heterogeneity: Chi² = 111.89, df = 9 (P < 0.00001), I² = 92.0%
Test for overall effect: Z = 3.73 (P = 0.0002)
 0.1  0.2  0.5  1  2  5  10
 Favours treatment  Favours control  
Figure 9.2f Oral misoprostol (tablet) vs injectable uterotonics; Outcome: Pyrexia 
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Oral solution misoprostol 
Oral solution misoprostol versus intramuscular oxytocin (two studies, 897 women) 
Misoprostol was given as an aqueous solution in two studies by dissolving 
the tablets in 50 mL of water before administration to the women (Table 9.3). One 
study used a dose of 400 µg [Walley et al 2000] while the other used 600 µg [Oboro 
& Tabowei 2003]. Both compared misoprostol to intramuscular oxytocin 10 IU. 
 
The study using oral solution 400 µg showed that the risk of having 
postpartum haemorrhage (RR 0.19, 95% CI 0.01-4.02), and the use of additional 
uterotonics (RR 0.77, 95% CI 0.27-2.17) was reduced when compared with women 
given oxytocin. The study using oral solution 600 µg showed the converse results 
with an increased risk of postpartum haemorrhage (RR 3.02, 95% CI 0.32-28.88), 
and the use of additional uterotonics (RR 1.16, 95% CI 0.71-1.88). For both studies, 
the results were not statistically significant (Figure 9.3a). 
 
Both studies confirmed that oral solution misoprostol resulted in a four-fold 
rise in the risk of shivering (RR 4.06, 95% CI 2.93-5.62; RR 3.90, 95% CI 2.01-
7.57, respectively). However, there was a trend towards a dose-response effect with 
pyrexia, and 600 µg tended to increase the risk of fever (RR 3.02, 95% CI 0.32-
28.88) while 400 µg tended to be protective (RR 0.77, 95% CI 0.27-2.17). Both 
these results were not statistically significant (Figure 9.3c). 
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Table 9.3 Oral solution misoprostol versus injectable uterotonics (2 studies) 












401 women after 
vaginal delivery. 
 











i/m oxytocin 10 
IU 
 
Management of third stage: 
cord traction. 
 
Outcome data missing for 
9/401 (2.2%) women. 
 
Measurement of blood 
loss:  estimated by 
clinician. 














496 women after 
vaginal delivery. 
 











i/m oxytocin 10 
IU 
 
Management of third stage: 
cord traction, oxytocics at 
delivery of anterior 
shoulder. 
 
No withdrawals after 
randomization. 
 
Measurement of blood 





Review: New review (MISOPROSTOL)
Comparison: 13 Oral misoprostol (solution) vs Injectable uterotonics-Oxytocin [Without WHO trial]                         
Outcome: 02 Severe postpartum haemorrhage (> 500mls)                                                                   
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 600 mcg
 Oboro 2003                 3/247              1/249        56.99      3.02 [0.32, 28.88]       
Subtotal (95% CI) 247                249  56.99      3.02 [0.32, 28.88]
Total events: 3 (Treatment), 1 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
02 500 mcg
Subtotal (95% CI) 0                  0         Not estimable
Total events: 0 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 400 mcg
 Walley 2000                0/202              2/196        43.01      0.19 [0.01, 4.02]        
Subtotal (95% CI) 202                196  43.01      0.19 [0.01, 4.02]
Total events: 0 (Treatment), 2 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Total (95% CI) 449                445 100.00      0.93 [0.06, 13.52]
Total events: 3 (Treatment), 3 (Control)
Test for heterogeneity: Chi² = 2.05, df = 1 (P = 0.15), I² = 51.2%
Test for overall effect: Z = 0.05 (P = 0.96)
 0.1  0.2  0.5  1  2  5  10
 Favours misoprostol  Favours inje uteroto  
Figure 9.3a Oral misoprostol (solution) vs injectable uterotonics - oxytocin; Outcome: Postpartum haemorrhage (>500 mL) 
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Review: New review (MISOPROSTOL)
Comparison: 13 Oral misoprostol (solution) vs Injectable uterotonics-Oxytocin [Without WHO trial]                         
Outcome: 03 Blood Loss (mls)                                                                                           
Study  Treatment  Control  WMD (random)  Weight  WMD (random)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
01 600 mcg
Oboro 2003             247    341.00(19.30)        249    339.00(18.90)    100.00      2.00 [-1.36, 5.36]       
Subtotal (95% CI)    247                         249 100.00      2.00 [-1.36, 5.36]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
02 500 mcg
Subtotal (95% CI)      0                           0         Not estimable
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 400 mcg
Walley 2000            202    190.00(78.00)        196    187.00(91.00)    100.00      3.00 [-13.67, 19.67]     
Subtotal (95% CI)    202                         196 100.00      3.00 [-13.67, 19.67]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
 -100  -50  0  50  100
 Favours treatment  Favours control  
Figure 9.3b Oral misoprostol (solution) vs injectable uterotonics - oxytocin; Outcome: Blood loss (mL) 
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Review: New review (MISOPROSTOL)
Comparison: 13 Oral misoprostol (solution) vs Injectable uterotonics-Oxytocin [Without WHO trial]                         
Outcome: 04 Use of additional uterotonics                                                                              
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 600 mcg
 Oboro 2003                31/247             27/249        82.05      1.16 [0.71, 1.88]        
Subtotal (95% CI) 247                249  82.05      1.16 [0.71, 1.88]
Total events: 31 (Treatment), 27 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
02 500 mcg
Subtotal (95% CI) 0                  0         Not estimable
Total events: 0 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 400 mcg
 Walley 2000                6/168              8/172        17.95      0.77 [0.27, 2.17]        
Subtotal (95% CI) 168                172  17.95      0.77 [0.27, 2.17]
Total events: 6 (Treatment), 8 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
Total (95% CI) 415                421 100.00      1.08 [0.69, 1.67]
Total events: 37 (Treatment), 35 (Control)
Test for heterogeneity: Chi² = 0.49, df = 1 (P = 0.48), I² = 0%
Test for overall effect: Z = 0.32 (P = 0.75)
 0.1  0.2  0.5  1  2  5  10
 Favours treatment  Favours control  
Figure 9.3c Oral misoprostol (solution) vs injectable uterotonics - oxytocin; Outcome: Use of additional uterotonics 
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Review: New review (MISOPROSTOL)
Comparison: 13 Oral misoprostol (solution) vs Injectable uterotonics-Oxytocin [Without WHO trial]                         
Outcome: 05 Shivering                                                                                                  
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 600 mcg
 Oboro 2003               141/247             35/249        80.55      4.06 [2.93, 5.62]        
Subtotal (95% CI) 247                249  80.55      4.06 [2.93, 5.62]
Total events: 141 (Treatment), 35 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 8.44 (P < 0.00001)
02 500 mcg
Subtotal (95% CI) 0                  0         Not estimable
Total events: 0 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 400 mcg
 Walley 2000               39/176             10/176        19.45      3.90 [2.01, 7.57]        
Subtotal (95% CI) 176                176  19.45      3.90 [2.01, 7.57]
Total events: 39 (Treatment), 10 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 4.03 (P < 0.0001)
Total (95% CI) 423                425 100.00      4.03 [3.01, 5.40]
Total events: 180 (Treatment), 45 (Control)
Test for heterogeneity: Chi² = 0.01, df = 1 (P = 0.91), I² = 0%
Test for overall effect: Z = 9.35 (P < 0.00001)
 0.1  0.2  0.5  1  2  5  10
 Favours treatment  Favours control  
Figure 9.3d Oral misoprostol (solution) vs injectable uterotonics - oxytocin; Outcome: Shivering 
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Review: New review (MISOPROSTOL)
Comparison: 13 Oral misoprostol (solution) vs Injectable uterotonics-Oxytocin [Without WHO trial]                         
Outcome: 06 Pyrexia                                                                                                    
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 600 mcg
 Oboro 2003                 3/247              1/249        22.39      3.02 [0.32, 28.88]       
Subtotal (95% CI) 247                249  22.39      3.02 [0.32, 28.88]
Total events: 3 (Treatment), 1 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
02 500 mcg
Subtotal (95% CI) 0                  0         Not estimable
Total events: 0 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 400 mcg
 Walley 2000                6/168              8/172        77.61      0.77 [0.27, 2.17]        
Subtotal (95% CI) 168                172  77.61      0.77 [0.27, 2.17]
Total events: 6 (Treatment), 8 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
Total (95% CI) 415                421 100.00      1.04 [0.34, 3.21]
Total events: 9 (Treatment), 9 (Control)
Test for heterogeneity: Chi² = 1.18, df = 1 (P = 0.28), I² = 15.2%
Test for overall effect: Z = 0.07 (P = 0.94)
 0.1  0.2  0.5  1  2  5  10
 Favours treatment  Favours control  
Figure 9.3e Oral misoprostol (solution) vs injectable uterotonics - oxytocin; Outcome: Pyrexia 
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Rectal misoprostol versus placebo or injectable uterotonics (six studies, 3975 
women) 
 Only one study compared rectal misoprostol 400 μg with placebo 
[Bamigboye et al 1998] (Table 9.4). The results for severe postpartum haemorrhage 
(≥1000 mL) favoured rectal misoprostol but was not statistically significant (RR 
0.69, 95% CI 0.35-1.37) (Figure 9.4a).  
  
Four trials compared rectal misoprostol 400 μg with injectable uterotonic 
agents [Bamigboye et al 1998a; Bugalho et al 2001; Gerstenfeld & Wing 2001; 
Karkanis et al 2002]. One used 600 μg in separate doses- 400 μg, 100 μg, 100μg 
alone, and with intravenous infusion of oxytocin 10 IU over 30 minutes [Caliskan et 
al 2002].  
 
The use of rectal misoprostol was associated with higher risks of severe 
postpartum haemorrhage (≥1000 mL) and postpartum haemorrhage (≥500 mL) 
compared to parenteral oxytocin, but the results were not statistically significant at 
400 µg and 600 µg (Figure 9.4b, c).   Use of additional uterotonics was significantly 
more common in patients treated with rectal misoprostol 400 µg compared with 
patients given parenteral oxytocin (RR 1.63, 95% CI 1.16-2.30) (Fig 9.4d).  
 
For rectal misoprostol 600 μg, the risks of severe postpartum haemorrhage, 
postpartum haemorrhage, and use of additional haemorrhage were higher compared 
to intravenous oxytocin but the differences were not statistically significant. 
However, if intravenous oxytocin were given with intramuscular methylergonovine, 
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the combination was significantly more effective than rectal misoprostol 600 µg in 
preventing severe postpartum haemorrhage (RR 2.47, 95% CI 1.03-5.88) (Figure 
9.4b), postpartum haemorrhage (RR 2.83, 95% CI 1.56-5.13) (Figure 9.4c), and the 
use of additional uterotonic agents (RR 3.72, 95% CI 1.80-7.68) (Figure 9.4d). 
 
At both doses, rectal misoprostol caused significantly more shivering than 
parenteral oxytocin (400 µg: RR 2.01, 95% CI 1.34-3.04; 600 µg: RR 3.02, 95% CI 
1.74-5.23). There was also significantly more pyrexia with rectal misoprostol 600 μg 
than with parenteral oxytocin (RR 2.74, 95% CI 1.08-6.93) (Figure 9.4f). However, 
this difference was not statistically significant with rectal misoprostol 400 μg (RR 
1.71, 95% CI 0.88-3.33). 
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Table 9.4 Rectal misoprostol versus injectable uterotonics/placebo (6 studies) 
Study Methods Participants Interventions Comments 
Bamigboye 


























Management of third 
stage: placenta delivered 





women in placebo group 
(1.4%). 
 
Measurement of blood 
loss:  blood collected in 
bedpan for 1 hour after 
delivery; linen weighed. 
 
Bamigboye 

























Management of third 
stage: not mentioned. 
 
Some women (number 
small but unspecified) 
allocated to syntometrine 
excluded after 
randomization because of 
high blood pressure. 
 
Primary outcome data 
missing for 2-3% of 
women; postpartum 
haemoglobin measured in 
only 65-67%. 
 
Measurement of blood 




























i/m oxytocin 10 
IU 
 
Management of third 




(7.4%) in the misoprostol 
group, and 11/350 (3.1%) 
in the oxytocin group, 
because of emergency 




Measurement of blood 
loss:  metallic collector 
placed under buttocks 
after delivery until patient 




















400 women in 
labour. 
 










i/v oxytocin 20 IU 






Management of third 
stage: not mentioned. 
 
Exclusions after 
randomization: 73 women 
(18.3%) because of 
caesarean delivery; no 
details of distribution by 
group. 
 
Measurement of blood 
loss:  drape placed under 







admission and on 























i/v or i/m 
oxytocin 5 IU 
 
Management of third 
stage: not standardized. 
 
Exclusions after 
randomization: 15 women 
(6.3%) because of 
caesarean delivery or loss 
to follow-up; no details of 
distribution by group. 
 
Measurement of blood 
loss:  haemoglobin on 












similar in size 
and colur but 

















misoprostol 600 µg 
in total plus i/v 
oxytocin 10 IU 









i/v oxytocin 10 IU 





0.2 mg plus i/v 
oxytocin 10 IU 
over 30 min 
 
Management of third 
stage: early cord 
clamping, cord traction 
with uterine massage; 
manual removal of 
placenta if not delivered 
after 30 minutes. 
 
Exclusions after 
randomization: 27 women 
(1.6%) because of lack of 
haemoglobin testing; no 
details of distribution by 
group. 
 
Measurement of blood 
loss:  estimated by 
physician in charge of 
labour; blood collected in 
bedpan for 1 hour after 
delivery; gauzes and pads 
weighed; haemoglobin on 




Review: New review (MISOPROSTOL)
Comparison: 16 Rectal misoprostol Vs Placebo                                                                              
Outcome: 01 Severe postpartum haemorrhage (>1000 mls)                                                                  
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 600 mcg
Subtotal (95% CI) 0                  0         Not estimable
Total events: 0 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 400 mcg
 Bamigboye 1998            13/270             19/272       100.00      0.69 [0.35, 1.37]        
Subtotal (95% CI) 270                272 100.00      0.69 [0.35, 1.37]
Total events: 13 (Treatment), 19 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Total (95% CI) 270                272 100.00      0.69 [0.35, 1.37]
Total events: 13 (Treatment), 19 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
 0.1  0.2  0.5  1  2  5  10
 Favours treatment  Favours control  





Review: New review (MISOPROSTOL)
Comparison: 19 Rectal misoprostol Vs Injectable uterotonics                                                               
Outcome: 01 Severe postpartum haemorrhage (>1000mls)                                                                   
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 500 mcg misoprostol vs oxytocin+methylergometrine
 Caliskan 2002             17/396              7/402       100.00      2.47 [1.03, 5.88]        
Subtotal (95% CI) 396                402 100.00      2.47 [1.03, 5.88]
Total events: 17 (Treatment), 7 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.04)
02 500 mcg vs oxytocin
 Caliskan 2002             17/396             14/407       100.00      1.25 [0.62, 2.50]        
Subtotal (95% CI) 396                407 100.00      1.25 [0.62, 2.50]
Total events: 17 (Treatment), 14 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
03 400 mcg vs oxytocin
 Bugalho 2001               0/323              1/339         4.50      0.35 [0.01, 8.56]        
 Gerstenfeld 2001          15/154             14/161        95.50      1.12 [0.56, 2.24]        
Subtotal (95% CI) 477                500 100.00      1.06 [0.54, 2.09]
Total events: 15 (Treatment), 15 (Control)
Test for heterogeneity: Chi² = 0.49, df = 1 (P = 0.48), I² = 0%
Test for overall effect: Z = 0.18 (P = 0.86)
 0.1  0.2  0.5  1  2  5  10
 Favours treatment  Favours control  
Figure 9.4b Rectal misoprostol vs injectable uterotonics; Outcome: Severe postpartum haemorrhage (>1000 mL) 
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Review: New review (MISOPROSTOL)
Comparison: 19 Rectal misoprostol Vs Injectable uterotonics                                                               
Outcome: 02 Severe postpartum haemorrhage (>500mls)                                                                    
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 500 mcg misoprostol Vs oxytocin+methylergometrine
 Caliskan 2002             39/396             14/402       100.00      2.83 [1.56, 5.13]        
Subtotal (95% CI) 396                402 100.00      2.83 [1.56, 5.13]
Total events: 39 (Treatment), 14 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.43 (P = 0.0006)
02 500 mcg vs oxytocin
 Caliskan 2002             39/396             33/407       100.00      1.21 [0.78, 1.89]        
Subtotal (95% CI) 396                407 100.00      1.21 [0.78, 1.89]
Total events: 39 (Treatment), 33 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
03 400 mcg vs oxytocin
 Bugalho 2001              10/323             15/339        30.25      0.70 [0.32, 1.53]        
 Gerstenfeld 2001          70/154             61/161        65.93      1.20 [0.92, 1.56]        
 Karkanis 2002              1/110              1/113         3.82      1.03 [0.07, 16.22]       
Subtotal (95% CI) 587                613 100.00      1.14 [0.89, 1.46]
Total events: 81 (Treatment), 77 (Control)
Test for heterogeneity: Chi² = 1.69, df = 2 (P = 0.43), I² = 0%
Test for overall effect: Z = 1.00 (P = 0.32)
 0.1  0.2  0.5  1  2  5  10
 Favours treatment  Favours control  
Figure 9.4c Rectal misoprostol vs injectable uterotonics; Outcome: Postpartum haemorrhage (>500 mL) 
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Review: New review (MISOPROSTOL)
Comparison: 19 Rectal misoprostol Vs Injectable uterotonics                                                               
Outcome: 03 Use of additional uterotonics                                                                              
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 500 mcg vs oxytocin+methylergometrine
 Caliskan 2002             33/396              9/402       100.00      3.72 [1.80, 7.68]        
Subtotal (95% CI) 396                402 100.00      3.72 [1.80, 7.68]
Total events: 33 (Treatment), 9 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.56 (P = 0.0004)
02 500 mcg vs oxytocin
 Caliskan 2002             33/396             26/407       100.00      1.30 [0.80, 2.14]        
Subtotal (95% CI) 396                407 100.00      1.30 [0.80, 2.14]
Total events: 33 (Treatment), 26 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
03 400 mcg vs oxytocin
 Bugalho 2001               7/323              7/339        17.35      1.05 [0.37, 2.96]        
 Gerstenfeld 2001          36/159             18/166        40.89      2.09 [1.24, 3.52]        
 Karkanis 2002             28/110             20/113        41.77      1.44 [0.86, 2.40]        
Subtotal (95% CI) 592                618 100.00      1.63 [1.16, 2.30]
Total events: 71 (Treatment), 45 (Control)
Test for heterogeneity: Chi² = 1.79, df = 2 (P = 0.41), I² = 0%
Test for overall effect: Z = 2.79 (P = 0.005)
 0.1  0.2  0.5  1  2  5  10
 Favours treatment  Favours control  
Figure 9.4d Rectal misoprostol vs injectable uterotonics; Outcome: Use of additional uterontonics 
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Review: New review (MISOPROSTOL)
Comparison: 19 Rectal misoprostol Vs Injectable uterotonics                                                               
Outcome: 04 Shivering                                                                                                  
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 500 mcg vs oxytocin+methylergometrine
 Caliskan 2002             47/396             19/402       100.00      2.51 [1.50, 4.20]        
Subtotal (95% CI) 396                402 100.00      2.51 [1.50, 4.20]
Total events: 47 (Treatment), 19 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.51 (P = 0.0005)
02 500 mcg vs oxytocin
 Caliskan 2002             47/396             16/407       100.00      3.02 [1.74, 5.23]        
Subtotal (95% CI) 396                407 100.00      3.02 [1.74, 5.23]
Total events: 47 (Treatment), 16 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.94 (P < 0.0001)
03 400 mcg vs oxytocin
 Bugalho 2001             123/323             51/337        71.61      2.52 [1.89, 3.36]        
 Gerstenfeld 2001           7/159              7/166         7.10      1.04 [0.37, 2.91]        
 Karkanis 2002             26/110             15/113        21.29      1.78 [1.00, 3.18]        
Subtotal (95% CI) 592                616 100.00      2.01 [1.34, 3.04]
Total events: 156 (Treatment), 73 (Control)
Test for heterogeneity: Chi² = 3.36, df = 2 (P = 0.19), I² = 40.5%
Test for overall effect: Z = 3.34 (P = 0.0008)
 0.1  0.2  0.5  1  2  5  10
 Favours treatment  Favours control  
Figure 9.4e Rectal misoprostol vs injectable uterotonics; Outcome: Shivering 
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Review: New review (MISOPROSTOL)
Comparison: 19 Rectal misoprostol Vs Injectable uterotonics                                                               
Outcome: 05 Pyrexia                                                                                                    
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 500 mcg vs oxytocin+methylergometrine
 Caliskan 2002             16/396              6/402       100.00      2.71 [1.07, 6.85]        
Subtotal (95% CI) 396                402 100.00      2.71 [1.07, 6.85]
Total events: 16 (Treatment), 6 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.04)
02 500 mcg vs oxytocin
 Caliskan 2002             16/396              6/407       100.00      2.74 [1.08, 6.93]        
Subtotal (95% CI) 396                407 100.00      2.74 [1.08, 6.93]
Total events: 16 (Treatment), 6 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.03)
03 400 mcg vs oxytocin
 Bugalho 2001               0/1                0/1                 Not estimable         
 Gerstenfeld 2001           0/1                0/1                 Not estimable         
 Karkanis 2002             20/110             12/113       100.00      1.71 [0.88, 3.33]        
Subtotal (95% CI) 112                115 100.00      1.71 [0.88, 3.33]
Total events: 20 (Treatment), 12 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
 0.1  0.2  0.5  1  2  5  10
 Favours treatment  Favours control  
Figure 9.4f Rectal misoprostol vs injectable uterotonics; Outcome: Pyrexia 
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Oral misoprostol versus injectable uterotonics during caesarean delivery (two 
studies, 100 women) 
 Only two small studies [Acharya et al 2001; Lokugamage et al 2001a] 
compared oral tablet misoprostol against intravenous oxytocin during caesarean 
delivery (Table 9.5). The two studies used different doses of misoprostol so the 
treatment effects could not be combined. The risks of severe postpartum 
haemorrhage were equal with both doses of misoprostol compared to intravenous 
oxytocin (Figure 9.5a). For postpartum haemorrhage, the risk was equal with 
misoprostol 500 µg, but non-statistically decreased with misoprostol 400 µg (RR 
0.20, 95% CI 0.01-4.00) (Figure 9.5b). Compared to intravenous oxytocin, 
misoprostol 500 µg increased the risk (RR 6.00, 95% CI 0.79-45.42) while 
misoprostol 400 µg decreased the risk (RR 0.67, 95% CI 0.12-3.71) of using 
additional uterotonics (Figure 9.5c). Both effects were not statistically significant. 
Oral tablet misoprostol 500 µg increased the risk of shivering (RR 1.63, 95% CI 
0.87-3.04) (Figure 9.5d) and pyrexia (RR 6.00, 95% CI 0.79-45.42) (Figure 9.5e) 
but the effects were not statistically significant. 
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Table 9.5 Oral misoprostol versus injectable uterotonics during caesarean 
delivery (2 studies) 



























i/v oxytocin 10 
IU 
Management of third 
stage: individual 
caesarean section 
technique not specified. 
 
No withdrawals after 
randomization. 
 
Measurement of blood 
loss:  estimated by 
surgeon and anaesthetist 
after inspecting swabs, 
drapes, suction apparatus 




































i/v oxytocin 10 
IU  
Management of third 
stage: “active” during 
caesarean section. 
 
No withdrawals after 
randomization. 
 
Measurement of blood 
loss:  estimated visually 
from volume of blood in 
suction bottle plus soiling 




Review: New review (MISOPROSTOL) (Version 02)
Comparison: 20 Oral misoprostol Vs Intravenous Syntocinon [Caesarian section delivery]                                    
Outcome: 01 Severe postpartum haemorrhage (>1000mls)                                                                   
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 500 mcg misoprostol vs Syntocinon
 Lokugamage 2001            3/20               3/20        100.00      1.00 [0.23, 4.37]        
Subtotal (95% CI) 20                 20 100.00      1.00 [0.23, 4.37]
Total events: 3 (Treatment), 3 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
03 400 mcg Oral mispprostol vs Syntocinon
 Acharya 2001               1/30               1/30        100.00      1.00 [0.07, 15.26]       
Subtotal (95% CI) 30                 30 100.00      1.00 [0.07, 15.26]
Total events: 1 (Treatment), 1 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
 0.1  0.2  0.5  1  2  5  10
 Favours misoprostol  Favours Inj Syntocin  




Review: New review (MISOPROSTOL) (Version 02)
Comparison: 20 Oral misoprostol Vs Intravenous Syntocinon [Caesarian section delivery]                                    
Outcome: 02 Severe postpartum harmorrhage (>500 mls)                                                                   
Study  Treatment  Control  RR (fixed)  Weight  RR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
02 500 mcg misoprostol vs Syntocinon
 Lokugamage 2001           17/20              17/20        100.00      1.00 [0.77, 1.30]        
Subtotal (95% CI) 20                 20 100.00      1.00 [0.77, 1.30]
Total events: 17 (Treatment), 17 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
03 400 mcg oral misoprostol Vs Syntocinon
 Acharya 2001               0/30               2/30        100.00      0.20 [0.01, 4.00]        
Subtotal (95% CI) 30                 30 100.00      0.20 [0.01, 4.00]
Total events: 0 (Treatment), 2 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
 0.1  0.2  0.5  1  2  5  10
 Favours misoprostol  Favours Inj Syntocin  
Figure 9.5b Oral misoprostol vs intravenous syntocinon (caesarian section delivery); Outcome: Postpartum haemorrhage (>500 mL) 
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Review: New review (MISOPROSTOL) (Version 02)
Comparison: 20 Oral misoprostol Vs Intravenous Syntocinon [Caesarian section delivery]                                    
Outcome: 03 Use of additional uterotonics                                                                              
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
02 500 mcg oral misoprostol vs Syntocinon
 Lokugamage 2001            6/20               1/20        100.00      6.00 [0.79, 45.42]       
Subtotal (95% CI) 20                 20 100.00      6.00 [0.79, 45.42]
Total events: 6 (Treatment), 1 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.08)
03 400 mcg oral misoprostol vs Syntocinon
 Acharya 2001               2/30               3/30        100.00      0.67 [0.12, 3.71]        
Subtotal (95% CI) 30                 30 100.00      0.67 [0.12, 3.71]
Total events: 2 (Treatment), 3 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
 0.1  0.2  0.5  1  2  5  10
 Favours misoprostol  Favours Inj Syntocin  
Figure 9.5c Oral misoprostol vs intravenous syntocinon (caesarian section delivery); Outcome: Use of additional uterotonics 
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Review: New review (MISOPROSTOL) (Version 02)
Comparison: 20 Oral misoprostol Vs Intravenous Syntocinon [Caesarian section delivery]                                    
Outcome: 04 Shivering                                                                                                  
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
02 500 mcg oral misoprostol vs Injectable Syntocinon
 Lokugamage 2001           13/20               8/20        100.00      1.63 [0.87, 3.04]        
Subtotal (95% CI) 20                 20 100.00      1.63 [0.87, 3.04]
Total events: 13 (Treatment), 8 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
03 400 mcg oral misoprostol vs Injectable Syntocinon
 Acharya 2001               2/30               2/30        100.00      1.00 [0.15, 6.64]        
Subtotal (95% CI) 30                 30 100.00      1.00 [0.15, 6.64]
Total events: 2 (Treatment), 2 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
 0.1  0.2  0.5  1  2  5  10
 Favours misoprostol  Favours Inj Syntocin  
Figure 9.5d Oral misoprostol vs intravenous syntocinon (caesarian section delivery); Outcome: Shivering 
 
 186 
Review: New review (MISOPROSTOL) (Version 02)
Comparison: 20 Oral misoprostol Vs Intravenous Syntocinon [Caesarian section delivery]                                    
Outcome: 05 Pyrexia                                                                                                    
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
02 500 mcg oral misoprostol vs Injectable Syntocin
 Lokugamage 2001            6/20               1/20        100.00      6.00 [0.79, 45.42]       
Subtotal (95% CI) 20                 20 100.00      6.00 [0.79, 45.42]
Total events: 6 (Treatment), 1 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.08)
03 400 mcg oral misoprostol vs Injectable Syntocinon
Subtotal (95% CI) 0                  0         Not estimable
Total events: 0 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
 0.1  0.2  0.5  1  2  5  10
 Favours treatment  Favours control  
Figure 9.5e Oral misoprostol vs intravenous syntocinon (caesarian section delivery); Outcome: Pyrexia 
 
 187 
Review: New review (MISOPROSTOL) (Version 02)
Comparison: 20 Oral misoprostol Vs Intravenous Syntocinon [Caesarian section delivery]                                    
Outcome: 06 Blood Loss                                                                                                 
Study  Treatment  Control  WMD (fixed)  Weight  WMD (fixed)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
01 400 mcg misoprostol Vs Syntocinon
Acharya 2001            30    545.00(192.80)        30    533.00(296.00)   100.00     12.00 [-114.41, 138.41]   
Subtotal (95% CI)     30                          30 100.00     12.00 [-114.41, 138.41]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Total (95% CI)     30                          30 100.00     12.00 [-114.41, 138.41]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
 -100  -50  0  50  100
 Favours misoprostol  Favours Inj Syntocin  





Table 9.6 Excluded studies (4 studies) 
Study Methods Participants Interventions Comments 











































oxytocin 20 IU 
plus i/v oxytocin 
20 IU  
 
Blood loss within 2 hours 
of delivery measured. 
Mean blood loss in 
misoprostol group was 212 
± 56.0 mL, in misoprostol 
and oxytocin group was 
208 ± 55.4 mL, and 345 ± 
64.7 mL in oxytocin 
group. 
 
Excluded because data not 
presented in a form that 
can be extracted for meta-
analysis. 






















i/v oxytocin 20 
IU infusion  
Management of third 
stage: uterotonics given 
after delivery of the 
placenta. 
 
35 women excluded 
because of forceps or 
caesarean delivery. 
 
Measurement of blood 
loss: weighing of blood 
loss at delivery and for 24 
hours after delivery. 
 
The reported rate of PPH 
was unusually high 
(78/115 in misoprostol 
group, 74/115 in the 
oxytocin group). 
 
Excluded because and the 
figures in the abstract did 
not tally (e.g. 78/115 































1 mL stat plus 
oxytocin 10 IU in 
500 mL normal 
saline infusion. 
There was a 28.1% 
difference between 
misoprostol and combined 
syntometrine/oxytocin 
therapy (p=0.01) favoring 
misoprostol. 
 
Excluded because this 
study assessed treatment of 
and not prophylaxis for 
postpartum haemorrhage. 
Primary outcome measure 
was whether haemorrhage 




































i/m or i/v 
oxytocin 10 IU 
 
Women who received 
misoprostol had more 
shivering and pyrexia in 
the first hour (RR 6.4, 95% 
CI 3.9-10.4; RR 2.8, 95% 
CI 1.4-5.3 respectively), 
and 2-6 hours following 
delivery (RR 4.7, 95% CI 
1.9-11.2; RR 6.3, 95% CI 
3.7-10.8 respectively). 
 
Excluded because this was 
a subset of the WHO 
Misoprostol multicentre 







The existing evidence comparing oral and rectal tablet misoprostol against 
placebo or no treatment is inconclusive. Four trials [Bamigboye et al 1998; Hofmeyr 
et al 1998; Surbek et al 1999; Hofmeyr et al 2001] showed a non-significant 
protective effect against postpartum haemorrhage, while one unpublished study 
[Hofmeyr et al 1998a] showed a significantly increased risk of postpartum 
haemorrhage. The overall treatment effect was not significantly increased or 
decreased. There is place for a large well-conducted RCT to further test the 
hypothesis that misoprostol is more effective than placebo in preventing postpartum 
haemorrhage. Unfortunately, it will be difficult to ethically conduct any placebo-
controlled trials for the third stage of labour as there is good evidence that 
conventional uterotonic agents can reduce the incidence of postpartum haemorrhage 
[Prendiville et al 2003]. 
 
The majority of the RCTs conducted to compare misoprostol against 
injectable uterotonic agents were not adequately powered to prove equivalence or 
non-inferiority. Only the WHO study [Gulmezoglu et al 2001a] was adequately 
powered with clear sample calculation done a priori. As a consequence, the results 
of the trials were mostly not statistically significant. However, except for two studies 
[Lumbiganon et al 1999; Bugalho et al 2001], they showed that the risk of 
postpartum haemorrhage was increased with misoprostol. Two studies [Cook et al 
1999; Gulmezoglu et al 2001a], including the very large WHO multcentre trial 
proved that misoprostol significantly increased the risk of postpartum haemorrhage. 
The overall treatment effect was thus in favour of injectable uterotonic agents. On 
the basis of the current evidence, we can conclude that oral tablet misoprostol 400 
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µg to 600 µg is less effective than conventional injectable uterotonic agents. There is 
no need for further trials to compare oral tablet misoprostol against injectable 
uterotonic agents for use in the third stage of labour. We can also conclude that 
rectal tablet misoprostol is probably less effective than injectable uterotonic agents 
at preventing postpartum haemorrhage although further trials may help clarify the 
situation. 
 
Unfortunately, the majority of the trials used misoprostol administered either 
as an oral or rectal tablet. Both these routes of administration result in a substantial 
delay in the onset of the uterotonic action of misoprostol relative to conventional 
injectable uterotonic agents. It is thus not surprising that this meta-analysis has 
concluded that injectable uterotonics are significantly more effective that 
misoprostol in preventing postpartum haemorrhage. 
 
There were only two trials using oral solution misoprostol and both showed 
no significant difference between oral solution misoprostol and intramuscular 
oxytocin 10 IU in preventing postpartum haemorrhage and the use of additional 
uterotonics. These two trials were well conducted but lacked the power to prove 
equivalence or non-inferiority. The two studies comparing oral tablet misoprostol 
against intravenous oxytocin for use during caesarean deliveries were too small to 
reach any conclusions about the effectiveness of misoprostol against oxytocin. 
 
Unlike the clinical efficacy of misoprostol, there is little uncertainty that 
misoprostol significantly increases the risks of shivering and pyrexia after delivery. 
When compared to placebo or no treatment, misoprostol significantly increased both 
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the risks of shivering and pyrexia. The magnitude of the risk was dose-related. 
Compared to injectable uterotonics, misoprostol also significantly increased the risk 
of shivering at 400 µg to 600 µg in a dose-related manner. However, the risk of 
pyrexia was only significantly increased with doses of misoprostol above 500 µg. 
 
The two systematic reviews written by the authors of the WHO multicentre 
randomised trial [Gulmezoglu et al 2003; Villar et al 2002a] included the same 
RCTs and had similar conclusions. The date of their latest search was March 1, 
2002. The reviewers concluded that conventional injectable uterotonics were more 
effective and had less side effects than misoprostol in the active management of the 
third stage of labour. They also recommended that there was no need for further 
trials comparing misoprostol with injectable uterotonics except, perhaps, the role of 
higher doses of misoprostol given by different routes in the treatment of postpartum 
haemorrhage. The most recent published systematic review by Joy and colleagues 
[Joy et al 2003] covered a similar period, and included 15 of the 16 studies reviewed 
in the earlier systematic reviews. Joy and colleagues reviewed data from two studies 
[Daly et al 1999; Benchimol et al 2001] not previously included, and did not include 
unpublished data from one study [Hofmeyr et al 1998a]. Their conclusion was that 
misoprostol was inferior to conventional injectable uterotonics, but that misoprostol 
reduced the need for additional uterotonics compared to placebo. They suggested 
that there may be a role for misoprostol in less developed countries where parenteral 
uterotonic drugs may not be easily available. They also recommended that further 




Our systematic review included all the RCTs reviewed by the above three 
systematic reviews, as well as an additional four RCTs [Caliskan et al 2002; 
Karkanis et al 2002; Caliskan et al 2003; Oboro & Tabowei 2003]. We separated out 
studies using oral tablet and oral solution misoprostol, and examined the different 
routes by which misoprostol was administered. We also examined the role of 
misoprostol for use in caesarean delivery. The results of the later RCTs that we 
included favoured conventional injectable uterotonic agents over misoprostol for use 
in the third stage of labour. It is thus not surprising that the our review lends support 
to the Cochrane review in finding misoprostol inferior to conventional uterotonics 
for routine prevention of postpartum haemorrhage in the third stage of labour. 
 
Conclusions 
Currently, there is no evidence that misoprostol, given by any route, is a 
more effective uterotonic agent than placebo or no treatment. Compared to 
injectable uterotonics, oral tablet misoprostol 600 μg is significantly less effective in 
preventing postpartum haemorrhage (≥ 500 mL) and the use of additional 
uterotonics. Rectal misoprostol 400 μg was less effective than injectable uterotonics 
in preventing the use of additional uterotonics. The role of misoprostol for caesarean 
delivery remains uncertain. There is good evidence that misoprostol, given by any 
route and at 400-600 μg, increases the risk of shivering. Doses of misoprostol above 







Based on the current evidence, and the findings of our studies, we 
recommend that no further trials be undertaken to compare the effectiveness of oral 
tablet misoprostol single therapy against parenteral uterotonic agents for the routine 
prevention of postpartum haemorrhage. Oral tablet or rectal misoprostol could be 
tested as adjunct therapy along with other drugs with a faster onset of action but will 
probably not be appropriate for routine use alone. On the other hand, studies are 
required to determine whether there is a place for misoprostol administered bucally 
or as an oral solution to shorten its onset of action. To avoid excessive side effects, 
we recommend that low doses of misoprostol be used. However, clinical trials 














Excessive bleeding at or after childbirth accounts for almost half of all the 
postpartum maternal mortalities in developing countries, and is the single most 
important cause of maternal death worldwide. Postpartum haemorrhage can lead to 
irreversible shock and death within a short time and is a true obstetric emergency 
that demands fast vigorous treatment and proactive preventive management 
strategies. The introduction of the concept of active management of the third stage 
of labour and, in particular, the prophylactic use of oxytocics has led to a significant 
decrease in the incidence of postpartum haemorrhage in many countries.  
However, active management of the third stage of labour is not practiced 
universally. One of the unfortunate reasons for this is the unavailability of uterotonic 
agents that are suitable for use by traditional birth attendants for deliveries outside 
hospitals. Most uterotonic agents used for the prevention of postpartum haemorrhage 
are given by injection intramuscularly or intravenously and require sterile needles 
and syringes as well as proper storage conditions. There is thus a need for a 
uterotonic agent that is inexpensive, can be administered orally, vaginally or 
rectally, and is stable and easily stored. One such agent is misoprostol, a 
prostaglandin E1 analogue. 
 
My hypothesis is that misoprostol, given in the correct dose and by the 
correct route, should produce a similar uterotonic effect to other uterotonic agents 





The current management of the third stage of labour 
Despite evidence that active management of the third stage of labour reduces 
the incidence of postpartum haemorrhage, it is not universally practised. Factors 
accounting for this situation include the unavailability of conventional uterotonic 
agents, the desire for a more natural experience of childbirth, the philosophy that 
active management is unnecessary in low risk women, and avoidance of the adverse 
effects of conventional uterotonic agents. I evaluated the evidence for the various 
strategies and uterotonic agents currently used for the prevention of primary 
postpartum haemorrhage. 
 
Earlier studies explored various strategies for the management of the third 
stage of labour. Since publication of the first systematic review comparing active 
versus expectant management in 1988, active management of the third stage using 
oxytocics has become increasingly adopted. Recent surveys, however, show that 
there are still wide variations in practice around the world. Much interest has been 
focused recently on the use of misoprostol for the prevention of postpartum 
haemorrhage. 
 
There is good evidence from Cochrane systematic reviews that active 
management of the third stage of labour is superior to expectant management in 
terms of blood loss, postpartum haemorrhage, and other serious complications, but is 
associated with unpleasant side effects and hypertension when ergometrine is 
included. Intramuscular oxytocin has less side effects. Of the remaining uterotonic 
agents evaluated, carbetocin, an oxytocin analogue, and misoprostol appear the most 
promising. 
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Misoprostol: the accidental uterotonic agent 
Misoprostol is a prostaglandin E1 analogue originally developed for use in 
preventing NSAID-induced gastric ulcers. However, because of its cervical ripening 
and uterotonic properties, misoprostol has become one of the most useful drugs in 
obstetric and gynaecologic practice. 
 
Misoprostol has proven to be a very convenient and adaptable drug because 
of its formulation as a tablet that is stable and that can be administered orally, 
rectally, vaginally and by the sublingual route. Beginning with its abuse for illegal 
abortion in the late 1980s, misoprostol has quickly become established as one of the 
most effective drugs for terminating pregnancies in the first and second trimesters, 
as well as for inducing labour in the third trimester. Its use in the third stage of 
labour has also recently become a subject of great interest. 
 
Despite the large body of medical evidence about its efficacy and relative 
safety, the use of misoprostol in pregnant women remained off-label until the spring 
of 2002 when it was finally approved by the FDA for obstetric and gynaecologic 
use. 
 
Measuring the uterotonic effect of oxytocics 
The gold standard for the assessment of any intervention in the third stage of 
labour for preventing postpartum haemorrhage is the quantitative measurement of 
blood loss. Unfortunately, like most reference standards, the objective measurement 




Even if a convenient method is found for accurately measuring the blood loss 
in the third stage of labour, it should be borne in mind that if the intervention being 
assessed is a uterotonic agent, then blood loss may not truly reflect the efficacy of 
the therapy. Blood loss in the third stage does not only come from the placental bed. 
Blood is also lost from episiotomy wounds, lacerations, and other trauma to the birth 
canal. The type of vaginal delivery performed and the skill of the accoucheur, all 
influence the amount of blood lost from sites outside the uterus.  
 
However, any uterotonic agent being used can only influence the blood loss 
by inducing contraction and retraction of the uterine muscles and, hence, occluding 
the open vessels in the placental bed. Interventions that influence more than one 
aspect of the third stage, such as comparing active versus expectant management, or 
non-uterotonic drugs such as tranexamic acid are still best assessed by measuring 
blood loss. But for uterotonic drugs, the key factor that should be assessed is the 
uterotonic effect they induce, as they do not affect blood loss from other factors.  
 
We tested the reliability of catheter-tip transducers for the measurement of 
intrauterine pressure in the postpartum uterus. To demonstrate the reliability of the 
Gaeltec catheter-tip pressure transducers for measuring postpartum uterine activity, 
catheter-tip transducers were used in 20 women randomly allocated into two groups 
of 10. In each case in the first group, two catheters were tied together and introduced 
transcervically into the uterine cavity after delivery of the placenta. In the second 
group, the two catheters were inserted independently into the same uterine cavity. 
The active pressures recorded from the pairs of catheters within each uterine cavity 
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were compared. Comparison of individual active pressure readings from separate 
transducers revealed good agreement whether the catheters were tied together or 
were separate. We therefore concluded that intrauterine catheter-tip transducers can 
be used reliably to measure uterine activity in the postpartum uterus although there 
may be minor contraction by contraction differences in recordings of individual 
active pressures. 
 
Determining the optimum dose of oral tablet misoprostol using intramuscular 
syntometrine for comparison 
The use of oral misoprostol 500 µg for preventing postpartum haemorrhage 
was first described in an observational study in The Lancet in 1996 [El-Refaey et al 
1996]. At this time, the optimum dose and route for administering misoprostol for 
the prophylaxis of postpartum haemorrhage was still undetermined, and its side 
effects in the immediate postpartum period were unknown. My studies were 
commenced in 1997 to address these issues. 
  
To investigate the effect of oral misoprostol in dosages varying from 200 μg 
to 800 μg on postpartum uterine contractility and to document their side effects, we 
performed a prospective descriptive study in 57 women who delivered vaginally 
after spontaneous, unaugmented labours. These women were assigned to receive 
either oral tablet misoprostol 200 µg, 400 µg, 500 µg, 600 µg, 800 µg, or 




Within 5 minutes of delivery of the placenta, a calibrated Gaeltec® catheter 
with an intrauterine pressure transducer at its tip was inserted transcervically into the 
uterine cavity. Cumulative uterine activity was documented for 30 minutes in each 
woman before administering the oral misoprostol tablets and continued for a further 
90 minutes after its administration. Thus each woman acted as her own control 
regarding changes in uterine contractility. Uterine activity was measured by a 
Sonicaid® Meridian fetal monitor, which measures active contraction area 
automatically. The incidence of side effects was also documented.  
 
There was no statistical difference (p=0.887) in the adjusted mean difference 
in cumulative uterine activity following all the doses of oral misoprostol compared 
to intramuscular Syntometrine, the largest difference being seen in oral misoprostol 
200 μg (adjusted mean difference –2282 kPas sec, 95% CI –7954 to 3390 kPas sec). 
The mean onset of action of oral misoprostol (6.1, SD 2.1 min) was significantly 
slower than that of intramuscular Syntometrine (3.2, SD 1.5 min) (p=0.002), but 
their durations of action were similar (p=0.637). In the misoprostol group, the 
commonest side effects were shivering (36%) and a rise in body temperature above 
38°C (40%).  
 
The results of this study show that oral misoprostol has a definite uterotonic 
effect on the postpartum uterus. At doses of 200 μg to 400 μg, oral misoprostol 
produced a similar uterotonic effect to intramuscular Syntometrine. Higher doses of 
oral misoprostol were associated with significantly more side effects. Hence, we 
decided to proceed to determine the optimum route for administering misoprostol 
400 µg in terms of uteoronic effect and side effects. 
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Determining the optimum route of administration for misoprostol 
To compare the postpartum uterotonic effect and side effects of misoprostol 
administered by different routes, we performed a prospective, descriptive study in 
which 50 women were given misoprostol 400μg either by the oral solution, oral 
tablet, rectal or vaginal route, or intramuscular Syntometrine 1mL after spontaneous 
vaginal delivery. Pre- and post-treatment uterine activity were measured with 
intrauterine pressure catheters.  
 
The uterine activity produced by oral solution misoprostol 400μg was 
significantly higher than that of oral tablet, rectal and vaginal misoprostol (p=0.045, 
p=0.004, p=0.002 respectively). Onset of action after oral solution misoprostol was 
faster than by the oral tablet (p=0.01), rectal (p<0.001) and vaginal (p<0.001) routes. 
Unfortunately, shivering and pyrexia were also most common with oral solution 
misoprostol. Maximum body temperature recorded was significantly higher with 
oral solution misoprostol than with oral tablet, rectal and vaginal misoprostol 
(p=0.005, p=0.009, p=0.001 respectively). 
 
Different routes of administering misoprostol greatly influence the effects 
achieved. Oral solution misoprostol produces the fastest and strongest uterotonic 
effect, with the most side effects.  
 
The side effects of shivering and pyrexia when oral misoprostol is administered 
in the immediate postpartum period 
As mentioned in Chapter 2, oral misoprostol, a prostaglandin E1 analogue, 
has been used for the prevention of nonsteroidal anti-inflammatory drug-induced 
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gastric ulcers since the 1980s and the induction of abortions and labour since the 
1990s. No significant side effects had been reported in the early studies with 
normally prescribed doses of misoprostol up to 800 µg, with only two reports of 
misoprostol toxicity involving large overdosages. We describe a case of severe 
hyperthermia in a patient after an 800 μg oral dose of misoprostol in the immediate 
postpartum period. 
 
A 20-year-old multiparous woman was given 800μg of misoprostol orally 
after an uneventful vaginal delivery as part of a clinical trial. She developed severe 
hyperthermia with a core temperature of 41.9°C one and a half hours later. Despite 
vigorous treatment, her body temperature only returned to normal three and a half 
hours later. Serum creatinine phosphokinase was raised to 4715 IU/L but there was 
no myoglobinuria. The patient recovered with no deleterious effects and was 
discharged three days later. 
 
Oral misoprostol, even in routinely-prescribed doses, may cause severe 
shivering and hyperthermia that requires vigorous treatment. This was the first time 
the side effects of shivering and pyrexia have been reported with non-excessive 
doses of misoprostol. 
 
Relationship of side effects with dose of misoprostol, uterine workload 
produced, and route of administration 
My studies suggested that the safe dose of misoprostol for use in the third 
stage would be 200 to 400 µg. Oral solution misoprostol, while producing the fastest 
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onset of action and strongest uterine activity, unfortunately also produced the most 
side effects. 
 
We examined the relationship between the side effects of misoprostol and the 
dose given, route of administration, and uterine activity produced. Based on the 
findings of our dose and route studies, we concluded that the dose of misoprostol 
and the route by which it is administered after vaginal delivery are both significantly 
associated with its side effects of shivering and pyrexia, while uterine activity 
produced was not. 
 
Since misoprostol 400 µg given as an aqueous oral solution produced the 
fastest and strongest uterotonic effect but also the most side effects, we decided to 
test if a lower dose of misoprostol (200 µg) given as an oral solution would result in 
less side effects while maintaining a good level of uterine activity. 
 
Comparing the uterotonic effect and side effects of oral tablet and oral solution 
misoprostol 200 μg and 400 μg 
To compare the postpartum uterotonic effect and side effects of oral solution 
misoprostol 200 μg and 400 μg, and intramuscular syntometrine 1mL, we performed 
a prospective, descriptive study in which 30 women were given either oral solution 
misoprostol 200 μg or 400 μg, or intramuscular Syntometrine 1mL after 
spontaneous vaginal delivery. Pre- and post-treatment uterine activity were 
measured with intrauterine pressure catheters.  
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Uterine activity produced by oral solution misoprostol 200 μg was not 
significantly different from that of misoprostol 400 μg (p=0.758) or intramuscular 
syntometrine (p=0.623). There was no significant difference in onset of action 
among the three groups (p=0.132). Shivering and pyrexia occurred less frequently 
(20% versus 50%, p=0.350; 10% versus 80%, p=0.005 respectively), and maximum 
body temperature recorded was significantly lower (p=0.001) with 200 μg compared 
to 400 μg oral solution misoprostol. 
 
Oral solution misoprostol 200 μg produced uterotonic effects that were not 
significantly different from that of oral solution 400 μg or intramuscular 
Syntometrine 1mL, with significantly less side effects. We recommend that further 
studies be performed in a clinical setting to determine if oral solution misoprostol 
200 µg may be used as alternative to conventional oxytocics. 
 
The use of misoprostol administered by different routes in the third stage of 
labour to prevent postpartum haemorrhage: a systematic review 
The work for this thesis was commenced directly after the first report was 
made in 1996 of the use of oral misoprostol for the prevention of postpartum 
haemorrhage in the third stage of labour. By 1998, the first randomised controlled 
trial (RCT) was published, and over the next five years, another 24 RCTs were 
reported. Most were small to medium sized trials ranging from 40 to 2058 subjects. 
The largest single study was that by the WHO Collaborative Group, with 18530 
subjects, published in 2001. 
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The WHO Misoprostol multicentre trial concluded that oral tablet 
misoprostol 600 µg given in the third stage of labour was associated with a higher 
risk of severe postpartum haemorrhage, need for additional uterotonics, shivering, 
and pyrexia compared to intramuscular or intravenous oxytocin 10 IU. Until this 
study, none of the RCTs had proven conclusively that misoprostol was either more 
or less effective than injectable uterotonics in preventing postpartum haemorrhage or 
the need for additional uterotonics. As expected, the results of the large WHO study 
overwhelmed the existing evidence, and the resulting Cochrane systematic review 
that followed concluded that conventional injectable oxytocics were preferable to 
misoprostol for the routine prevention of postpartum haemorrhage. 
 
Based on our own observations (Chapter 5), we feel that misoprostol given 
orally as a tablet may not be the optimal method of administering this drug for the 
purpose of preventing postpartum haemorrhage. Pharmacokinetic studies have 
shown that the peak plasma concentration of misoprostol acid with oral tablet 
administration after delivery is around 18 to 20 minutes. From our intrauterine 
pressure measurement studies, we have found that the onset of uterotonic action 
after swallowing misoprostol tablets is 6 minutes (Chapter 5). This compares with a 
peak plasma concentration of oxytocin within 3 minutes of intramuscular injection, 
and onset of uterotonic action by 2.5 minutes. These few minutes difference in onset 
of action is of great clinical significance as delay in uterine contraction in the third 
stage can lead to a large volume of blood loss within a very short period of time. The 
delay in onset of action for rectal misoprostol is even greater, with peak plasma 
levels at 40.5 minutes, and onset of uterotonic activity at 11 minutes (Chapter 5). 
Hence, we feel that the current RCTs, which have either used misoprostol as oral 
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tablets, or as rectal suppositories (for which most misoprostol tablets were not 
formulated), will not show misoprostol to be an effective uterotonic agent for the 
purpose of preventing postpartum haemorrhage in the third stage. We separated out 
the two trials using oral solution misoprostol from those using oral tablet 
misoprostol as we feel that this method of administration may result in quicker 
absorption and greater uterotonic efficacy.  
 
The purpose of this systematic review was to determine the effectiveness and 
safety of routine administration of misoprostol by different routes for the prevention 
of postpartum haemorrhage after vaginal delivery compared to no treatment or 
treatment with injectable uterotonics. Electronic databases were searched to identify 
randomised trials that compared misoprostol administered by different routes. 
Eligibility and trial quality were assessed by selected criteria which were determined 
a priori. Primary outcomes were chosen to address clinical effectiveness (severe 
postpartum haemorrhage ≥ 1000 mL, postpartum haemorrhage ≥ 500 mL, and the 
use of additional uterotonics) and safety (side effects of “any shivering”, and pyrexia 
> 38ºC). Data were extracted and analysed using RevMan 4.2 software. All meta-
analyses were based on the intention-to-treat principle. Overall treatment effects 
were expressed as relative risk (95% confidence intervals). Where there was result 
heterogeneity a random effects model was used. To explore the dose-response 
relationship a sub-group analysis was done. The date of the latest search was July 1, 
2003. 
 
Five studies (2,367 women) compared oral tablet misoprostol with placebo. 
There were no statistically significant differences in the risks of severe PPH (≥ 
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1000ml), PPH (≥ 500 ml), and use of additional uterotonics. Eight studies (25,402 
women) assessed oral tablet misoprostol against injectable uterotonics. Oral tablet 
misoprostol 600 µg was significantly less effective than injectable oxytocics in 
preventing PPH (RR 1.27, 95% CI 1.01-1.58), and use of additional uterotonics (RR 
1.30, 95% CI 1.03-1.65). Two trials (897 women) compared oral solution 
misoprostol with intramuscular oxytocin for the third stage of labour, and two 
studies (100 women) compared oral misoprostol against intravenous oxytocin for 
preventing PPH during caesarean delivery. There were no statistically significant 
differences in the primary outcomes for these four trials as they were underpowered 
statistically. Rectal misoprostol was studied in six trials (3,975 women). Rectal 
misoprostol 400mcg was less effective than injectable uterotonics in preventing use 
of additional uterotonics (RR 1.63, 95% CI 1.16-2.30). There was an increased risk 
of having shivering and pyrexia with all concentrations of misoprostol compared to 
placebo and injectable uterotonics. 
 
There is currently no evidence that misoprostol, given by any route, is more 
effective than placebo.  Compared to injectable uterotonics, oral tablet misoprostol 
600 µg was less effective in preventing PPH and the use of additional uterotonics. 
Rectal misoprostol 400 µg was less effective than injectable uterotonics in 
preventing the use of additional uterotonics. Misoprostol, given by any route, 
increases the risk of shivering and pyrexia.  
 
We recommend that tablet misoprostol, given orally or rectally, should not 
be used alone for the routine prevention of postpartum haemorrhage in the third 
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stage of labour if injectable uterotonics are available. Care givers and patients should 
be aware of the dose-related side effects of misoprostol. 
 
Conclusion 
Misoprostol is capable of producing contractions in the postpartum uterus 
similar to those induced by intramuscular Syntometrine, a standard oxytocic used for 
preventing postpartum haemorrhage. The uterotonic action of misoprostol is 
significantly influenced by the dose administered and the route of administration. 
The route of administration that produces the fastest onset of action as well as the 
greatest uterine activity is an oral aqueous solution. This is followed in descending 
order by misoprostol administered as oral tablets, rectally, and vaginally.  
There was a trend towards stronger uterotonic activity with increasing doses of oral 
tablet misoprostol from 200 µg to 600 µg. Unfortunately, with doses of oral tablet 
misoprostol above 400 µg, the side effects of shivering and pyrexia was significantly 
increased. We therefore proceeded with doses of misoprostol 200 to 400 µg in our 
studies. 
 
With the increased speed of onset as well as strength of uterine activity 
produced by misoprostol 400 µg given as an oral solution, there were also more side 
effects. However, misoprostol 200 µg given as an oral solution produced good 
uterotonic activity with significantly less side effects. 
 
A systematic review of the randomized controlled trials using misoprostol 
administered by different routes for the prevention of postpartum haemorrhage 
showed that conventional injectable oxytocics are more effective and have less side 
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effects. The two randomised trials using oral solution misoprostol were 
underpowered statistically to prove the effectiveness of misoprostol but did confirm 
the increased risk for shivering and pyrexia with doses of 400 µg and 600 µg. 
 
From my studies, I conclude that my hypothesis that misoprostol, given in 
the correct dose and by the correct route, is able to produce a similar uterotonic 
effect to intramuscular Syntometrine is true. However, it can only be achieved with 
the production of the troublesome and potentially dangerous side effects of shivering 
and pyrexia. From large clinical trials, it has been shown conclusively that 
misoprostol administered as oral tablets or rectally are not as effective as 
conventional uterotonic agents and produce more side effects. 
 
I therefore recommend that tablet misoprostol, given orally or rectally, 
should not be used alone for the routine prevention of postpartum haemorrhage in 
the third stage of labour if injectable uterotonics are available. Care givers and 
patients should also be aware of the dose-related side effects of misoprostol. In a 
trial setting, misoprostol 200 µg administered as an aqueous oral solution may be 
studied for the prevention of postpartum haemorrhage in low risk deliveries. Oral 
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